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The molecular mechanism that leads to ischemic preconditioning and hence to ischemic 
tolerance, are not completely understood although it is clear that multiple effectors and 
pathways contribute to the instauration of this neuroprotective profile. To study the 
mechanism/pathway involved in the ischemic tolerance, brain proteins, plasma proteins and 
plasma metabolites were analyzed in preconditioning stimulus (7'Middle Cerebral Artery 
occlusion or 7'MCAo), in severe stroke (permanent Middle Cerebral Artery occlusion or 
pMCAo) and in preconditioned (7'MCAo/pMCAo) mouse model. 
A conventional 2-DE approach was used to study technical replicates of pooled brain proteins 
revealing an involvement of energy metabolism, mitochondrial electron transport, synaptic 
vesicle transport and antioxidant processes; moreover network analysis suggested an 
involvement of the androgen receptor that was validated on technical replicates of pooled 
brain proteins by western blot analysis revealing an increased expression in preconditioned 
stimulus animals (J'MCAo). 
Plasma proteins were analyzed using a l-DE LC-MS/MS approach on technical replicates of 
pooled plasma proteins revealing decreased levels of epidermal growth factor receptor (EGFR) 
and increased levels of insuline like growth factor acid labile subunit (IGFALS), which 
expression was paralleled by increased insulin like growth factor 1 (IGF1) plasma 
concentration, as validated by ELISA on biological replicates, in preconditioning stimulus 
animals (7'MCAO). 
Finally an untarget metabolomics analysis was applied to technical replicates of pooled plasma 
proteins revealing fatty acid oxidation and branched-chain aminoacid metabolism as the main 
biological processes modulated in ischemic tolerance and highlighted an involvement of the 
aminoacid leucine, carnitine esters and adenosine. 
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The correlation of all the omics data obtained, indicates androgen receptor as an important 
mediator able to interact with brain and plasma proteins and plasma metabolites involved in 
brain ischemic tolerance. 
The results described in this thesis represents the first application of both proteomic and 
metabolomic approaches in cerebral ischemic sets, highlighting the cross-talk between 
proteins and metabolites and adding new evidence to the current knowledge on ischemic 
preconditioning that may represent a starting point for future experiments on investigating 
candidate pathways that relate to Androgen receptor. 
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Ischemic stroke is characterized by a sudden interruption of the cerebral blood flow due to an 
occlusion of a cerebral vessel, and accounts approximately for 80% of all cases of stroke (Stoll, 
Kleinschnitz et al. 2008). The ischemic brain injury is a global health problem, representing the 
third leading cause of morbidity and mortality in Western countries. Globally there are 50 
million survivors of stroke and transient ischemic attack, of whom 20% will suffer a subsequent 
stroke in the following 5 years, and 15-20% suffer permanent disability (Adams 1993; Lloyd-
Jones, Adams et al. 2010). 
Ischemic brain injury results from a complex sequence of pathophysiological events that 
evolve over time and space. The main pathogenic mechanisms include excitotoxicity, peri-
infarct depolarisations, inflammation and apoptosis (Dirnagl, ladecola et al. 1999) (Figure.1.1). 
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Figure 1.1. Temporal cascade of the main pathogenic events in stroke (adapted from Dirnagl, ladecola et 01. 1999), 
A large amount of oxygen is required by the brain to generate sufficient ATP by oxidative 
phosphorylation to maintain and restore ionic gradients, When blood flow is reduced, there is 
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an inhibition of ATP synthesis that leads to ionic deregulation and neuronal plasma membrane 
depolarization. This depolarisation causes the release of the excitatory neurotransmitter 
glutamate, the activation of N-methyl-D-aspartate (NMDA), alpha-amino-3-hydroxy-S-methyl-
4-isoxazolepropionic acid (AMPA), metabotropic glutamate receptors, and an increase in the 
level of intracellular calcium with the activation of many calcium-dependent proteases. These 
enzymes degrade cytoskeletal and extracellular matrix proteins, and also activate 
phospholipase A2 and cyclooxygenase. This leads to the generation of free-radical species that 
overwhelm endogenous scavenging mechanisms, producing lipid peroxidation, membrane 
damage, mitochondrial impairment, and finally activation of inflammatory system and 
induction of apoptosis (Figure1.2). 
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Figure 1.2. Simplified scheme of pathophysiological mechanisms of stroke (adapted from Dirnagl, ladecola et 01. 
1999). 
Peri-infarct depolarizations are spontaneous waves of depolarization that propagate through 
the penumbra following focal stroke. Peri-infarct depolarization may be caused by the release 
of potassium and excitatory amino acids from the ischemic core and are associated with 
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increased ischemic injury. Fabricius and colleagues (Fabricius, Fuhr et 01. 2006) demonstrated 
the existence of peri-infarct depolarization in the acutely injured human brain, suggesting the 
therapeutic use of hypothermia or glutamate receptor antagonism to limit the development of 
ischemic injury within the penumbra. 
Inflammation contributes to stroke-related brain injury. The inflammatory response is a 
composite process that involves many different cell types, inflammatory mediators and 
extracellular receptors. 
Increased levels of Ca 2+, and free-radical species, activate pro-inflammatory genes that induce 
the synthesis of transcription factors and hence the production of mediators of the 
inflammations, such as cytokines. 
Cytokines and chemokines, in turn, contribute to stroke-related brain injury (Gong, Qin et 01. 
1998). 
During ischemia a variety of activated cell types (i.e. endothelial cells, microglia, neurons, 
platelets, leukocytes, fibroblasts) induces the production of cytokines (IL-l, IL-6, TNF-a, TGF-~) 
and chemokines such as CINC and MCP-l (Huang, Upadhyay et al. 2006) (Figure 1.3). After 
permanent or transient cerebral ischemia in microglia, astrocytes, and neurons there is an 
increased production of IL-1. The exact role of IL-l in propagating tissue damage is unclear, 
although it's possible deleterious effects include fever, arachidonic acid release, enhancement 
of NMDA-mediated excitotoxicity, and stimulation of nitric oxide synthesis (Huang, Upadhyay 
et 01. 2006). The biological activity of IL-6 overlaps with that of IL-l, and data from human 
studies suggest a pro-inflammatory role for IL-6 in stroke. The level of IL-6 in peripheral blood 
is higher in stroke patients and detectable within a few hours of stroke onset. Further, higher 
CSF and serum levels of IL-6 correlate with larger infarct size and poorer clinical outcome 
(Huang, Upadhyay et 01. 2006). However, IL-6 also has anti-inflammatory properties due to its 
ability to induce IL-l receptor antagonist synthesis (Relton, Martin et 01. 1996) therefore the 
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role of IL-1 in the context of stroke is still unclear. Up-regulation of TNF-a mRNA parallels that 
of IL-1 and IL-6 mRNA within the first hours after ischemia (Huang, Upadhyay et 01. 2006). Both 
experimental and human data indicate a positive correlation between TNF-a and the extent of 
ischemic injury. Like IL-1, TNF-a induces the expression of adhesion molecules in cerebral 
endothelial cells and promotes the accumulation and transmigration of neutrophil. In addition, 
TNF-a stimulates the production of acute-phase proteins, disrupts the blood-brain barrier and 
stimulates the induction of other inflammatory mediators in rats. It was observed that the 
administration of TNF-a neutralizing antibody reduces brain injury after focal ischemia 
suggesting a TNF-a-targeted therapies for stroke treatment (Nawashiro, Martin et 01. 1997). 
Growing evidence suggests that TGF-~ plays a neuroprotective role in the pathogenesis of 
stroke (Huang, Upadhyay et 01. 2006). It is likely that the neuroprotective effect of TGF-~ is the 
concerted result of the activation of several neuroprotective pathways. Cytokines induces the 
expression of three classes of cell adhesion molecules: selectins, integrins, and 
immunoglobulins (Huang, Upadhyay et 01. 2006). These adhesion molecules mediate the 
transmigration of neutrophils in the brain as early as 30 min after permanent middle cerebral 
artery occlusion (MCAo). The recruitment of neutrophils to the ischemic brain begins with 
neutrophil rolling on activated endothelial blood vessel walls, mediated by selectins, followed 
by neutrophil activation and adherence, mediated by integrins and immunoglobulins (Figure 
1.3). When adhered to cerebral blood vessel walls, neutrophils transmigrate into the cerebral 
parenchyma, a process facilitated by disruption of the blood-brain barrier (BBB). The 
recruitment of neutrophils can obstruct the microcirculation and prevent complete restoration 
of cerebral blood flow after reperfusion. This blockage may cause further tissue damage after 
ischemia and is described as the ischemic no-reflow phenomenon (Huang, Upadhyay et 01. 
2006). Once neutrophils penetrate into the ischemic brain they cause tissue damage by 
releasing reactive oxygen species and proteolytic enzymes. Lymphocytes also appear to be 
responsible for mediating damage in response to brain ischemia. Although lymphocytes are 
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ordinarily excluded from the CNS, they appear within 24h in post ischemic brain (Schroeter, 
Jander et 01. 1994). While the mechanism producing their infiltration into the brain remains 
unclear, it is likely that disruption of the BBB plays a major role in the influx, either by directly 
allowing the free movement of lymphocytes, or by leakage of brain antigens resulting in the 
transmigration of activated lymphocytes that could contribute to development of the lesion. 
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Figure 1.3. Inflammatory cascades following vessel occlusion (adapted from Huang, Upadhyay et 01. 2006) . 
Abbreviations used: Integrins macrophage-l antigen (Mac-l); lymphocyte function-associated-l antigen (LFA-l); 
intercellular adhesion molecule-l and -2 (ICAM-l, ICAM-2), vascular cell adhesion molecule-l (VCAM-l); neutrophil 
chemoattractant (ClNC), interieukin-l{IL-l), Monocyte chemoattractant protein-l{MCP-l). 
1.1.1.4. Apoptosis 
Mild ischemic injury preferentially induces cell death via an apoptotic-like mechanism rather 
than necrosis. Because the ischemic penumbra sustains milder injury and preserves ATP, 
apoptosis predominates in this region (Kerr, Wyllie et 01. 1972). Triggers of apoptosis include 
reactive oxygen species, death receptor ligation, DNA damage, protease activation and ionic 
imbalance. Subsequent to mitochondrial impairment, Cytochrome C is released and enters the 
19 
cytosol from its location on the external side of the inner mitochondrial membrane, and in 
presence of dATP activates an apoptosome complex [apoptosis-activating factor (APAF1) plus 
pro-caspase 9] (Green and Reed 1998). The formation of the apoptosome complex, which is 
suppressed by BcI-xL, a protein of the BcI-2 family, promotes clipping and activation of 
caspases 3 and 7, which are aspartate-specific cysteine proteases that exist as zymogens in 
cells. These caspases induce the dismantling of the cell by cleaving homeostatic, cytoskeletal, 
repair, metabolic, and cell signalling proteins; they also cause further DNA fragmentation by 
activating caspase-activated deoxyribonuclease (CAD) by cleaving the inhibitor protein ICAD. 
Activation of the extrinsic pathway of death receptors can induce caspase activation 
independent of the release of cytochrome C. Death receptor ligation results in activation of 
caspase-8 and caspase-10, which in turn can activate effector caspase 3 (Namura, Zhu et 01. 
1998) (Figure 1.4). Activation of death receptors such as FasjCD95, TNFR1, and the TRAIL 
receptor is promoted by the TNF family of ligands, including FASL, TNF, LT-alpha, LT-beta, 
CD40L, LIGHT, RANKL, and TRAIL, which are released as part of the inflammatory response to 
ischemia (del Zoppo, Ginis et 01. 2000). 
Figure 1.4. Apoptosis pathway activated during stroke (adapted from Doyle, Simon et al. 2008). 
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1.2. PRECONDITIONING 
In 1964 Janoff introduced the terms 'tolerance' and 'preconditioning', referring to an organism 
that responds with protective mechanisms to potentially recurring challenges (Janoff 1964). 
Practically any stimulus capable of causing injury can, when applied close to (but below) the 
threshold of damage, protect the brain against subsequent ischemia (Figure 1.5). 
Control 
(naive tissue) 
r --.. 
Precondilloned 
(proteclIVe mechanisms 
already Inducod) 
Ischemia-induced 
protectIVe mechanisms 
Ischemia-Induced 
destructive mechanisms 
Final infarct and 
scattered injury 1 /' 
Figure 1.5. Brain preconditioning (adapted from Dirnagl, Simon et 0/. 2003). 
By analogy to Janoff's terminology, this phenomenon has been termed 'ischemic 
preconditioning' (IPC) or 'ischemic tolerance' (IT) . 
Identified in the heart by Murry et 01., preconditioning and subsequent ischemic tolerance 
were then demonstrated for the first time in cerebral ischemia models (Murry, Jennings et 01. 
1986; Kitagawa, Matsumoto et 01. 1990; Kirino, Tsujita et 01. 1991). The effect of 
preconditioning ischemia is as robust as that of hypothermia, which has attracted much 
attention as a promising therapy for ischemic stroke. Although the stress response had been 
considered a candidate for induced tolerance, the molecular mechanisms underlying this 
phenomenon are much more complex than initially expected (Kirino 2002; Dirnagl, Simon et al. 
2003; Dirnagl, Becker et al. 2009; Gidday 2006). Amongst various brain regions, the 
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hippocampus, cerebral cortex, basal ganglia and thalamus were often reported to acquire 
ischemic tolerance (Kitagawa, Matsumoto et at. 1991). 
Preconditioning triggers a fundamentally different adaptive response and, in mammals, this 
response is characterized by at least two distinct time frames of induced tolerance relative to 
the preconditioning stimulus and the subsequent ischemia: a rapid phase and a delayed phase 
(Figure 1.6). A short-lasting protective phenotype (rapid phase) can be induced within minutes 
of exposure to preconditioning stimuli (lu, Yu et at. 2005; Perez-Pinzon, Xu et at. 1997; Schurr, 
Reid et at. 1986), as a result of changes in ion channel permeability, protein phosphorylation 
and other post-translational modifications; this is known as rapid preconditioning. Ischemic 
tolerance also requires gene activation and de novo protein synthesis; this 'classical 
preconditioning' requires many hours or even days to become fully manifest (delayed phase). 
Without another preconditioning stimulus to sustain it, the window for protection also wanes 
within days. The expression profile of gene activation and repression set in motion by 
preconditioning is not only temporally specific, but also differs between neurons, glia and 
endothelial 
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The overall implication is that different families of pro-survival genes are activated which 
encode proteins that serve to enhance the brain's resistance to ischemia. Protection is 
achieved by attenuation of injury-inducing mechanisms like excitotoxicity, ion/pH imbalance, 
oxidative and nitrosative stress, metabolic dysfunction, inflammation, necrotic and apoptotic 
cell death (Dirnagl, Becker et 01. 2009). Protection is also manifested by engaging innate 
survival mechanisms and enhancing endogenous repair processes (for example, the 
proliferation and mobilization of bone marrow and other stem cells) that lessen the overall 
extent of injury and concomitantly facilitate the recovery of brain function (Sommer 2009). 
The acquisition of the ischemia-tolerant phenotype involves particular adaptation response 
cascades to specific stimuli occurring over distinct time frames (Bernaudin, Tang et 01. 2002), 
(Stenzel-Poore, Stevens et 01. 2003). Whether the triggering stimulus is preconditioning alone, 
ischemia alone, or ischemia with prior preconditioning, each of the cascades can be 
characterized by gene-dependent responses involving a unique family of sensors, transducers 
and transcription factors that activate them and the effector proteins that are produced. 
Gene-independent, post-translational modifications of existing proteins also contribute 
concomitantly to the response (Figure 1.7) leading to the establishment of a 'latent' 
cerebroprotective phenotype. Ischemia in a preconditioned brain then activates a unique and 
separate set of adaptive responses. Although changes in the expression of some genes and the 
modification of some proteins may be shared between these two protective responses, the 
studies carried out so far suggest different genetic and molecular bases. In addition, with 
respect to the response to ischemic injury, preconditioning genetically reprogrammes the 
response to ischemia and not simply activate competing mechanisms to counteract these 
injury cascades (Dhodda, Sailor et 01. 2004; Stenzel-Poore, Stevens et 01. 2003; Tang, Pacary et 
01. 2006). 
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Figure 1.7. Cerebroprotection by preconditioning. (adapted from Gidday 2006) . 
1.2.1. Preconditioning stimulus 
Many stimuli, stressors, and chemicals can serve to induce resistance in the brain to ischemic 
injury: hyperthermia, hypothermia, hypoxia, reactive oxygen species, inflammatory cytokines, 
spreading depression, mitochondrial inhibition, resveratrol, volatile anaesthetics, K-ATP 
channel openers, antibiotics, myelin basic proteins, E-selectin and also the transient ischemic 
attack . Therefore, "cross-tolerance," in which one stressor promotes resistance to another 
, 
can be induced in the brain . The sheer variety of stimuli capable of inducing an ischemia-
resistant phenotype in the brain indicates that the signalling pathways activated by these 
different triggers converge downstream on some common, fundamental mechanisms that 
ultimately account for the protection. 
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Transient Ischemic Attack (TIA) is defined as "a brief episode of neurological dysfunction 
caused by focal brain or retinal ischemia, with clinical symptoms typically lasting less than one 
hour, and without evidence of acute infarction" (Albers, Caplan et 01. 2002). TIAs have recently 
become the centre of attention among basic ischemia researchers since TIAs have been 
postulated to potentially represent the clinical analogue of experimental ischemic 
preconditioning (Fu, Sun et 01. 2008; Moncayo, de Freitas et 01. 2000;Wegener, Gottschalk et 
01. 2004; Weih, Kallenberg et 01. 1999). This hypothesis has been scrutinized and corroborated 
by a retrospective study on stroke patients with a history of TIAs, who, indeed, presented a 
more favorable clinical outcome after stroke compared to patients lacking preceding TIAs 
(Weih, Kallenberg et 01. 1999). Subsequent studies, which examined a much larger number of 
patients, impressively corroborated these findings (Wegener, Gottschalk et 01. 2004). In a 
retrospective study, Schaller clearly demonstrated that stroke patients only showed a more 
favourable neurological outcome when the preceding TIAs occurred 1-7 days prior to stroke 
and the duration of TIAs did not exceed 20 min (Schaller 2005). Therefore, TIAs would provide 
neuroprotection only for a limited period. A plethora of changes after TIAs have to be 
expected, at both the functional and structural level. In this thesis, a TIA was used as trigger of 
ischemic preconditioning. 
The induction of ischemic tolerance is accompanied by changes in gene expression conferring 
cytoprotection and survival to cells. Preconditioning changes the expression of genes involved 
in the suppression of metabolic pathways, immune response, ion-channel activity and blood 
coagulation (Stenzel-poore, Stevens et 01. 2007). Gene expression is regulated by transcription 
factors like response elements binding protein (CREB) that is activated after preconditioning, 
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inducing an up regulation of Bcl-2 an important gene against cell death; the nuclear factor NF-
KB, a key regulator of apoptosis and inflammation, is activated after preconditioning and is 
linked to an up-regulation of key survival regulators such as superoxide dismutase or proteins 
that inhibits apoptosis. Following ischemic preconditioning, the activation of the mitogen-
activated protein kinase (MAPK) induces an increase of the binding activity of the protein AP-l 
but this was not demonstrated to be involved in the induction of tolerance. p53 is a 
transcriptional factor historically associated to the promotion of cell death and in models of 
preconditioning/severe ischemia, it is down-regulated in such conditions (Stetler, Zhang et 01. 
2009). Gene expression is also regulated by epigenetic mechanisms such as DNA methylation 
and histone modification, which modify the structure of chromatin thereby controlling the 
access of transcription factors to regulatory loci. These findings indicate that genomic 
reprogramming is closely involved in ischemic tolerance and suggest that metabolic down-
regulation underlies the common pathways of neuroprotection seen in ischemic tolerai1ce, 
hibernation, and hypothermia (Yenari, Kitagawa et 01. 2008). The hypometabolic state, under 
all three conditions seems to occur, appears to be mediated in part by covalent attachment of 
the small ubiquitin-related modifier (SUMO) to a large number of substrates (Lee, Miyake et 01. 
2007; Lee, Castri et 01. 2009; Yang, Ma et 01. 2009). Most of the SUMO targets are in the 
nucleus, including transcription factors, transcriptional coactivators, and chromosome 
remodelling regulators (Hay 2005). SUMOylation of a wide range of transcription factors is 
likely to attenuate its activity and result in a hypometabolic state. 
One of the latest discoveries in post-translational regulation was the miRNAs (microRNA), 
single-stranded RNA molecules approximately 21-23 nucleotides in length that regulate gene 
expression by the degradation or translational repression of target mRNAs. In the brain, 
miRNAs are abundant and play important roles in development, function and synaptic 
plasticity. Based on the discovery that almost the same numbers of mRNA species are up- and 
down-regulated under ischemic tolerance, miRNA microarray analysis showed both up- and 
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down-regulation of multiple miRNA profiles in the brain after ischemic preconditioning 
(Dharap and Vemuganti 2010; Saugstad 2010). 
One of the most important key regulators of the genomic response after a preconditioning 
stimulus is the transcription factor named Hypoxia-inducing factor (HIF). The a-subunit of HIF 
(HIFa) is unstable and is hydroxylated by prolyl-4-hydroxylase, an oxygen sensor, and 
processed for proteasomal degradation. Under hypoxic conditions, the inactivation of prolyl-4-
hydroxylase increases the amount of HIF, which can then bind the hypoxia-responsive 
elements (HREs) in the promoter region of a number of genes, including erythropoietin (EPO), 
vascular endothelial growth factor (VEGF), angiopoietin 2, insulin-like growth factor (IGF), and 
glucose transporters. The expression of the isoform HIF-1a was increased after hypoxic 
preconditioning in neonatal rat and adult mice brains (Bergeron, Gidday et 01. 2000). Among 
the genes whose transcription is mediated specifically by HRE, erythropoietin (Ruscher, Isaev 
et 01. 1998; Bernaudin, Nedelec et 01. 2002), adrenomedullin (Tixier, Leconte et 01. 2008), VEGF 
(Wick, Wick et 01. 2002), Na-Ca exchanger (Valsecchi, Pignataro et 01. 2011), and sphingosine 
kinase 2 (Wacker, Park et 01. 2009) have been shown to be involved in ischemic or hypoxic 
tolerance. However, the role of HIF-1a remains controversial, because hypoxic tolerance was 
preserved in neuron-specific HIF-1a-deficient mice (Baranova, Miranda et 01. 2007). 
Furthermore, ischemic injury after transient global ischemia was mitigated, not augmented, in 
neuron-specific HIF-1u-deficient mice (Helton, Cui et 01. 2005). Therefore, the involvement of 
HIF-1a-mediated gene expression in brain ischemic tolerance does not appear to be robust. 
HIF might actively down-regulate oxidative metabolism by lowering mitochondrial biogenesis, 
augmenting glycolysis, decreasing metabolite entry into the citric acid cycle, promoting 
removal of free-radical-generating mitochondria by autophagy (Tracy and Macleod 2007), 
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(Zhang, Li et 01. 2008) and optimising respiratory efficiency by the differential regulation of 
cytochrome oxidase :,ubunits (Fukuda, Zhang et 01. 2007). 
Tolerance mechanisms, working at the level of endoplasmic reticulum function, result in 
improved rates of recovery of neuronal protein synthesis (Paschen and Mies 1999); 
specifically, better preservation of the initiation and elongation steps of transcription, and 
increased levels of the chaperone heat shock protein 70 (HSP70) are realized (Hayashi, Saito et 
01. 2003). HSP70 contributes to preconditioning maintaining mitochondria physiology, 
inhibiting intrinsic and caspase independent apoptosis; inhibiting programmed necrosis; 
contributing to initiation of the inflammatory response acting by "danger signal" for the toll 
like receptors; suppressing the up-regulation of matrix metalloproteinases, involved in the 
inflammatory response. 
In addition during preconditioning, post-ischemic protein aggregation, redistribution and 
conjugation are reduced. The rate of repair of oxidative DNA damage is also enhanced (Li, Luo 
et 01. 2006). Overall, many facets of ischemic mitochondrial dysfunction, including changes in 
the redox activity of the respiratory chain components, oxidative phosphorylation deficits 
(Dave, Saul et 01. 2001), calcium overload and the initiation of apoptosis, are abrogated in 
ischemic tolerance (Zhang, Du et 01. 2003). Compared with the naive brain, the preconditioned 
brain also shows post-ischemic increases in the Mn and CuZn isoforms of superoxide 
dismutase (Garnier, Demougeot et 01. 2001), glutathione peroxidise and glutathione reductase 
(Arthur, Lim et 01. 2004), uric acid (Glantz, Avramovich et 01. 2005), and heme oxygenase-1 
(Garnier, Demougeot et 01. 2001), which enhance the tissue's capability to scavenge free 
radicals, contributing to the protective phenotype. 
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Glutamate is an excitatory neurotransmitter well known for its capability to kill neurons 
through the N-methyl-D-aspartic acid (NMDA) receptor -mediated mechanism. Some evidence 
(Bond, Lodge et 01. 1999), (Grabb and (hoi 1999) suggests that a mild activation of the NMDA 
receptor is involved in the protective effect of the ischemic tolerance and this neuroprotection 
could be achieved by two different mechanisms. One is a rapid calcium adaptation that may 
alleviate the neuronal damage caused by calcium overload (Shimazaki, Nakamura et 01. 1998); 
the other is the rapid release of the brain-derived neurotrophic factor (BDNF), which activates 
its cognate tyrosine kinase B (TrkB) receptors. Both NMDA and TrkB activate NF-KB, which 
protects against oxidative stress-induced apoptosis. Brain ischemic preconditioning results in a 
robust release of the gamma-aminobutyric acid (GABA), an inhibitory neurotransmitter, and 
the GABAa receptor seems to be the receptor activated during neuroprotection (Dave, Lange-
Asschenfeldt et 01. 2005). Adenosine (an endogenous neuroprotectant that can inhibit the 
release of excitatory amino acids), adenosine A1 receptors and ATP-sensitive K+ channels play 
an essential role in the ischemic preconditioning (Heurteaux, Lauritzen et 01. 1995). In fact 
after ischemia, adenosine increases and inhibits synaptic transmission, decreases K+ -stimulated 
glutamate release, and inhibits presynaptic calcium fluxes via adenosine A1 receptors. 
Activation of the innate immune response is a consequence of stroke, and preclinical data 
indicate that inflammation contributes to ischemic brain injury (Wang, Tang et 01. 2007). 
Inflammatory stimuli can also induce ischemic tolerance. The production of pro-inflammatory 
cytokines is initiated by signalling cascades involving Toll-like receptors (TLR), which recognise 
host-derived molecules released from damaged tissue as well as common molecular motifs of 
invading pathogens. These proteins can exacerbate ischemic injury (Lehnardt, Lehmann et 01. 
2007; Tang, Arumugam et 01. 2007; Kilic et 01.2008) or, as in the case of TLR 2,4, and 9, could 
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mediate ischemic tolerance in the brain (Stevens and Stenzel-Poore 2006; Hua, Ma et 01. 2008; 
Stevens, Ciesielski et 01. 2008) and others might be involved (Kariko, Weissman et 01. 2004). 
Although the genomic reprogramming induced by Toll-like receptors differs from the gene 
expression pattern induced by ischemic preconditioning, the degree of protection is similar. 
Cerebral ischemia might activate adaptive immunity and innate immunity. The adaptive 
immune response is characterised by lymphocytes that recognise and respond to specific 
antigens; however, this response depends on the environment in which the lymphocytes 
initially encountered the antigen, driving the differentiation into different effectors cell types 
(Weaver, Harrington et 01. 2006). Because inflammation seems to worsen stroke outcome, 
induction of regulatory T cells to limit CNS inflammation presents a new opportunity for stroke 
treatment. Although these cells are activated in an antigen-specific way, they could control the 
immune response in an antigen non-specific way, an event referred to as bystander 
suppression (Miller, Lider et 01. 1991). Stroke induces dynamic changes in brain cytokines such 
as tumour necrosis factor (TNF-alpha), interleukin (IL-1b and IL-6), suggesting that different 
types of T-effector cells and regulatory T cells could emerge depending on the timing of the 
lymphocyte-antigen encounter. Experimental data indicate an upregulation of the endogenous 
regulatory T-effector cells after stroke (Becker, Kindrick et 01. 2005; Offner, Subramanian et 01. 
2006) and recently were reported to be cerebroprotective immunomodulators against stroke 
(Liesz, Suri-Payer et 01. 2009). 
Vascular remodelling could contribute to reducing the severity of the subsequent test ischemia 
by improving collateral blood supply in stroke models, thereby complementing the possible 
adaptation of energy metabolism and brain cell membrane ionic homeostasis (Obrenovitch 
2008). There is convincing evidence that the cerebrovascular system has such an adaptive 
capability through arteriogenesis (Heil and Schaper 2005) and angiogenesis (Greenberg and Jin 
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2005). When both carotid arteries are ligated in rats to produce a chronic hypoperfusion, 
cerebral blood flow (CBF) drops sharply right after the occlusion, but then increases gradually 
during the following weeks (Farkas, Luiten et 01. 2007; Otori, Katsumata et al. 2003), and 
recent studies confirmed that both arteriogenesis and angiogenesis may contribute to this 
adaptive process (Choy, Ganesan et 01. 2006; Ohtaki, Fujimoto et 01. 2006). Ischemic 
preconditioning in rats improved CBF during the reperfusion that followed the subsequent 30-
min forebrain ischemia, and this functional effect was associated with reduced brain oedema 
(Vlasov, Korzhevskii et 01. 2005). An up-regulation of endothelial nitric oxide synthase (eNOS) 
may also contribute to improved recirculation in tolerant brain regions, since increased 
expression of eNOS mRNA was associated with ischemic tolerance induced by ischemic 
preconditioning (Hash iguchi, Yano et 01. 2004). 
The BBB is anatomically defined by the tight junctions between adjacent endothelial cells lining 
the lumen of cerebral microvessels, but the BBB function also involves astrocytes, pericytes, 
neurons, and the extracellular matrix (Wolburg and Lippoldt 2002; de Vries, Kuiper et 01. 1997). 
The latter constitutes the basement membrane underlying the vasculature, and its disruption 
is strongly associated with increased BBB permeability in pathological states (Hawkins and 
Davis 2005). BBB breakdown with associated vasogenic oedema is an important and early 
feature of ischemic brain damage and appears as a precursor and good predictor of poor 
outcome (Latour, Kang et 01. 2004). Several studies have shown that ischemic tolerance 
includes a better preservation of the BBB and reduced oedema formation during the test 
ischemia (Masada, Hua et 01. 2001; Zhang, Chen et 01. 2006; Gesuete, Orsini et 01. 2011; 
Gesuete, Packard et 01. 2012). It is difficult to determine whether the preservation of BBB 
integrity contributes to, or is a consequence of, reduced ischemic damage. From mechanistic 
point of view, it is clear that a reduction of the brain inflammatory responsiveness is likely to 
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help maintain BBB integrity. However, preservation of BBB integrity may be a primary and 
important feature of ischemic tolerance, given that it is the interface between 
damaged/vulnerable tissue and circulating inflammatory cells during recirculation. 
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1.3. MASS SPECTROMETRY AS CORE-TECHNOLOGY FOR 
PROTEOMIC AND METABOLOMIC ANALYSES 
This project utilized mass spectrometry both for proteomic and metabolomic analyses of 
cerebral ischemic preconditioning. It is therefore appropriate to review some of the underlying 
principles to provide the reader with a comprehensive overview of the studies. 
1.3.1. Principle of Mass Spectrometry 
Mass spectrometry (MS) is an ana lytical technique that measures the mass to charge ratio 
(m/z) of a charged species based on its response to electric and/or magnetic fields (Baldwin 
2004; Domon and Aebersold 2006). As shown in figure 1.8, mass spectrometers consist of 
three basic components: an ion source, a mass analyzer and a detector. The ion source 
converts sample molecules into ions in gas phase, the mass analyzer separates the various 
ionised species according to their m/z ratios, and the detector records signal intensity at each 
m/z value. Conventionally, mass spectra are presented as a plot of m/z value against relative 
intensity. In proteomics, it is possible to use several types of mass spectrometers that differ in 
their physical principle, performance standards, mode of operation and ability to support 
specific analytical strategies (Guerrera and Kleiner 2005; Guerrero, Tagwerker et al. 2006; 
Wysocki, Resing et al. 2005). 
Figure 1.8. A block diagram indicating the main regions of a mass spectrometer 
(http ://people.stfx.ca/tsmithpa/Chem361/la bs/ms.html). 
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The two most common ionisation methods used at the moment in the analysis of peptides and 
proteins are matrix assisted laser desorption ionisation (MALOI) and electrospray ionization 
(ESI) (Wysocki, Resing et 01. 2005), while the four basic types of mass analysers are ion trap, 
quadrupole, time-of-flight, and Fourier-transform ion cyclotron analysers. 
For the work described in this thesis, two different mass spectrometers were used: the first 
was an HPLC-Chip coupled to an ESI-IT (ion trap) MS/MS (Agilent Technologies) (Figure 1.9a), 
used to identify the proteins separated on 2-DE gels; the second one was an LC-LTQ Orbitrap 
XL™ (Thermo Scientific) (Figure 1.9b), which was used to identify the proteins separated by the 
i-DE analysis and to perform untargeted metabolomic analyses. 
A B 
Figure 1.9. An overview of our Agilent 1200 Series HPLC-Chip/MS system (A) and our Thermo LTQ Orbitrap XL'M (B) . 
1.3.1.1. The significance of tandem mass spectrometry in proteomics 
MS-based proteomic methods divide into two different strategies, top-down and bottom-up 
(Millea, Krull et 01.2006; Wysocki, Resing et 01. 2005). In the top-down approach, intact protein 
ions are introduced into the gas phase and their masses are measured. Subsequent 
fragmentation may provide additional structural information in the form of partial amino acid 
sequences. In the bottom-up approach, proteins are cleaved with a proteolytic enzyme and 
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the resulting peptides are analyzed in the gas phase by MS. This approach is more widely used 
since MS of whole proteins is less sensitive than peptide MS, and the mass of an intact protein 
by itself is often insufficient for identification (Aebersold and Mann 2003). In this study a 
bottom-up approach was used. Currently, there are two major methods for proteins 
identification by MS analysis in the bottom-up proteomics approach : peptide mass 
fingerprinting and peptide sequencing by tandem MS (also known as MS/MS analysis). In 
peptide mass fingerprinting, the masses of the intact peptides in a protein digest are 
determined, and protein identification is based on the comparison of the experimentally 
determined peptide mass values with the predicted molecular mass of the peptides generated 
by a theoretical digestion of each protein in a database In MS/MS analysis, instead, protein 
identification relies on sequencing of its enzymatically cleaved peptides. Peptide ions are 
separated in a first mass analyser. Selected parent ions are fragmented, and the fragment ions 
are separated in the same/or a second mass analyser to produce information on the amino 
acid sequence of the peptide. The resulting tandem mass spectra are compared with computer 
generated fragmentation models derived from all the tryptic peptides computed from the 
entries in a protein or translated nucleic acid database. Various dissociation methods are used 
to fragment ions, but gas phase collision induced dissociation (CIO) is the most common. The 
CIO process involves multiple low energy collisions of the peptide precursor ion with an inert 
gas, which converts translational energy into vibrationally excited states, eventually resulting 
in bond cleavage. The fragments produced are the result of N-terminal and C-terminal 
fragmentations across the peptide bond to give sequence ions with charge retention on either 
the acylium ion fragment, which retains the original N terminal residue (b-type ion), or 
ammonium ion fragments retaining the C-terminus (y-type ion) (Figure 1.10) (Roepstorff and 
Fohlman 1984). Tryptic peptides by definition have readily protonated arginine or lysine 
residues at the C-terminus, which favour charge retention on the C-terminal containing 
fragment. Therefore, in their low energy CID spectra, y-type ions usually predominate, though 
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internal lysine or arginines resulting from incomplete tryptic cleavage, or histidines towards 
the N-terminus, can increase the incidence of b-type cleavages. Instrument type and geometry 
can also exert a significant influence on detailed fragmentation patterns (Steen and Mann 
2004) . 
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Figure 1.10. Peptide fragmentation nomenclature. 
Other fragments, derived from loss of water or ammonia from these ions, are commonly 
observed. B-ions can eliminate carbon monoxide, forming a-ions. Other common ions in the 
mass spectra are immonium ions (H 2N=CHR, where R is the amino acid side chain) and internal 
fragments containing neither the original N- or C-terminal residue. 
1.3.1.2. Sample introduction into the mass spectrometer 
The choice of sample introduction method depends on the mode of ionization employed, and 
on the complexity/purity of the sample. Samples that are well desalted, and that contain 
relatively few components of reasonable abundance, may be infused directly. In most cases, 
however, online liquid chromatography is the preferred introduction method, particularly in 
the case of ESI which, being a solution-phase technique operating at atmospheric pressure, is 
intrinsical.~y compatible with liquid chromatography. The experiments reported in this work are 
based on reversed phase liquid chromatography (RP-LC) coupled to MS. In this technique, the 
stationary phase is less polar than the mobile phase and hydrophobic interactions are the main 
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mechanism of analyte retention on the column. The RP-LC columns most commonly used in 
peptide separations are packed with a stationary phase composed of non-polar C18-alkyl 
chains covalently attached to silica particles. RP-LC usually achieves a considerable increase in 
the concentration of samples entering the ionisation source, since relatively large volumes of 
diluted sample in aqueous solution can be pumped through the column, with the analytes of 
interest being initially retained as a narrow band at the top of the column, and components 
being sequentially eluted as the proportion of organic solvent in the mobile phase is increased. 
This concentration effect is enhanced by using columns with small bore, as the same amount 
of sample will be eluted in a smaller volume. The signal-to-noise ratio is generally further 
improved by RP-LC because most ionic buffers and inorganic salts are not retained on RP 
columns, and so they can be diverted to waste. Reversed phase chromatography generally 
increases the number of peptides detected in complex mixtures because fewer separate 
components enter the source at anyone time, so the duty cycle of the mass spectrometer can 
be more efficiently exploited. 
1.3.2. Ion sources 
All the mass spectrometers used in my studies were equipped with ESI sources. ESI was first 
described by Dole and was developed as a practical ionization source for mass spectrometry, 
initially on quadrupole instruments, by John Fenn (Fenn, Mann et al. 1989). The mechanism of 
electrospray is visualized in Figure 1.11. ESI is an atmospheric pressure ionization technique in 
which the sample solution is sprayed from a fine capillary (usually around 10 ~m in diameter), 
which is maintained at a high potential difference with respect to the ion source orifice of the 
mass spectrometer. This voltage is applied either via direct contact with an electrode, or 
through a (metallic) coating on the spray tip. The potential difference generates a force 
extending the liquid to form a cone at the capillary tip (the Taylor cone) from which a fine mist 
of electrically charged droplets emerges. Positive charge is conferred by the presence of 
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protons or other cations. These droplets rapidly become smaller, due to evaporation of solvent 
molecules unt il Coulombic repulsion causes fission, forming smaller droplets with reduced 
charge density. 
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Figure 1.11. Schematic view of ESI (adapted from w eb source University of Bristol) . 
There are two mechanisms proposed for the desolvation and charging of analytes within the 
droplets: ion evaporation and charge residue models (IEM and CRM, respectively) . The IEM 
was the first mechanism to be proposed. This model states that when the droplets become 
smaller, the electric field will become strong enough to expel ions into the ambient gas. 
Evaporated ions can remain somewhat solvated. This model applies mainly to small ions. For 
the ionization and evaporation of proteins, i.e. considerably large ions, the CRM is more 
applicable. In this model large droplets dissociate via a sequence of Rayleigh instabilities, called 
Coulombic explosions, into successively smaller ones until eventually only one analyte 
molecule per droplet remains. Further evaporation of solvent results in fully desolvated 
charged protein molecule. The charges are statistically distributed over the analyte's potential 
charge bearing sites, enabling the formation of multiply charged ions. 
38 
1.3.3. Mass analyser 
The mass spectrometric analyses reported in this thesis were obtained using an Agilent MSD 
XCT Ultra (quadrupole ion trap mass analyzer) and an LTQ Orbitrap XL™ (Thermo Scientific), 
which is a hybrid mass spectrometer, composed of a linear ion trap and an orbitrap mass 
analyzer. 
3.3.1. Quadrupole ion trap 
The quadrupole ion trap (Figure 1.12), usually referred to simply as the ion-trap, is based on 
the same theory as the quadrupole analyzer with the quadrupole field generated within a 
three dimensional trap. 
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Figure 1.12. A schematic cutaway view of a Quadrupole Ion Trap Mass Analyser (adapted from web 
source University of Bristol) . 
The ion trap itself is filled with helium and comprises a ring electrode and two end cap 
electrodes, creating the electric field by applying a large frequency (RF) voltage to the ring 
electrode. The orbiting motion of the ions in the trap is governed by the large RF voltage and 
the cooling effects of collisions with the helium gas (that reduces the kinetic energy of the ions 
and helps focus the ions in the centre of the trap). A mass spectrum is acquired by sequentially 
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ejecting fragment ions from low mlz to high mlz. This is performed by scanning the RF voltage 
to make ion trajectories sequentially become unstable, the mass selective instability mode 
developed by Stafford's group (March 2009). A product ion MS/MS spectrum is obtained via 
resonance excitation. The precursor ion is isolated by the application of a waveform signal to 
the endcap electrodes. Fragmentation of the precursor ion is caused by the application of a 
small voltage across the endcap electrodes and collision with helium gas. 
The linear ion trap is a MS analyser that can store, isolate, and fragment ions. The basic design 
of the linear ion trap, composed by a square array of hyperbolic rods, is shown in Figure 1.13. 
Figure 1.13. A picture of the linear ion trap (adapted from Schwartz, Senko et al. 2002). 
The LTQ XL uses three direct current (dc) axial trapping voltages, one for each rod section, that 
establish axial (Z-axis) trapping by lowering the potential of the center section below the 
potential of the front and back sections. 
(http://www.thermo.com/eThermo/CMA/PDFs/Various/File_26638.pdf) 
The ion isolation waveform voltage, resonance excitation RF voltage, and resonance ejection 
RF voltage are ac voltages that are applied to the exit rods to stimulate motion of the ions in 
the direction of the ion detection system. The voltages applied to the exit rods are equal in 
amplitude but are 180 0 out of phase to one another. When the ac frequency applied to the 
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rods equals the resonance frequency of a trapped ion (which depends on its mass) the ion 
gains kinetic energy and is ejected from the mass analyzer in the direction of the ion detection 
system (X direction). The ion isolation waveform voltage consists of a distribution of 
frequencies containing all resonance frequencies except for those corresponding to the ions to 
be trapped. The ion isolation waveform voltage, in combination with the main RF Voltage, 
ejects all ions except those of a selected mass-to-charge ratio or narrow ranges of mass-to-
charge ratios. During the collision-induced dissociation step, the resonance excitation RF 
voltage is applied to the exit rods to fragment parent ions into product ions. The resonance 
excitation RF voltage is not strong enough to eject an ion from the mass analyzer. However, 
ion motion in the radial direction is enhanced and the ion gains kinetic energy. After many 
collisions with the helium damping gas, which is present in the mass analyzer, the ion gains 
enough internal energy to cause it to dissociate into product ions. The product ions are then 
mass analyzed. During ion scan out, the resonance ejection RF voltage facilitates the ejection 
of ions from the mass analyzer and thus improves mass resolution. The resonance ejection RF 
voltage is applied at a fixed frequency and increasing amplitude during the ramp of the main 
RF voltage. Only when an ion is about to be ejected from the mass analyzer cavity by the main 
RF voltage is it in resonance with the resonance ejection ac voltage. When an ion approaches 
resonance, it moves farther away from the centre of the mass analyzer, where the field 
generated by the main RF voltage is zero (and space-charge effects are strong), into a region 
where the field produced by the main RF voltage is strong (and space-charge effects are small). 
As a result, the ejection of the ion is facilitated, and mass resolution is significantly improved. 
A limitation on the use of linear ion traps is represented by the low stability of fragment ions 
with an mlz values less than 30% of the mlz for the precursor ion selected for fragmentation 
during MS/MS analyisis; this limitation, also known as one-third rule, is particularly important 
on low molecular weight metabolites analisys due the unreliable MS/MS detection of the 
metabolites fragment ions. 
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1.3.3.3. The Orbitrap mass analyser 
The orbitrap is an axially-symmetrical mass analyser composed of a spindle-shape central 
electrode surrounded by two bell-shaped outer electrodes, using the principle of orbital 
trapping in electrostatic field (Hu, Noll et al. 2005) (Figure 1.14). 
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Figure 1.14. Cutaway view of the orbitrap mass analyser. Ions are injected into the Orbitrap at the pOint indicated 
by the red arrow. (adapted from Hu, Noll et 01. 2005). 
Ions beams are injected in the Orbitrap with a velocity perpendicular to the long axis of the 
Orbitrap (the z-axis) so that ions start coherent axial oscillations without the need for any 
additional excitation cycle. During ion injection a rapidly changing electric field is created by 
shaping the electrodes appropriately to prevent collision of the ions with electrodes and ions 
are trapped around the inner electrode. The electrostatic attraction towards the central 
electrode is compensated by a centrifugal force that arises from the initial tangential velocity 
of ions. After ions have entered the Orbitrap, a stable electrostatic field is achieved, and image 
current detection is subsequently performed. During ion detection, stable ion trajectories 
rotate around the axial central electrode with harmonic oscillations along it. The frequency w 
of these oscillations along the z-axis depends only on the ion mass-to-charge ratio m/z and the 
instrumental constant w:V(z/m) * k. Two split halves of the outer electrode of the Orbitrap 
detects the image current produced by the oscillating ions. By Fast Fourier Transformation 
(FFT) of i 'he image current, the instrument obtains the frequencies of these axial oscillations 
and therefore the mass-to-charge ratios of the ions. During ion detection the outer electrode is 
split in half at z=O by an insulating ceramic ring. Moving from one half outer electrode to the 
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other, packets of positive ions characterised by a precise mass-to-charge ratio induce opposite 
currents on these halves, thus creating a signal to be detected by differential amplification (Hu, 
Noll et al. 2005). The amplitude of the created current is proportional to the number of ions in 
the analyser cell, while its frequency is the same as the frequency of ion axial oscillations. 
Because the frequency of axial oscillation is function of m/z, it is possible to obtain a spectrum 
as a function of m/z. The ions are therefore detected without ever colliding with the electrodes 
and this non-destructive scheme allows improved sensitivity. Moreover, since frequencies can 
be measured with very high precision, it is possible to achieve a high-accuracy mass 
measurement and high resolving power similar to those achievable with FT-ICR 
instrumentation (Schenk, Schoenhals et al. 2008). In contrast with FT-ICR, which is also based 
on Fourier-Transform principle, the Orbitrap does not require a superconducting magnet and 
supplies of liquid helium. 
API Ion Source Linear Ion Trap C-trap 
Differential Pumping 
Figure 1.15. Schematic view of the LTQ orbitrap (adapted from www.thermo.com). 
Depending on the requirements for the analysis, the two analysers (LTQ and Orbitrap) that 
form the" hybrid LTQ Orbitrap XL™ (Thermo Scientific) (Figure 1.15) instrument can be used 
independently or in concert. There are in fact several possible ways of operation in the linear 
ion trap hybrid system. In my experiments the two mass analysers were configured as follows: 
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ions generated by API were collected in the L TQ XL followed by axial ejection into the C-shaped 
storage trap, which was used to store and collisionally cool ions before injection into the 
orbitral trap. In the orbitrap mass analyser I performed the measurement of the precursor 
ions, while the linear ion trap was used to perform MS/MS experiments. The benefit of this 
configuration is that both mass analysers work in parallel, while a high resolution/high mass 
accuracy spectrum of the precursor ion is acquired in the orbitrap, the fast linear ion trap 
carries out fragmentation and detection of MS/MS spectra of selected ions. Parallel operation 
is achieved because the initial small part of the high resolution spectrum can be used for data-
dependent selection of precursors, which are then fragmented while the high resolution mass 
spectrum is still being acquired. It has been shown that one orbitrap spectrum acqui red at the 
resolving power 60 000 and 3-5 linear ion trap fragmentation spectra are obtained within 1 
second (Yates, Cociorva et 01. 2006). This configuration is particularly convenient for proteomic 
and metabolomic studies, because the very accurate and resolved measurement of precursor 
ion masses enables reduction of the false positive rate of rnolecules identification. 
1.4. INTRODUCTION TO PROTEOMIC ANALYSIS 
The term "proteome" was coined in 1996 to describe the set of all proteins encoded by the 
genome (Wilkins, Pasquali et 01. 1996). The study of the proteome was thereafter called 
"proteomics", a term that now encompasses not only all the proteins in any given cell, but also 
the set of all isoforms and modifications, the interactions between them, the structural 
description of proteins and their higher-order complexes, and for that matter almost 
everything "post-genomic" (Tyers and Mann 2003). The greatest challenge for proteomics 
technology is the inherently complex nature of cellular proteomes. A proteome is a highly 
dynamic entity: protein expression in a biological system changes with the state of 
development, in response to environmental stimuli, with the progression of a disease, etc. In 
addition, different ce lls within a multicellular organism have different proteomes. Moreover, 
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the dynamic range of protein expression spans seven or eight orders of magnitude and, 
consequently, proteins are present in vastly different quantities. With its ever-growing array of 
analytical, biochemical and bioinformatic tools and approaches, proteomics has now the 
power to identify the protein profile of different cell types, to assess differential expression 
between healthy and diseased tissues, and to discover their specific functions and interactions 
(Yarmush and Jayaraman 2002). Accordingly, an improved knowledge of ischemic 
preconditioning IP/IT should help to identify neuroprotective strategies potentially capable of 
suppressing multiple, parallel pathophysiological events that cause ischemic brain damage. In 
the brain, ischemic preconditioning triggers several adaptive molecular responses of cells to 
injury, characterized by different time frames during which proteins seem to playa relevant 
role. For instance, a rapid and short-lasting protection can be established within minutes of 
exposure to ischemic attack, as a result of post-translational modification of proteins. A second 
phase develops more slowly and requires gene activation and de novo synthesis of proteins 
(Barone, White et 01. 1998). 
A previous proteomic analysis of adult ischemic preconditioning rat brain showed increased 
expression of stress proteins such as chaperones, the intracellular "cleaning" molecules that 
contribute to the induction of tolerance (Dhodda, Sailor et 01. 2004). The authors performed a 
combined genomic and proteomics analysis showing the induction of putative neuroprotective 
transcripts such as heat shock proteins. Further, proteomic profile investigated by the 2-DE 
combined with MALDI-TOF analysis, confirmed the protein increased expression of the 
transcripts at 24 h after preconditioning suggesting also a temporal relationship between gene 
expression and neuroprotection (Dhodda, Sailor et 01. 2004). 
Moreover proteomics profiling of cortical neuronal culture showed that the proteosomal 
degradation of structural proteins after their ubiquitination results in a morphological 
phenotype change of neurons rendering them resistant to excitotoxicity (Meller, Thompson et 
01.2008). 
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So far, only a few studies in experimental models of IT, both in vivo and in vitro, have taken 
advantage of proteomic approaches though discovery-driven proteomic studies focused on 
f inding mediators of IP and brain injury are still limited (Stapels, Piper et 01. 2010; Dhodda, 
Sailor et 01. 2004) . 
In this study I applied two different proteomic approaches (Figure 1.16): 
1. Classical two-dimensional gel electrophoresis (2-D E) and liquid chromatography-tandem 
mass-spectrometry (LC-MSjMS) for the identification of differentially expressed proteins in 
various experimental conditions; 
2. One4 dimens/ona l gel electrophoresis (i -DE) In conjunction with LC-MS/MS for the 
identi ficat ion and semi-quantitat ion by spectral counts of proteins present in different 
experimental conditions. 
As indicated in Figure 1.16, these approaches have some common steps (in-gel digestion, 
MSjMS analysis, proteins identification and pathway analysis) that will be described in detail. 
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Figure 1.16. Proteomic workflows used in this study. 
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1.4.1. Two-dimensional gel electrophoresis analysis (2-DE) 
This approach comprises six main steps: (1) sample preparation, (2) protein separation by two-
dimensional gel electrophoresis (2-DE), (3) gel image analysis and statistical analysis, (4) in-gel 
digestion of spots with differentially expressed proteins and extraction of peptides, (5) 
separation of tryptic peptides by LC-MS/MS analysis, (6) identification of proteins by database 
searching. 2-DE and mass spectrometric analyses need both appropriate statistical and 
bioinformatics tools to minimize experimental artifacts and to avoid false positives or 
negatives in MS/MS protein identification. 
1.4.1.1. Sample preparation 
Sample preparation is a key step for good 2-DE results. Because of the great diversity of 
protein sample types and origi'ns, the best sample preparation procedure has to be 
determined empirically. An efficient and reproducible method is essential to get reliable 
analysis results. Ideally, the process will result in the complete solubilisation, disaggregation, 
denaturation and reduction of any disulfide bonds of the proteins in the sample. To fully 
analyse all intracellular proteins, the cells or tissues must be effectively disintegrated: the 
choice of the optimal disintegration method depends on the nature of the sample (e.g., cell 
suspensions, solid tissues) and whether the analysis is targeting all proteins or just a particular 
sub-cellular fraction. The protein composition of the cell lysate or tissue should be reflected in 
the pattern of 2-DE without any loss and the sample must not be contaminated with 
exogenous proteins. Moreover, the protein sample should be protected from proteolysis and 
contaminants (salt ions, phospholipids, nucleic acids) . 
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1.4.1.2. Protein separation by electrophoresis 
2-0E electrophoresis is the oldest technology used in proteomics, having first been described 
in 1975 by O'Farre ll and (separately) by Klose (O'Farrell 1975; Klose 1975),. It is a powerful and 
widely used method to analyze complex protein mixtures' extracted from different biological 
samples, since it allows the simultaneous separation of thousands of proteins according to two 
independent properties in two different steps. The first-dimension step, isoelectric focusing 
(IEF), separates the proteins according to their isoelectric point (pi). Proteins are amphoteric 
molecules, with acidic and basic buffering groups, that can become protonated or 
deprotonated depending on the pH of the environment: in basic environment the acidic 
groups become negatively charged, on the contrary, in acidic environment they become 
positively charged. The net charge of a protein is the sum of all negative or positive charges of 
its amino acid side chains; obviously, each protein has an individual net charge. The isoelectric 
point represents the pH at which -the net charge of the protein is zero; proteins are positively 
charged at pH values below and negatively charged at pH value above their pI. When an 
electric field is applied, a protein will start to migrate towards the electrode of the opposite 
sign of its net charge, until it will reach the pH of its isoelectric point, in which it has not net 
charge anymore and stops migrating. This is called the "focusing effect", which concentrates 
proteins at their pis and allows proteins to be separated based on very small charge 
differences. 
In the second-dimension step, sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
(50S-PAGE), the proteins are separated according to their molecular weights (MW), due to the 
ability of 50S to denature the proteins by wrapping their hydrophobic 'tails' around the 
polypeptide backbone. 5DS also disrupts hydrogen bonds, blocks hydrophobic interactions and 
substantially unfolds the molecules, minimizing differences in the molecular shape by 
eliminating the tertiary and secondary structures. Moreover, the proteins can be totally 
unfolded when a reducing agent such as dithiothreitol (DTI) is employed, since OTI cleaves 
48 
any disulfide bonds between cysteine residues. When an electric field is applied, the SDS-
denatured and negatively charged polypeptides move through a sieving polyacrylamide gel 
toward the anode, and thus they are separated by their molecular weights. Using 2-DE, 
proteins thus migrate to a co-ordinate on a 2D-gel defined by their molecular mass and pI. 
Thousands of different proteins can thus be separated, and information such as the protein pi, 
the apparent molecular weight and the relative amount of each protein can be obtained. 
Visualisation of proteins after their separation can be done with different staining techniques. 
Organic dyes like Coomassie R250 or Coomassie G250 (colloidal Coomassie) are widely used. 
Coomassie staining has a linear response of three orders of magnitude, but it suffers from low 
detection sensitivity in protein, though the colloidal version is somewhat better in this respect. 
Despite this limitation, colloidal Coomassie staining is still widely used, because of its low price, 
ease of use and compatibility with most subsequent protein analysis. Other visible staining 
methods include silver staining, which is generally more sensitive than Coomassie, though 
individual proteins are quite variable in their response and the range of linearity is rather 
limited. Moreover, some silver staining protocols show poor compatibility with MS analyses. 
Fluorescent dyes, such as Sypro Ruby, have a sensibility that is comparable to silver staining 
but their response is linear over a greater range of protein concentration (at least three orders 
of magnitude). Being end point stains the protocol is very simple, and they are highly 
compatible with in gel digestion and mass spectrometric analYSis (Gevaert and 
Vandekerckhove 2000; Scheler, Lamer et al. 1998), but they are unfortunately rather 
expensive. It is very important to know that different staining techniques stain protein 
differently: indeed, silver staining often produces a pattern different from the pattern 
achieved with Coomassie blue and other staining procedures like with Sypro Ruby (Gorg, 
Obermaier et al. 2000). 
An alternative to the classic 2-DE electrophoresis approach is represented by the difference gel 
electrophoresis (DIGE), introduced by Unlu et al. (Unlu et al. 1997). The DIGE consist in the 
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covalent labelling of proteins with different cyanine dyes (Cy2, Cy3 and Cy5) prior to IEF. After 
the SDS PAGE separation, the gels were acquired using the excitation wave light of each 
cyanine dyes. This technique overcomes the inter-gel reproducibility problems of the 2D-page 
since the proteins of the different samples are run on the same gel and can be compared each 
other. A cyanine labelled pool of all the samples is run on all gels for the normalization and the 
use of cyanine labelled internal standard allows the proteins quantification. 
1.4.1.3. Differential gel image analysis 
The reliable evaluation and the comparison of the complex 2-DE pattern by eye is impossible. 
Therefore, the gel images have to be converted into digital data with a scanner and compared 
using image analysis software. For an optimum computational analysis it is important to obtain 
a high resolution grey scale image ideally with a bit depth of 16 to maximise the number of 
distinguishable gray levels. The success of differential expression analysis depends critically on 
the accuracy and the reliability of the analytical software used for image processing. The 
software and the parameters chosen may have a profound effect on the interpretation of the 
protein pattern obtained and the amount of user intervention demanded during the analYSis. 
Currently, several 2-DE image analysis software packages are commercially available. These 
programs have been continuously improved and enhanced over the years in terms of faster 
matching algorithms with less manual intervention and greater automation. Novel algorithms 
offering more reliable spot detection, quantitation and matching have been introduced 
together with the inclusion of flexible statistical tools for a more robust differential expression 
analysis. This is the case of the state-of-the-art Progenesis SameSpots image analysis software 
(Nonlinear Dynamics, UK), which provides fully automated gel image processing (spot 
detection, gel alignment, spot matching and spot quantification). Indeed, SameSpots gel image 
analysis consists of a fast and streamlined 2D workflow, which includes an innovative visual 
tool for highly advanced and automated image alignment. The images are first aligned by 
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localised warping to an image selected as a master image. Then spots are detected 
simultaneously across all the images leading to one spot map, which is then overlaid on each 
warped gel image in the dataset leading to an identical spot outline across the gel series . After 
the alignment, SameSpots automatic analysis includes spot detection, background subtraction, 
normalisation and matching. The result is perfectly aligned images at the pixel level, with 100% 
matching and no missing values, which radically reduces the need for editing spot detection 
and re-matching. This method attempts to reduce the subjectivity of user matching and 
address the issue of missing values, which are a problem for data analysis as many techniques 
in multivariate analysis cannot be used with incomplete datasets. Results are then ready for 
validation and statistical analysis. This was the method used to calculate the protein 
abundance in the 2-DE brain analysis. 
1.4.1.4. 2-DE: strength and limitations 
The combination of 2-DE, MS and bioinformatics tools has been utilized extensively for 
proteomics research in industry and academia. The power of the 2-DE-based technology was 
early recognized by the research community and scientists from various disciplines were 
attracted to the field of proteomics. The 2-DE-based approach has several characteristics that 
are currently unmatched by other proteomics methodologies: 
• Hundreds of proteins can be resolved and visualized simultaneously on a single 2-DE gel; 
for each protein, the isoelectric point, the molecular weight and the relative quantity can be 
measured. 
• High-resolution capabilities of 2-DE allow the separation and visualization of post-
translationally modified (PTM) proteins. In many instances, PTM proteins can be readily 
located in 2-DE gels because they appear as distinctive horizontal or vertical clusters of spots. 
In addition, modified proteins can be revealed by MS analYSiS, when multiple spots of the 
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same protein are identified. On the other hand, several limitations and problem issues have 
been recognized to 2-DE proteomics approach: 
• The most important drawback of the 2-DE based proteomics is that it is not possible to 
analyze the entire proteome. Membrane proteins are not readily amenable to 2-DE (Santoni, 
Molloy et 01. 2000), because of their poor solubility in standard extraction solution. Moreover, 
proteins displayed in a single 2-DE gel represent only a portion of all the proteins that are 
present in the sample. Generally, proteins that are visualized in 2-DE gels by conventional 
staining methods are high-abundance proteins. The limit for the detection of proteins with 
Sypro-Ruby is approximately 1 ng (Le., 20 fmol for a 50 kDa protein) . Low-abundance proteins, 
which are not detected by conventional staining, include regulatory proteins, receptors and 
other proteins that play roles in cellular responses. 
Poor reproducibility of 2-DE patterns often results in difficulties during the spot matching. 
Correct identification of differentially expressed proteins can also be hindered by co-migrating 
proteins in a single spot, making it difficult to determine which protein is differentially 
expressed. The sources of variability that influence 2-DE results can mostly be grouped into 
two categories: biological and technical variability. The biological variability is due to genetic 
and/or environmental factors, differences in the physiological conditions of individual at the 
moment of sample collection. Technical variation can ensue not only from any stage of the 
experimental procedure, but also from reagents quality or handling variation . 
An important issue is the need to reduce technical and biological variation gaining increased 
power to detect treatment differences. A biological replicate is obtained analysing different 
samples from the same experimental group and any significant change in protein expression is 
considered significant above biological noise. A technical replicate is obtained when the same 
sample is analyzed multiple times. This allows the establishement of analytical technique 
variability. An ideal experiment design would always consist of a mix of biological and technical 
replicates, of which the biological replicates bear more weight for answering the underlying 
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biological questions. However, the reality of budget and sample limitations for biological 
variability assesment often force to compromise as in the case of this Thesis. To overcome 
resource constraints, often sample pooling is performed. Because pools represent averages, 
the dominant differences and similarities between experimental groups might be easier to find 
(Kendzioniski et 01 2005; Diz et 01 2009; Karp et 01 2009). The assumption of biological 
averaging is usually met in animal models where the source of bias (subject-to-subject 
variation) are small and can be neglected (Karp et 01 2009). However when sample pooling is 
performed, it is important to known that an artificially low variation has been created and 
consequently the p-values will look "better" than they might be if a biological variation was 
also included . 
Nevertheless, the identification of up- and down-regulated protein expression from pooled 
samples does not mean that the proteins are not interesting with the respect to the underlying 
biological population. It just means that there is no statistical confidence and the use of 
additional methods of validating the findings is highly recommended. 
1.4.2. One dimensional gel electrophoresis analysis (1-DE) 
To overcome 2-DE drawbacks, a large effort has been focused not only on improving the 
capabilities of 2-DE-based proteomics, but mainly on the developing of alternative approaches 
that significantly expand the array of tools available for proteome research. One of the most 
used and innovative is the i-DE gel approach for protein prefractionation coupled to high-
accuracy mass spectrometry for protein identification (i-DE-LC-MS/MS). Extracted proteins are 
quickly and broadly separated by i -DE gel to decrease the complexity of the samples, the gel is 
stained and cut into gel slices. The gel slices are then digested with trypsin, peptides extracted 
and identified by LC-MS/MS. The intensity of the resulting LC-MS/MS features is then used for 
relative quantification of peptides and proteins (details are reported in paragraph 1.4.2.4. 
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Quantitative approaches in proteomics). This workflow is capable of accurately identifying and 
quantifying thousands of peptides simultaneously. Advantage of this approach includes a 
comprehensive protein profile with re lative quantitative information for all the proteins 
identified in a sample. 
1.4.2.1. 1-DE and 2-DE approaches 
l-DE and 2-DE approaches represent different ways to separate complex mixtures of proteins, 
and provide different information at different level of the proteome. Only a limited subset of 
proteins is amenable to 2-DE, since this technique favours the detection of high abundant 
proteins with medium-size and medium hydrophobicity. However 2-DE allows the visualization 
of protein isoforms as multiple protein spots on 2-DE maps with either slightly different pi or 
molecular weight or both, as results of post-translational modifications (PTM). The l-DE-LC-
MS/MS method overcomes some 2-DE drawbacks providing a more complex protein 
repertoire and allowing a direct relative quantitation using the mass spectral output, but it 
cannot easily provide information on the presence of a protein PTM. 
1.4.2.2. Protein identification by Mass-Spectrometry 
Proteolytic digestion of proteins (Matherials and Methods, page 90) is particularly useful in 
both 2-DE and l -DE based workflows, since in-gel digestion provides a simple and efficient way 
of recovering the stained gel-entrained protein for subsequent characterization by MS. The 
most widely used enzyme is trypsin, which hydrolyzes the proteins on the C-terminal side of 
lysine and arginine, unless the following amino acid is proline. This is advantageous as every 
peptide other than the one including the original C-terminus has at least two sites for efficient 
protonation, the N-terminal amino group and the C-terminal basic residue, so peptides are 
readily ionized and detected as positive ions. Moreover, the presence of a basic residue at the 
C terminus favours simple and easily interpretable fragmentation pathways in collision-
induced dissociation experiments. 
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1.4.2.3. Protein identification and database searching 
The final stage is bioinformatic analysis of mass spectrometric data in order to allow 
identification and characterization of the proteins under study. Several search algorithms have 
been developed that compare the tandem mass spectra to a known in silico generated 
database of peptide spectra and identify the closest match or matches. The identified peptides 
are then used to derive their parent proteins. MS/MS search algorithms can be broadly 
classified in heuristic and probabilistic search algorithms (Omenn, States et al. 2005). The first 
category correlates the experimental MS/MS spectrum with a theoretical spectrum and 
calculates a score based on the similarity between the two spectra. These search algorithms 
are often based on the notion of "shared peak count" (SPC) since they simply count the 
number of peaks common to the two spectra. Sequest, Spectrum Mill, X!Tandem belong to 
this category. Probabilistic algorithms, such as Mascot, model the peptide fragmentation and 
calculate the probability that a particular peptide sequence produced the observed spectrum 
by chance. Although different search engines processing the same input spectra often produce 
comparable outputs, subtle differences remain (Fitzgibbon, Li et al. 2008) . An analysis can 
therefore benefit from the use of multiple search algorithms for consensus scoring (Wenger 
and Coon 2013; Omenn, States et al. 2005). 
In this work, I have used three different search algorithms: Phenyx, Mascot and X!Tandem . The 
Phenyx search engine applies a two-stage analytical strategy (see Table 2 in Material and 
Methods section) . The initial search typically uses stringent parameters with an extended 
database to obtain a filtered list of candidate proteins while minimising the computational 
overhead associated with too many combinatorial possibilities. In the second round a much 
more comprehensive search is performed on a limited database consisting only of the 
candidate proteins. This can encompass nonspecific cleavages and consider a wide selection of 
posttranslational and artefactual modifications. A search of a randomized version of the 
database enables estimation of the false-positive rate. The final assignments and associated 
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confidence levels calculated from the scores and the chosen database are then reported. The 
Mascot algorithm (http://www.matrixscience.com) is based on the MOWSE scoring algorithm. 
For each identified peptide, Mascot reports a probability-based ion score which is defined as -
lO*loglO(p) where p is the probability that the observed match between the experimental 
data and the database sequence is a random event. Knowing the size of the sequence 
database being searched it becomes possible to provide an objective measure of the 
significance of a result. Mascot also reports an expectation value (E-value) that is the number 
of matches with equal or better scores that are expected to occur by chance alone. Similar to 
Mascot, X!Tandem uses score distributions but extrapolates empirical Evalues to assess the 
significance of a peptide match, using cyclic permutations of all peptide candidates that are 
scored. Search algorithm mistakes in interpreting mass spectrometric data should lead to false 
positive identification of the protein/gene from which the peptide derives. False positive 
identification can arise for several reasons such as poor quality fragmentation, poor signal to 
noise ratio, amino acid sequence that do not produce a unique fragmentation pattern, but 
share enough of the same fragment ions to be indistinguishable from one another. In 
particular, small peptides, less than eight amino acids in length, may not produce a 
fragmentation pattern that achieves a unique result. To complicate this process there is the 
fact that often a peptide sequence exists in multiple proteins and without additional peptide 
data it would be impossible to determine which protein produced the peptide that generated 
the tandem mass spectrum (Sadygov, Cociorva et 01. 2004). A useful means to reduce the 
number of false positives is to perform a decoy search. During a decoy search, every time a 
protein sequence from the target database is tested, a random sequence of the same length is 
automatically generated and tested. The number of matches that are found from the "decoy" 
database is an excellent estimate of the number of false positives that are present in the 
results from the real or "target" database and allows an estimation of the quality of the 
obtained data (Elias and Gygi 2007). 
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1.4.2.4. Quantitative approaches in proteomics 
Earlier proteomic research was merely focused on the identification of proteins, but nowadays 
the quantitative and comparative aspects of proteomics increasingly attract the interest of 
researchers. Approaches employed in quantitative proteomics range from 2-DE to the more 
recent gel-free quantification methods (Ross, Huang et 01. 2004). In the 2-DE approach 
differences between samples are estimated by statistical analysis performed with image 
analysis software able to merge and compare a number of replicate sets of gels for controls 
and samples. In the last decade, in order to overcome the limitations of 2-DE related 
approaches (reported in the preceding section on 2-DE: strength and limitations), gel-free 
protein quantification methods alternative quantitative approaches were developed. These 
alternative quantitative approaches not only circumvent the 2-DE approach, but they 
significantly expand the spectrum of tools available for proteomic research. The numerous 
reported strategies to derive quantitative information from MS analysis can be classified into: 
1. Stable isotope labelling, based on the chemical tagging of proteins/peptides, followed by 
relative quantification of protein sample by LC-MS/MS analysis; 
2. Label free approaches. 
In protein-labelling approaches, different protein samples are combined together once 
labelling is finished and the pooled mixtures are then taken through the sample preparation 
step before being analyzed by a single LC-MS/MS experiment (Figure 1.17). In contrast, with 
label-free quantitative methods, each sample is separately prepared, then subjected to 
individual LC-MS/MS runs (Figure 1.17). 
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Figure 1.17. General approaches of quantitative proteomics. (a) Shotgun isotope labelling method, (b) label free 
quantitative proteomics. 
1.4.2.4.1. Stable isotope labelling approaches 
The stable isotope labelling strategies were first to emerge in the field of proteomics (Turck, 
Falick et al. 2007) . The prototypical stable-isotope labelling is isotope-coded affinity tags (lCAT) 
technology (Gygi, Rist et al. 1999). Proteins from two samples to be compared are labelled at 
cysteine residues with light and heavy tags carrying a biotin moiety, used for purification 
purposes. Light and heavy tags contain respectively hydrogen and deuterium atoms. A number 
of limitations to the prototypicallCAT technique has been reported (Patton 2002) and some of 
these have been solved by the new cleavable ICAT (cICAT) reagent, which employs C 13 
isotopes and an acid-cleavable biotin group (Hansen, Schmitt-Ulms et al. 2003) . Recently, a 
new quantitative method, isobaric tags for relative and absolute quantitation (iTRAQ), was 
developed (Ross, Huang et al. 2004). iTRAQ technology employs a 8-plex set of amine reactive 
isobaric ~.ags to derivatize peptides at the N-terminus and the lysine side chains, thereby 
labelling all peptides in a digest mixture. iTRAQ consists of three components, a balance group, 
a peptide reactive group, and a reporter group that have different masses (from 113.1 to 
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121.1). Preparing samples for iTRAQ is time consuming and expensive, making this approach 
less suitable for routine analysis. Moreover, the complexity of the sample is increased (Patel, 
Thalassinos et 01. 2009), and the dynamic range is low (about two orders of magnitude) (Ow, 
Salim et 01. 2009). In the quantitative approaches described above the labelling of 
proteins/peptides occurs after the proteins have been extracted, but a different technique 
called SILAC (stable-isotope labelling in cell culture) has been introduced where proteins are 
labelled in vivo (Ong, Blagoev et 01. 2002) . In SILAC, two groups of cells are grown in culture 
media that are identical except in one respect: one medium contains the 'light' and the other a 
'heavy' form of a particular amino acid (e.g. L-Ieucine or deuterated L-Ieucine). Then samples 
are combined and proteins are fractionated and quantified by LC-MS/MS. The SILAC approach 
has some interesting advantages, for example it does not require additional purifications to 
remove excess labelling reagent, nor does it involves multistep labelling protocols. SILAC 
enables discrimination between proteins derived from cells and those derived from other 
sources, such as serum. However, to obtain accurate quantitation the labelling process must 
be long enough to allow full incorporation of the heavy label (Ong, Foster et 01. 2003) and to 
guarantee a more complete sequence coverage in identification, the use of two labelled amino 
acids is advisable .. SILAC is quite impractical for the routine labelling of large organisms such as 
rats and mice, as the labelled amino acids are so expensive. Limitations of these labelling 
methods are mainly related to their high cost (Kuhner and Gavin 2007; Vandenbogaert, Li-
Thiao-Te et 01. 2008). 
1.4.2.4.2. Label free approaches 
The label free approaches have received increasing attention as alternative strategy of lower 
complexity and cost without the limitation in the number of compared samples. Free from the 
requirem~nt of sample mixing, the analysis can include data sets obtained at different time 
(Ackermann, Berna et 01. 2008). Protein quantification is generally based on the measurement 
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of ion intensity changes (such as peptide peak areas or peak heights in chromatography) or on 
spectral counting of identified proteins after MS/MS analysis (Van and Chen 2005; Zhu, Smith 
et 01. 2010). Peptide peak intensity or spectral counting is measured for individual LC-MS/MS 
runs and changes in protein abundance are calculated via a direct comparison between 
different analyses. Due to advances in instrumentation, specifically the stability and control of 
most of the physical properties of the analytical platform, it is possible to compare ion 
intensities of tryptic peptides without the need of labelling techniques. In LC-MS, an ion with a 
particular mlz is detected and recorded with a particular intensity, at a particular time. It has 
been observed that signal intensity from electrospray ionization (ESI) correlates with ion 
concentration (Voyksner and Lee 1999). In this study a label free approach was used to 
analyze the plasma proteome. 
1.4.2.4.3. Ion Intensity Changes 
The label-free quantification of the peptide/protein via peak intensity in LC-MS was first 
studied in 2002 on myoglobin peptides (Chelius and Bondarenko 2002), when the peak areas 
were found to increase with the increased concentration of injected peptides. Although this 
study showed that the relative quantification of the peptides could be achieved via direct 
comparison of peak intensity of each peptide ion in multiple LC-MS datasets, applying this 
method on the analysis of changes in protein abundances in complex biological samples had 
some practical constraints. First, experimental variations (sample preparation or sample 
injection) can lead to differences in the peak intensity of the peptides belong to the same 
sample from run to run. Thus, normalization is required to account for this kind of variation. 
Second, any experimental drifts in the retention time and mlz will significantly complicate the 
accurate comparison of multiple LC-MS datasets. Unaligned peak comparison will result in 
large vari~bility and inaccuracy in quantification. Thus, highly reproducible LC-MS and careful 
chromatographic peak alignment are required and critical in this comparative approach. Last, 
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the large volume of data collected during LC-MS/MS analysis of complex protein mixtures 
requires the data analysis of these spectra to be automated. Therefore, several algorithms 
have been developed to automatically compare the peak intensity data between LC-MS 
samples with high throughput, such as those integrated in Scaffold (Proteome Software Inc, 
Portland, OR) or in MSQuant (Center for Experimental Bioinformatics, University of Southern 
Denmark) . 
1.4.2.4.4. Absolute and relative proteins quantification 
A label free approach can be used to perform not only relative protein quantification but also 
an absolute quantification (Silva, Denny et al. 2006) . 
The Protein Abundance Index (PAl), was initially defined as the number of identified peptides 
divided by the number of theoretically observable tryptic peptides for each protein, 
(Rappsilber, Ryder et al. 2002) and was then later converted to exponentially modified PAl 
(em PAl, the exponential form of PAl minus one) (Ishihama, Oda et al. 2005) . em PAl, as well as 
most of other label-free methods, has been shown to correlate well with protein abundance in 
complex samples (Ishihama, Oda et al. 2005) . em PAl takes into account the number of 
identified peptides, normalized against the number of identifiable peptides for a given protein. 
The formula is emPAI=10N observed/N observable_1, where N observed is the number of 
experimentally observed peptides and N observable is the calculated number of observable 
peptides for each protein. Ishihama (Ishihama, Oda et al. 2005) estimated the number of 
observable peptides by performing in silico digestion of protein sequences. The peptide list 
was then filtered to exclude peptides outside the mass spectrometer scan range and the 
observed nano-LC retention time range. The values of emPAI can be calculated easily with a 
simple script and do not require additional experimentation in protein identification, it can be 
routinely ·used for reporting approximate absolute protein abundance in a large-scale analYSis. 
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Recently, an alternative approach was developed termed absolute protein expression (APEX) 
profiling. This measures the absolute protein concentration per cell from the proportionality 
between the protein abundance and the number of peptides observed (Lu, Vogel et al. 2007). 
The key to APEX is the introduction of appropriate correction factors that make the fraction of 
expected number of peptides and the fraction of observed number of peptides proportional to 
another. The protein's absolute abundance is indicated by an APEX score, which is calculated 
from the fraction of observed peptides mass spectra associated with one protein, corrected by 
the prior estimate of the number of unique peptides expected from a given protein during a 
MudPIT (multidimensional protein identification technology) experiment. The MudPIT 
technology is a non-gel approach for the identification of proteins from complex mixtures that 
consists of a 2-dimensional liquid chromatography separation, prior to electrospray mass 
spectrometry). Another strategy is represented by the normalized spectral abundance factor, 
NsAF that divides counts by the protein length, analogously to the Fabb index, that normalizes 
by the protein molecular weight (Cappadona, Baker et al. 2012). Absolute protein copy 
numbers have been recently reported based on precursor ion currents (Schwan hausser, Busse 
et al. 2011) and the technique, called intensity-based absolute quantification (iBAQ), proposes 
the sum of peak intensities of all peptides matching to a specific protein, normalized by the 
number of theoretically observable peptides, as an accurate proxy for protein levels 
(Cappadona, Baker et al. 2012). 
In the spectral counting approach, relative protein quantification is achieved by comparing the 
number of identified Ms/Ms spectra from the same protein in each of the multiple LC-Ms/Ms 
data sets. This is possible because an increase in protein abundance typically results in an 
increase in the number of its proteolytic peptides, and vice versa. This increased number of 
tryptic digests then usually results in an increase in protein sequence coverage, the number of 
identified unique peptides and the number of identified total Ms/Ms spectra (spectral counts) 
for each protein (Washburn, Wolters et al. 2001). Liu et al. studied the correlation between 
62 
relative protein abundance and sequence coverage, peptide number and spectral count. It was 
demonstrated that among all factors of identifications, only spectral count showed strong 
linear correlation with protein abundance with a dynamic range over 2 orders of magnitude 
(Liu, Sadygov et 01. 2004). Moreover, it has been demonstrated that spectral counting yields 
good reproducibility between replicate experiments (Old, Meyer-Arendt et 01. 2005). 
Therefore, spectral count can be used to provide a semi-quantitative measure of protein 
abundance (Ishihama, ada et 01.2005; Lu, Vogel et 01.2007; Old, Meyer-Arendt et 01.2005). In 
contrast to the chromatographic peak intensity, which requires delicate computer algorithms 
for automatic LC-MS peak alignment and comparison, no specific tools or algorithms have 
been developed specially for spectral counting due to its ease of implementation. However, 
normalization and statistical analysis of spectral counting data sets are necessary for accurate 
and reliable detection of protein changes in complex mixtures. Overall spectral counting 
proved to be more sensitive method for detecting proteins that undergo changes in 
abundance, whereas peak area intensity measurements yielded more accurate estimates of 
protein ratios (Old et 01. 2005). A problem with the spectral counting approach could be the 
low sensitivity with the low abundant proteins, but as reported by Hoehenwarter 
(Hoehenwarter and Wienkoop 2010) this problem could be resolved using high mass accuracy 
mass spectrometer (like Orbitrap), minimizing redundant MS/MS acquisition and maximizing 
the resolution of the proteome by accurately measured m/z ratios From these considerations, 
the spectral counting approach was the label-free method chosen for quantifying the proteins 
in the plasma samples of this study. 
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1.5. INTRODUCTION TO METABOLOMIC ANALYSIS 
Metabolomics is a scientific discipline that aims to identify and quantify the meta bolo me, 
which is the total quantitative collection of small molecular compounds present in an 
organism or biological sample. Metabolomics was first discussed in 1998 by Stephen Oliver, 
who not only coined the term but saw the enormous potential of the application of 
metabolomics for functional genomics (Oliver, Winson et al. 1998) . 
Metabolites are the reactants and products of a metabolic network; therefore, the 
quantification of the metabolome provides a direct method for the analysis of internal 
metabolism kinetics (Buchholz, Hurlebaus et al. 2002). Metabolomics is a logical 
progression from the analyses of genes, RNA and protein at the systems level. It provides 
the correlation between genes and the functional phenotype of an organism, which is the 
ultimate purpose of a functional genomics approach. In contrast to transcriptomics and 
proteomics, metabolomics can provide direct evidence rather than indications of changes in 
biochemical pathways (Heijne, Kienhuis et al. 2005) . Metabolomics is considered to be a 
downstream analysis, in that the changes occurring in the metabolome reflect 
amplifications of the changes that occurred in the transcriptome and the proteome (Kell 
2005) . Another benefit of metabolomics is that, unlike a transcript or protein, a given 
metabolite is the same in every organism that contains it. Although the development of 
metabolomic methods and technologies is progressing rapidly, there are still issues and 
drawbacks that must be considered. DNA, RNA and proteins all have some structural 
properties in common, allowing the development of analytical methods that apply to 
basically all members of the class. On the other hand, metabolites within a cell have no 
shared chemical features on which a single general isolation, separation or identification 
method can be developed (Fridman and Pichersky 2005). The number of metabolites and 
derivatives of known metabolites expected in mammals, plants and bacteria is still largely 
unknown. Moreover it is difficult to assign changes in metabolite levels to changes in the 
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expression of specific genes and/or proteins . The metabolome is made up of very diverse 
compounds, ranging from ionic inorganic species to hydrophobic lipids, in a dynamic range 
of concentrations (Villas-Boas, Rasmussen et al. 2005) . Many major advances in the design 
and applications of analytical instrumentations for metabol.omics have been made over the 
past few decades, allowing a broader and more comprehensive study of small molecules. 
However, in order for the true potential of metabolomics to be realized, efforts must be 
focused on improving sensitivity as a truly comprehensive analysis of the metabolome is not 
yet technically possible. 
Since the cerebroprotection by ischemic preconditioning requires a complex response 
cascades that involves many genes, proteins and their products (metabolites) responsible for 
establishing the ischemia-tolerant phenotype, I decided to integrate my PhD project with a 
metabolomics investigation aimed at defining whether changes in circulating metabolites 
might have a link with brain and plasma proteomic profiles in my experimental model of 
ischemic preconditioning. 
The use of an integrated proteomics and metabolomics analysis allowed me to obtain a more 
comprehensive picture of the molecular changes that occur during ischemic preconditioning. 
1.5.1. Metabolomics approaches 
There are two fundamental approaches that can be used when analyzing metabolites: 
targeted and un-targeted. 
A targeted approach is restricted to the analysis of defined groups of chemically characterized 
compounds. Targeted metabolomic approaches are commonly driven by a specific biochemical 
question or hypothesis that motivates the investigation of a particular pathway. A robust 
improvement of this method had been made using triple quadrupole (QqQ) mass 
spectrometry. In the triple quadrupole (QqQ)-based targeted metabolomic workflow, standard 
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compounds for the metabolites of interest are first used to set up selected reaction monitoring 
methods. Here, optimal instrument voltages are determined and response curves are 
generated for absolute quantification. After the targeted methods have been established on 
the basis of standard metabolites, metabolites are extracted from tissues, body fluids or cell 
cultures and analysed. The data output provides quantification only of those metabolites for 
which standard methods have been built (Patti, Yanes et 01. 2012). The untargeted approach is 
the comprehensive analysis of all measurable analytes in a sample with no prior knowledge 
about their structure. The power of the non-targeted approach allows for the generation of a 
data-driven hypothesis, whereas a targeted approach is intended to address a hypothesis 
and not to generate a new one. To date there is not a single analytical method capable 
of detecting and quantifying all metabolites in a system. This is largely due to the chemical 
complexity of compounds that comprise the meta bolo me. However, there have been many 
advances made in metabolomics analyses and the combination of these technologies may 
make the detection of all metabolites attainable in the near future. 
1.5.2. Metabolomics technologies 
There are numerous technologies available for studying the metabolome, each with 
advantages and limitations. Mass spectrometry (MS) and nuclear magnetic resonance (NMR) 
are the most commonly applied analytical technologies in metabolomics studies. 
NMR is a powerful technique and is particularly useful in the structure elucidation of .unknown 
organic compounds. The main limitations of this approach are the complex computational 
requirements to resolve complex mixtures, the low sensitivity, and the cost of the NMR 
equipment that can be significantly more expensive than MS-based technologies (Villas-Boas, 
Mas et 01. 2005). MS is a widely applied technology in the study of metabolites as it provides a 
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system which is both sensitive and capable of identifying and quantifying a wide range of 
metabolites (Dunn, Bailey et 01.2005). 
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Traditionally, gas chromatography-mass spectrometry (GC-MS) and liquid chromatography-
mass spectrometry (LC-MS) have been used to study metabolites in a biological system. GC-
MS can be used for the simultaneous separation, identification and quantification of volatile 
and non-volatile metabolites. The advantages of using GC-MS for the analysis of biological 
metabolites are the high chromatographic resolution and the ability to simultaneously 
analyze different classes of metabolites (Villas-Boas, Mas et 01. 2005). The major drawbacks 
of this technology are that non-volatile compounds must be derivatized before they can be 
analyzed, large thermally-labile compounds cannot be detected due to their limited volatility, 
and that electron impact causes fragmentation (Dunn, Bailey et 01.2005; Villas-Boas, Mas et 01. 
2005). MS is a widely applied technology in the study of metabolites as it provides a system 
which is both sensitive and capable of identifying and quantifying a wide range of metabolites 
(Dunn, Bailey et 01. 2005). LC-MS is also capable of separating, identifying and quantifying a 
broad range of metabolites, especially metabolites with similar molecular masses. The 
advantages of this approach are that derivatization is not needed and thermo-labile 
metabolites can be analyzed; however, the potential for identification can be a limitation 
unless a MS-MS fragmentation approach is used (Dunn, Bailey et 01. 2005). Fourier Transform 
Ion Cyclotron Resonance-Mass Spectrometry (FTICR-MS) is a mass spectrometry platform, 
which is highly attractive for non-targeted metabolic profiling as it offers the highest 
mass accuracy and resolution of any other mass spectrometry technology. Although this 
analytical technique is very powerful, and extremely useful in metabolomic studies, it does 
have a few limitations that must be overcome in order for it to be a stand-alone metabolomic 
tool. These include the inability to discriminate between isomers, and a lower mass limit of 
approximately 100 Da. These limitations can be dealt with through the use of a targeted 
mass spectrometry platform, such as a liquid chromatography tandem mass spectrometer (LC 
MS/MS), which can be optimized to detect lower weight masses and discriminate between 
isomers. One of the new type of mass analyzer is the Orbitrap (Makarov 2000) in which a FTICR 
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ion detection is followed by a fast Fourier transform to convert the recorded time domain 
signal into a mass/charge spectrum and is characterized by an high mass accuracy (2-5 ppm) 
that make this kind of mass analyzer very useful for a metabolomic study. 
1.5.3. Mass-spectrometry based-metabolomic data analysis 
1.5.3.1. Data preprocessing 
Raw data acquired by MS are typically pre-processed to provide structured data in an 
appropriate format for data analysis. The data are pretreated to reduce noise and 
background, alignment of mass spectra or mass chromatograms, automated picking and 
annotation of mass spectrometric or total-ion/extracted ion chromatographic peaks of 
metabolic features. Currently several public and proprietary software tools exist to implement 
data export and subsequent data analysis. 
In this thesis I report the main characteristics of the commercially available software I used to 
analyze my metabolomics data. The software is SIEVE from Thermo Fisher, Cambridge, MA, 
US. 
The mass spectra obtained by non-target approach are analyzed using SIEVE v2, a software 
package that allows the semi-quantitative differential expression analysis. The first step in 
data elaboration is the alignment of all the raw chromatograms to make them comparable. 
The SIEVE software performs a chromatographic alignment using full scan spectra shape (no 
peaks). User-defined peak threshold like minimum height, signal to noise, width etc. are 
applied to detect MS peak. Alignment of drift (retention time and accurate mass) in data 
related to run order is performed and ensures that a chromatographic peak is identified with 
the same parameters in each sample. The second step is finding peaks, also called features. A 
metabolic feature is defined as a detected chromatographic peak with associated retention 
time and unique accurate mlz. An important issue is to relate peaks to individual ions and 
then to molecular species. A single metabolite is often detected as multiple metabolic 
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features, each having the same retention time, but a difference in m/z. The difference in m/z 
relates to different derivative ions of the same metabolite. Each molecule produces many ions 
(molecular fragments, adducts formation), even under the most gentle ionization conditions. 
As a result, a typical ESI LC-MS data set from a body fluid sample may contain tens of 
thousands of peaks (millions if one considers noise) that represent only hundreds of 
compounds. The SIEVE software uses a new signal detection algorithm called component 
extraction for automatic matching of the metabolic features derived from the same 
metabolite. Metabolic features derived from the same metabolite are identified, annotated 
and grouped together using accurate m/z, m/z differences, adduct relationship, retention time 
similarity, peak shape similarities. Consequently, metabolite identification for one metabolic 
feature is linked to all other derived metabolic feature for that metabolite. 
For identification of the features of interest, the SIEVE software provides a web services query 
Application Program Interface that links the software directly to metabolic spectral library 
databases such as ChemSpyder or others by Internet connection. 
1.5.3.2. Metabolite identification 
The effort required for identification of metabolites depends on the scope of the study, be it 
targeted or untargeted. If the search is for known metabolites the identification involves 
comparing the experimental data with that of pure standards. If the metabolites can be 
predicted, then the metabolic identification involves finding representative standards and 
searching for the predicted metabolites. If nothing is known about the metabolites in the 
experimental data, as in the untargeted strategy, the metabolite identification is much more 
complicated and does not provide 100% coverage. This approach is widespread in mass 
spectrometry-based metabolomics due to MS high sensitivity and hereby the possibility to 
discover"new and low-abundant metabolites. The identification strategy takes advantage of 
the accurate mass measurement and fragmentation pattern obtained from up-to-date 
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instrumentations such as the Orbitrap mass analyser that has high resolving power and 
excellent mass accuracy (1-5 ppm). Usually, identification by MS uses the accurate mass to 
define molecular formulae and to query electronic resources (metabolomic databases and 
mass-spectral libraries) . The accuracy of the mlz measurement defines the number of 
molecular formula matches; the greater the accuracy the lower the error range and the lower 
the number of molecular formula matches (Kind and Fiehn 2006). 
Usually, an experimentally determined accurate mass, within a specific mass error for a single 
metabolic feature, is matched to the theoretical accurate mass related to a single or multiple 
molecular compounds searching for molecular formulae in the databases to define putative 
metabolic identification. Various public mass-spectral libraries exist so far such as the Human 
Metabolome Database (HMO); METLlN; ChemSpyder; NIST; MassBank. However these 
repositories suffer from some intrinsic limitations. This is because the metabolome (e.g. 
human metabolome) has not been completely and experimentally characterized yet and 
therefore the libraries used for identification do not yet reflect all known metabolites. 
Moreover, not all metabolites of those known to be present can be synthesized or purchased 
to construct mass spectral libraries to aid identification processes. A further constraint exists 
for LC-MS libraries insofar as fragmentation spectra vary between different type of mass 
analyzer (Bristow, Webb et 01. 2004, Jansen, Lachatre et 01. 2005) . Thus the creation of 
universal libraries for LC-MC is impeded. Therefore, definitive identification of all detectable 
metabolites is not currently achievable and is a significant limitation in metabolic profiling. 
1.5.3.3. Network and pathway analysis ofproteomic and metabolomic data 
The increasing amount of data derived from global gene, protein and metabolite expression 
measurements necessitates the use of computational technologies to store, analyze, correlate 
and inte~pret this information. A major challenge of contemporary biology is to embark on an 
integrated theoretical and experimental program to map out, understand and model in 
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quantifiable terms the topological and dynamics proprieties of the various networks that 
control the behaviour of the cell (Barabasi and Oltvai 2004). The main aim of the network 
biology is to study and understand the interactions among molecules in a living cell. This is 
important since it is now clear that a discrete biological function cannot be ascribed to an 
individual molecule. Currently, several different pathway databases and network building tools 
are available, allowing the visualization of cellular components as networks of signalling, 
regulatory and biochemical interactions. Although most of these techniques were developed 
to accommodate the huge amount of data derived from gene microarray experiments, they 
have been applied to proteomic/metabolomic data more recently. Mapping of up- and/or 
down-regulated proteins or metabolites onto known pathways, combining functional 
enrichment and transcription regulation analysis, is indeed a useful means to provide 
information to supplement the conventional approach of linking proteins and metabolites to 
biological process via review of the literature. This may allow a richer interpretation of 
proteomic and metabolomic experiments, suggesting pathways involved in pathological 
processes and helping formulate new hypotheses to be tested and validated with different ad-
hoc approaches. 
In this thesis two different bioinformatic tools were used to understand the biological 
significance of proteomics and metabolomics data: the commercially available Metacore 
software package, and the public available MetaboAnalyst software. 
1. MetaCore (Thomson Reuters, NY, USA) is an integrated analytical suite of algorithms, based 
on a manually annotated and regularly updated databases of human and rodent protein-
protein interactions, transcriptional factors, signalling, metabolism and bioactive molecules 
linked to functional processes (ww~enego.com). The databases consist of millions of 
relationships between proteins and metabolites that are derived from literature publications 
on proteins and small molecules. The content of MetaCore's underlying database is packaged 
into pathway maps or networks that describe a biological function, then further organized into 
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ontologies, such as biological process or disease. GeneGo's biological process ontology consists 
of about 1000 networks that summarize regulatory functions. Networks provide a clear 
representation of complicated relationships between large numbers of elements 
(genes/proteins). These elements represent the nodes, often graphically depicted as small 
circle. Nodes are connected by links, called edges (Figure 1.18). 
node 
Figure 1.18. Schematic representation of the relationships provided from networks. 
Edges represent functional relationships or physical interactions between nodes. Depending 
on the nature of interaction, an edge can also have associated numerical values corresponding 
to the strength, or weight, of the relationship. In addition to representing a wealth of diverse 
data as a coherent and synthetic picture, networks can also be dissected according to the rules 
of network analysis, which helps extracting biological insights. MetaCore contains many 
options for network building. It currently has many network building algorithms (Analyze 
Network, Analyze transcriptional regulation, Analyze transcription factors, Analyze receptors, 
Shortest Paths, and Self Regulations, Direct Interactions, Auto Expand and Expand by One 
Interaction) as well as many options to modify these algorithms. Analyze network creates a 
large network and breaks it up into smaller sub-networks which can be built separately. The 
resulting networks are ranked by a p-Value. Analyze transcription regulation works similar to 
analyze network, but the subnetworks created are centered on transcriptional factors. The 
other two additional "Analyze" network algorithms (transcription factors and receptors) focus 
on the presence of either start-nodes or end-nodes of a certain pathway in the submitted list 
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of genes/proteins. As reported in the MetaCore user manual 
(https:/ /portal.genego.com/help/MetaCore_Advanced_ Training_Manual_S.O. pdf) the Direct 
interactions algorithm creates a network only from the objects in the original list; no other 
objects from the database will be added. This algorithm is good to start with because it can 
show if any of the objects in the list "cluster" together by interacting with each other. The Auto 
expand algorithm adds objects until it creates a fairly dense network; this is best used to see 
the neighboring interactions and objects around a few nodes. Finally, Expand by one 
interaction simply adds all the one-step interactions around each node from the list. In 
MetaCore, different networks and pathways modules can be prioritized based on their 
statistical significance. Significance is evaluated based on the size of the intersection between 
user's dataset and MetaCore set of genes/proteins corresponding to a network 
module/pathway in question. MetaCore software calculates p-values on the basis of 
hypergeometric distribution probability test. The resulting networks are evaluated for which 
algorithm have succeeded in creating modules that have higher than random saturation with 
the protein of interest. 
2. MetaboAnalyst (www.metaboanalyst.ca) is an integrated web-based platform for 
comprehensive analysis of metabolomic data. MetaboAnalyst version 2 is designed to perform 
a variety of complex metabolomic data analysis tasks that includes data processing, 
normalization, statistical analysis and high-level functional interpretation. In this thesis, this 
last function has been particularly used for elucidating possible biological mechanisms. 
MetaboAnalyst presents the following types of enrichment analysis: 
Over-representation analysis (ORA): a list of compound names obtained by multivariate 
analysis is subjected to a hypergeometric test and the p-value obtained indicates the 
possibility of observing at least a particular number of metabolites from a certain metabolite 
set in a given compound list. 
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Simple-sample profiling (SSP): the method first identifies those metabolites with 
concentrations in biological fluids deviating significantly from the reported normal reference 
ranges and then subjects this metabolites to ORA 
Quantitative enrichment analysis (QEA): a compound concentration table is analyzed with 
the globaltest algorithm and the p-value obtained indicates the probability that none of the 
matched compounds in the metabolite set is associated with the class label 
Current analytical technologies offer a partial metabolome coverage, which makes 
metabolomic studies intrinsically biased toward metabolite sets containing compounds that 
are more abundant or more easily detected by a given technology platform. MetaboAnalyst 
supports application of a platform-specific reference metabolome to correct for this potential 
bias (Xia and Wishart 2011) 
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1.6. STATISTICAL MULTIVARIATE APPROACHES USED IN 
PROTEOMIC AND METABOLOMIC ANALYSIS 
Proteomics and metabolomics data typically contains thousands of variables from each 
sample . The multidimensionality of this type of data is difficult to comprehend and visualise, 
and invoke for analytical techniques, which can extract the relevant information. Chemometric 
methods are here an obvious choice due to their ability to decompose complex multivariate 
data into simpler and potentially interpretable structures (Wold 1991). Depending on the aim 
of the analysis, unsupervised or supervised methods may be applied and assist in obtaining an 
overview of data, in variable selection, in group classification or to relate the data set to a 
reference value for construction of prediction models. 
To this purpose two main tools are generally used: principal component analysis (PCA) and/or 
partia l least square regression (PLS) . 
1. Principal component analysis (PCA) can be generally described as a method that reveals the 
internal structure of a data set in a way that best explains the variance in the data. 
Mathematically a PCA model can be written as: X = T P'+E where X is the data matrix 
representing samples and variables decomposed into a score matrix (T) and a transposed 
loading matrix (P'). The E matrix contains the residuals, the part of the data not 'explained' by 
the principal component model. In this way, the score and loading matrix contains the 
systematic variation with respect to samples and variables, leaving the unsystematic variation 
in the residual (Wold 1991). PCA offers a reduced dimensional model that summarises the 
major variation in the data into few axes, and in this way, systematic variation is captured in a 
model that can be used to quickly visualise which samples in the data set are similar or 
dissimilar to each other. From this, possible spectral loadings causing any treatment-related 
separation may be identified. 
2. Partial least square regression is a powerful algorithm that can analyse data with numerous 
strongly correlated X-variables (e.g. spectra) and also simultaneously model one or several Y-
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variables (e.g. a response variable/biomarker) (Wold 1991). This enables establishment of a 
linear model that can predict Y from the measured spectra in X. Like PCA, PLS regression 
generates a linear model of the data, but where PCA models the major variation in the data 
itself, PLS derives a model that describes the correlation between the X variables and a feature 
(Y variable) of interest (Keun 2006). PLS is often used as a classification tool in metabolomics 
studies by applying the discriminant analysis approach (PLS-OA). For this analysis, a class vector 
is constructed of one variable of each class with a value of 1 if the sample belongs to a 
particular class and 0 if not. By regression against this class vector, latent variables can be 
derived that separate the classes from each other. It seems worth mentioning that PLS-OA can 
suffer severely from overfitting, since the number of samples used in metabolomics 
applications is usually much smaller than the number of variables, and this can easily lead to 
chance classifications. Consequently, the PLS-OA algorithm can separate two groups comprised 
completely of random data. Therefore, a focus on the validation process is particularly 
important in this analysis (Westerhuis 2008). 
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CHAPTER 2 
AIM OF THE STUDY 
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2.1. RATIONALE 
Ischemia indicates an insufficient influx of blood in a specific organ or tissue including the 
heart, muscle, kidney or brain . Among these, brain ischemia represents the primary cause of 
permanent invalidity and the third most common cause of death in industrialized states. The 
symptoms are consequences of a transient or permanent loss of some cerebral funct ion and 
these are strictly dependent on the location of the damaged area. To date, an effective 
therapy to t reat such injuries is still lacking. 
A considerable body of evidence supports the hypothesis that a brief ischemic insult, below 
the threshold of damage, evokes endogenous defence mechanisms that confer protection 
against a subsequent severe ischemic attack (Oirnagl et 01. 2003; Weih et 01. 1999; Moncayo et 
01. 2000). This phenomenon is termed ischemic preconditioning (IP) and the resulting 
protection is known as ischemic tolerance (IT). IP and IT can occur in different tissues and 
organs and have been shown in experimental models and in humans too. These phenomena 
are attracting much attention because preconditioning-induced ischemic tolerance is an 
effective experimental probe to understand how the brain protects itself (Obrenovitch, 2008) . 
To date, the molecular mechanisms that lead to IT are not yet completely understood, 
although it is clear that multiple effectors such as the activation of cellular defence 
mechanisms and reduced inflammatory responsiveness, contribute to IT (Schaller and Graf, 
2003; Muramatsu et 01. 2004; OeGracia and Montie 2004) . In this complex scenario, 
proteomics and metabolomics represent powerful tools to identify the constellation of protein 
and metabolite alterations that occur during IT development, by exploring expression profiles 
globally. Moreover, the integration of these two strategies raises the possibility of detecting 
new biological mechanisms/pathways underlying neuro-protection, and could eventually lead 
to the-discovery of a panel of protein and metabolite mediators that could serve as pred ictors 
for preconditioning traits and as putative diagnostic markers of brain injury. 
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2.2. AIMS OF THE PROJECT 
Based on the above considerations, the principle aim of this project is to perform an 
exploratory analysis to investigate changes in the proteome profile of the brain cortex and 
plasma, together with changes in the profiles of metabolites in plasma, using a murine model 
of IT induced by TIA. Specifically, the project aims to: 
(i) clarify the mechanisms of preconditioning and endogenous neuro-protection, identifying 
possible IT mediators that can be used as possible therapeutic tools and/or targets for acute 
brain injury. 
(ii) search for a panel of candidate protein mediators in the plasma of the IT animal model. 
Particular attention will be made to evaluate the correlations between brain and plasma 
proteins, in order to discover a panel of protein candidates mediators for stroke progression 
and prognosis. 
(iii) identify circulating metabolites that could be involved in ischemic preconditioning and 
might represent, together with plasma and brain proteins, an innovative array of candidate 
mediators. 
To achieve the above-mentioned goals three different analytical strategies were used: 
• a conventional 2-0E approach was applied to protein samples of right brain cortices to 
identify differentially expressed components. 
• A 1-0E LC-MS/MS approach was applied to analyse qualitatively and quantitatively the 
protein repertoire of whole plasma. 
• An untargeted metabolomics approach was applied to obtain a metabolic plasma profile 
that could be related to the proteomic changes in plasma and also to such changes in the brain 
cortex. 
The three analytical strategies were performed on pooling samples due to budget constrains 
(e.g. expensive surgical procedure for the ischemic models) and sample limitations for 
biological variability assesment. The results of each experiment consist only of technical 
replicates and this means that the statistical analysis has weak relevance. Nevertheless, the 
identification of altered proteins expression and metabolites abundance from pooled samples 
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does not mean that these features are not interesting with the respect to the underlying 
biological population. It just means that the statistical confidence is limited and the use of 
additional methods of validating the findings is highly recommended. 
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CHAPTER 3 
MATERIALS AND METHODS 
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3.1. ANIMALS 
The ARRIVE guidelines have been followed in this study (Kilkenny et 01. 2010). 
C5781/6 mice (11 week-old male mice, Harlan Laboratories, Italy), housed in specific pathogen 
free vivarium, were used. Procedures involving animals and their care are conducted in 
conformity with the institutional guidelines that are in compliance with national (D.L. N. 116, 
G.U., Suppl. 40, 18 febbraio 1992, Circolare No.8, G.U., 14 luglio 1994) and international laws 
and policies (EEC Council Directive 86/609, OJ L 358, 1, Dec. 12, 1987; Guide for the Care and 
Use of Laboratory Animals, U.S. National Research Council, 1996). 
3.1.2. Focal permanent cerebral ischemia 
For permanent MCAo (pMCAo), a vertical midline incision was made between the right orbit 
and tragus (Gesuete, Orsini et 01 2011; Storini et 01 2005) . The temporal muscle was excised , 
and the distal branch of the right MCA was exposed through a small burr hole in the right 
temporal bone. The dura mater was cut with a fine needle, and the MCA was permanently 
occluded by electrocoagulation just proximally to the origin of the olfactory branch (Figure 
3.2) . Intraoperative rectal temperature was kept at 37"C ± OSC using a heating pad (LSI Letica, 
Spain). The mortality rate for this model is 13.5%. Sham-operated mice received an incision 
between the right orbit and tragus and the subsequent exposure of the temporal bone. The 
bone was drilled, but the dura mater and the middle cerebral artery were left intact. Similar to 
ischemic mice, sham-operated mice were maintained at 37"C during surgery. 
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Figure 3.2. Permanent occlusion of the middle cerebral artery. Schematic drawing of ventral view of mouse cerebral 
vessels, showing permanent MeAo procedure. 
3.1.1. Focal transient cerebral ischemia 
Transient focal cerebral ischemia was achieved by middle cerebral artery occlusion (MCAo) as 
previously described (Gesuete, Orsini et a/20ll), (Figure 3.1). Eleven week-old male mice were 
anesthetized by 5% isoflurane in N20/02 (70/30%) mixture and maintained by 1.5 to 2% 
isoflurane in the same gas mixture. To confirm the adequacy of the vascular occlusion in each 
animal, blood flow was measured by laser Doppler flowmetry (Perimed PFs010) using a 
flexible O.s-mm optic fibre probe (type M, 0.5 mm diameter; Transonic) positioned on the 
brain surface and secured with impression material on the skull at the following coordinates: 
AP= -1 mm; L= -3.5 mm. The animals were placed supine on a homeothermic pad equipped 
with a rectal probe to maintain a constant core temperature of 37"C ± OSC (LSI-Letica, 
Barcelona, Spain) . A midline neck incision was made and the carotid sheath was exposed. The 
following surgical steps were performed under an operating microscope (Nachet, Dijon, 
France) . The right common carotid artery was exposed and a siliconized monofilament (7-0, 
Doccol Corp., Redlands, CA, USA), was introduced in it to reach the middle cerebral artery 
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(MCA) and advanced until the cerebral blood flow was decreased by 70% compared to the 
baseline. The suture blocked only the middle cerebral artery due to the minor diameter of 
MCA compared to anterior cerebral artery (Figure 3.1). After the ischemic period, blood flow 
was restored by carefully removing the filament. This surgical procedure has been previously 
shown not to affect physiologic parameters. Sham operated mice received a midline neck 
incision, and the subsequent exposure of the carotid sheath without artery occlusion. Similar 
to ischemic mice, sham operated mice were maintained at 37"C ± O.5°C during surgery. 
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Figure 3.1. Transient occlusion of the middle cerebral artery. Schematic drawing of ventral view of mouse cerebral 
vessels, showing transient MeAo procedure. 
3.1.3. Experimental design 
The length of MCAo to mimic a TIA was setup testing 3 short periods (10', 7' and 5') and the 
neurological deficits were evalueted 48 hours later. Ten minutes of MCAo induce a small lesion 
in the striatum that wasn't present at 7' and 5' minutes. Since the 7'MCAo is the longest non-
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injurious stimulus close to but below the threshold of damage (Dirnagl et 01 2003), this time 
point was selected to mimic the TIA (Gesuete, Orsini et 01. 2011). 
Then different time point between the preconditioning stimulus and the severe ischemia 
(1,2,3,4 and 5 days) were evaluated to assess the neuroprotection. When pMCAo was 
performed after 1 or 2 days from 7'MCAo, the lesion volumes (12.91 ± 1.48 mm 3, 10 ± 2.2 mm 3 
respectively) were similar to non-preconditioned mice (13.61 ± 0.8 mm 3 ) instead after 3 or 4 
days a significant reduction was observed (8.95 ± 1.02 mm 3 and 8.45 ± 0.7 mm 3 respectively) 
that was not anymore present after 5 days of interval (Gesuete, Orsini et 01. 2011)1. 
To dissect the selective involvement of the different cell population in the IPC, gene expression 
for neuronal, microglial, astrocytic, oligodentrocytic and endothelial component were 
analyzed after 48 hours from pMCAo. The results showed that only astrocytic population 
seems to be involved in IPC (Gesuete, Orsini et 01. 2011). 
In this thesis, for proteomics and metabolomics analysis, the whole tissue was processed 
without fractioning the different cells types, hence it wasn't possible to establish if the protein 
and metabolite expression levels observed were or not a consequence of biological process 
related to a specific cell population, like astrogliosis, strictly connected to inflammation. 
On the basis of the above results, the experimental design of this study was set-up as shown in 
Figure 3.3. Mice (five per group) were assigned to five experimental groups, in the following 
sets: SET la, mice receiving 7' middle cerebral artery occlusion (MCAo) (IPC stimulus); SET 1b, 
sham surgery, and killed by cervical dislocation 4 days later; SET 2a, mice receiving sham 
7'MCAo followed, 4 days later, by pMCAo, and killed 7 days later (severe ischemia); SET 2b, 
mice receiving sham 7'MCAo followed, 4 days later, by sham pMCAo, and killed 7 days later; 
SET 2(:, mice receiving 7'MCAo followed, 4 days later, by pMCAo (7'MCAo/ pMCAo), and killed 
7 days later (ischemic tolerance). SET 2b served as sham control for SETS 2a and 2c. 
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Figure 3.3. Experimental Design. SET la, Preconditioning stimulus: mice received 7'MCAo or lb, 7'MCAo sham 
surgery and were sacrificed 4 days later. SET 2a, Severe ischemia: mice received 7'MCAo sham surgery followed, 4 
days later, by pMCAo and sacrificed 7 days later; SET 2b, 7'MCAo sham surgery and, 4 days later, pMCAo sham 
surgery, and were sacrificed 7 days later; SET 2c, Preconditioning/severe ischemia: mice received 7'MCAo and, 4 
days later, pMCAo (7'MCAo/pMCAo), and were sacrificed 7 days later. SET 2b served as sham control for both SET 
2a, and SET 2c. 
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Brains were rapidly removed, right cortices dissected (De Simoni, Storini et of. 2003, Gesuete, 
Orsini et 01. 2011), frozen on dry ice and stored at -80°C until proteomic analysis. For each 
animal proteins were extracted from frozen tissue by disintegrating about 90 mg of right brain 
cortex with Mikro-Dismembrator S (3000 rpm, 40 seconds). The powder obtained was 
resuspended in 1.8 ml of lysis buffer containing 5M urea, 2M tiourea, 2%(w/v) CHAPS, 2% 
(w/v) Zwittergent and a mixture of protease inhibitors, and homogenised for 1 minute. The 
samples were sonicated 3 minutes, and 250 Units of benzonase endonuclease were added in 
each sample. The homogenates were mixed for 30 minutes at 1000 rpm, at 25°C. The samples 
were then ultracentrifuged at 100,OOOxg, for 30 minutes at 15°C. The pellets were discarded 
and the supernatant collected. 
Since cortex is a tissue rich in lipids that can dramatically interfere with protein extraction and 
with subsequent protein separation by 2-DE, their elimination is mandatory (Healthcare 1998). 
Lipids were therefore removed by performing a methanol/chloroform extraction. For each 100 
III of protein supernatant, 400 III of methanol were added, the mixture was vortexed 30 
seconds and centrifuged 1 minute at 9000xg. Then 100 III of chloroform were added and the 
mixture was vortexed again and centrifuged 1 minute at 9,OOOxg. Then 300 III H20 were added 
and the mixture was centrifuged 5 minutes at 9,OOOxg. The top layer was removed (proteins 
were between layers), 300 III methanol were added and centrifuged 5 minutes at 9,OOOxg, the 
methanol was immediately removed without disturbing the pellet. The protein pellets were 
resuspended in 50 III of rehydration solution (5M urea, 2M thiourea, 2% CHAPS, 2% 
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Zwittergent), perfectly compatible with the next steps of bi-dimensional electrophoresis. 
Sample protein concentration was measured with the PlusOne 2-D Quant kit protein assay 
reagent (GE Healthcare, Italy) before and after precipitation. Protein recovery was more than 
85% of the total protein extract. Proteins, delipidated by methanol/chloroform extraction, 
were quantified using PlusOne 2-D Quant Kit. This kit is designed for the accurate 
determination of protein concentration in samples to be analyzed by 2-D electrophoresis. 
Many of the reagents used in the preparation of such samples, (e.g. detergents, reductants, 
chaotropes and carrier ampholytes), are incompatible with the majority of commercially 
available protein quantification kits. The PlusOne 2-D Quant Kit works by quantitatively 
precipitating proteins while leaving interfering substances in solution. The assay is based on 
the specific binding of copper ions to protein. Precipitated proteins are resuspended in a 
copper-containing solution and unbound copper is measured with a colorimetric agent. The 
color density is inversely related to the protein concentration. The assay has a linear response 
to protein concentration in the range of 0-50 Ilg. The absorbance of each sample and standard 
is read at 480 nm using water as reference, by UltraSpect 2100 pro (Amersham Biosciences). 
Due to budget and sample limitations for biological variability assesment , I adopted a samples 
pooling strategy to overcome the resource constraints. Pool cortices samples were prepared 
mixing equal amounts of protein (lOOllg proteins/animal) extracted from individual brain 
cortices (5 animals/experimental group). Five technical replicate gels were run for each pooled 
sample. Another limiting factor to consider is that two animal groups (7'MCAo/pMCAo and 
SHAM 7'MCAo/pMCAo) were processed and analyzed separately afterwards so the results 
obtained could be affected by the batch effect that can mask the underlying biology. 
One hundred Ilg pooled proteins were diluted to a final volume of 130 III with rehydration 
buffer containing also 100mM DeStreak reagent (GE Healthcare, Milan, Italy), added to protect 
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cysteinyl groups and prevent non-specific oxidation during the isoelectric focusing (IEF) run, 
and with 0.5% (v/v) IPG buffer (GE Healthcare, Milan, Italy) (Olsson, Larsson et 01. 2002). The 
samples were loaded on 13 cm long strips, linear pH 3-10 gradient (IPG Strips, GE Healthcare, 
Milan, Italy). IEF was performed at 20°C using an IPGphor apparatus (GE Healthcare, Italy) as 
previously described with minor modifications (Carpi, Korkalainen et 01. 2009). Briefly, after a 
rehydration step for l6h at 30V, focusing was run over about lOh until about 46000 VhT were 
reached. After the first-dimension run, proteins were reduced and alkylated, the strips were 
then embedded in 0.6% agarose (w/v) on the top of lmm thick acrylamide gels cast at 12%. 
Proteins were separated by apparent molecular mass at lOmA for 30 min and 35mA to 
completion. 
3.2.2.1. 2-DE gel image analysis 
After gel fixation and staining with colloidal Coomassie Blue (Pierce, Rockford, IL), the gel 
images were acquired at l6-bit resolution using an ImageScanner III (GE Healthcare). TIFF 
image analyses for spot quantification were performed using the Progenesis SameSpot (v4) 
and Progenesis Workstation (PG240, v2006) software (Nonlinear Dynamics Group, Newcastle 
upon Tyne, UK) to discriminate spots with a l.S-fold or greater increases or decreased intensity 
across the experimental groups (reported in detail in the Introduction section, paragraph 
1.4.1.3). 
3.2.2.2. Statistical analysis 
The Progenesis Stats Package (Progenesis Workstation PG240, v2006) integrated in the 
Progenesis SameSpot software was used to explore the differential expression of brain 
proteomics 2-DE data. This package allows multivariate and univariate analyses, including one-
way ANOVA, and provides the q-value for each tested spot. The q-value controls for the false 
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discovery rate (FOR), as ANOVA does not take account of the multiple testing effect. Significant 
one-way ANOVA p-values and FOR (q-values) were set at < 0.05. As multivariate approach was 
used the principal component analysis (PCA) that allows a quickly visualization of similar and 
dissimilar samples in the given dataset. Between-groups comparisons were computed by a 
multiple comparison test (Tukey-Kramer honestly significant difference (HSD), p < 0.05) using 
JMP v8 software (SAS Institute, Inc., Cary, NC, USA). 
3.2.2.3. Protein identification by tandem mass spectrometry 
Protein identification is based on mass spectrometric analysis of peptides generated by 
proteolytic digestion. To this purpose, the protease of choice is generally sequencing-grade 
trypsin, which hydrolyzes the protein on the C-terminal side of lysine and arginine, unless the 
subsequent amino acid in the sequence is a proline. 
3.2.2.4. Protein in-gel digestion 
Protein spots with a significant modulation in their intensity were excised manually from the 
gel by pipette tip under laminar flow sterilized hood, wearing powder-free gloves, to avoid 
keratin contamination. Excised spots were placed into an Eppendorf tube and smashed by 
sterile surgical blades into small pieces to increase the surface area of proteins/peptides in the 
solution for improving trypsin accessibility. The gel pieces were then washed with 100 III 
water and then dehydrated with 100 III acetonitrile twice. Cysteine residues were reduced by 
incubating gel pieces 30 minutes at 56 ·C with dithiothreitol (10 mM DTI/0.1 M NH 4HC03). Gel 
pieces were washed three times with acetonitrile and derivatized by treatment with 
iodoacetamide (55 mM IM/0.1 M NH 4HC03) for 20 min at room temperature in the dark. The 
reduction and alkylation of cystein residues are intended to ensure maximum sequence 
coverage and to secure identification of proteins with a large number of disulphide bridges. 
Gel pieces were washed three times with 0.1 M ammonium bicarbonate, dehydrated three 
times with 100% acetonitrile and dried in a SpeedVac centrifuge. Twenty III of digestion buffer 
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were added to the gel pieces and incubated one hour at 4°C. The digestion buffer consisted of 
12.5 ng/Ill sequencing-grade (i.e., modified by reductive methylation to reduce its 
susceptibility to autolysis) bovine trypsin (Roche, Switzerland) in 50mM ammonium 
bicarbonate with 5mM CaCI2 (since calcium ions retard trypsin autolysis). Although trypsin is 
active over a wide pH range (pH 7-9L the optimum pH for digestion with modified trypsin is 
between 7.8 and 8.1, so the presence of ammOniUr11 bicarbonate (pH 8.1) is useful to improve 
trypsin activity. Once the gel plugs had become swollen with absorbed digestion buffer, the 
excess was removed and replace with the same buffer without trypsin, to ensure that the gel 
plugs were kept wet during the digestion process. In-gel protein digestion was performed 
overnight at 37 °C, shaking the tubes in a Thermomixer apparatus. To maximize peptide 
recovery, after collecting the peptide-rich supernatant, the gel plugs were extracted twice 
(37"C, 15 minutes) with 30 III of acetonitrile. The two peptide supernatants obtained were 
collected, pooled, dried and dissolved in the supernatant previously collected. This final 
sample, hereafter referred to as "digest", containing all peptides recovered from the digestion 
of a single spot was directly analyzed by mass spectrometry. 
3.2.2.5. Liquid chromatography- tandem mass spectrometry 
Liquid chromatography-tandem mass spectrometry (lC-MS/MS) analysis was performed using 
a microfluidic chip-based technology for nanoelectrospray, whose functionality is equivalent to 
conventional nanospray lC/MS, coupled to an ion trap mass spectrometer (Agilent 1200 
lC/MSD Trap XCT) . Sample digest aliquots (6 Ill, equal to one third of the total digest) were 
directly injected into a G4240-62001 HPlC-Chip (Agilent 1200 G4240A HPlC-Chip CubeL 
composed of a 40 nl enrichment column and a 75 11m x 43 mm separation column packed with 
Zorbax 300S8-C18 (5 11m) at a flow rate of 0.3 Ill/min. The mobile phases consisted of 0.1% 
fOrmic acid in water (eluent A) and 0.1% formic acid in CH 3CN (eluent 8) . The linear solvent 
gradient was as follow: from 5% of 8 to 30% of 8 in 28 min, then to 90% of 8 in 15 min and 
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finally re-equ ilibration to 5% of B for 10 min. The electrospray source operated in positive ion 
mode, with the following conditions: capillary voltage, -1750 V; Cap exit voltage 100V, skimmer 
voltage, 30.0 V; dry gas flow, 3 L/min; dry temperature, 300°C. Data were acquired 
sequentially in MS mode (scan range of 200 to 2000 amu) and in data dependent mode, 
automatically recording the MSjMS spectra of the four most abundant ions in every scan cycle. 
The MS/MS spectra were acquired with isolation width of 4 m/z and fragmentation amplitude 
of 1.3V. 
3.2.2.6. Database searching and protein identification 
Tandem mass spectra were analysed using the MS/MS search engine Phenyx version 2.1 
(GenBio, Switzerland) (www.phenyx-ms.com.phenyx@genebio.com). against the 
UniProt_Swiss Prot database (version 54.6). The search was enzymatically constrained for 
trypsin, and allowed for one missed cleavage site. Further search parameters were : no 
restriction on molecular weight (MW) and isoelectric point; taxonomy: mus musculus; fixed 
modification carbamidomethylation of cysteine; variable modification: oxidation of 
methionine. Table 3.1 concisely restates the main submission parameters including algorithm, 
scoring models, thresholds. Protein identification has been considered valid when: (i) two or 
more peptides independently matched the same protein sequence, (ii) the peptide score was 
significant (p < 0.05), and (iii) the manual interpretation confirmed agreement between spectra 
and peptide sequence. 
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Table 3.1. Submission parameters to Phenyx MS/MS search engine. 
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3.2.2.7. Western blot analysis of brain proteins 
Pooled protein extracts (15 Ilg) were separated on NuPAGE 10% Bis-Tris Gels 1mm x 10 well 
(Invitrogen, CA, USA) using a Mighty Small II for 8x9 cm gels apparatus (Amersham Bioscience, 
MN, USA) at 200V for 1h. Each pool was run in triplicate (technical replicates). Resolved 
proteins were transferred to a nitrocellulose membrane (Bio-Rad) using the transfer buffer 
(10mM Tris-HCI pH 8, 150mM HCI, 0.05% (v/v) Tween-20) and blocked in TBS-T 5% (w/v) 
nonfat dried milk (Nestle, Italy) for 2h. After transfer, membranes were incubated overnight 
with either of the following primary antibodies diluted in TBS-T 5% nonfat dried milk: heath 
shock protein 70 (3A3), superoxide dismutase-2 (A-2) (Santa Cruz Biotechnology, Santa Cruz, 
CA, USA, 1:1000) and mouse anti-Actin (Chemicon International, CA, USA, 1:2000) mouse 
monoclonal antibody; androgen receptor C-19 rabbit polyclonal antibody, (Santa Cruz, 1:1000). 
After washing with TBS-T, the membranes were incubated with secondary antibodies (goat 
anti-rabbit IgG-HRP and goat anti-mouse IgG-HRP, Santa Cruz Biotechnology) diluted 1:1000 in 
TBS-T 5% nonfat dried milk. The secondary antibody goat anti-mouse IgG-HRP used for anti-
Actin was diluted 1:4000. Blots were detected by enhanced chemiluminescence (ECl-plus, GE 
Healthcare), visualized on autoradiography film (Hyperfilm ECl, GE Healthcare) and scanned at 
16-bit images (ImageScanner III, GE Healthcare). The resulting TIFF images were analyzed using 
Progenesis software (PG240, v2006, Nonlinear Dynamics Group, UK). Expression data were 
normalized relative to actin. 
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3.3. PLASMA PROTEOMICS 
Plasma proteomics analysis was performed using 1-0E for plasma protein prefractionation and 
subsequent LC-MS/MS for protein identification (1-0E-LC-MS/MS). This approach has been 
applied on all the experimental groups. Plasma samples were from the same animals used for 
brain proteomics analysis. 
3.3.1. One-dimensional gel electrophoresis (l-DE) and in-situ digestion 
of gel slices 
As already mentioned, due to budget and sample limitations for biological variability 
assesment, I adopted a samples pooling strategy to overcome the resource constraints . 
Protein samples were prepared by pooling plasma protein from individual animals (20 ~g 
proteins/animal) in each of the experimental group (5 animals/experimental group). Since 
plasma is a highly complex mixture of proteins/peptides with a high dynamic range, the first 
step was the depletion of high abundance protein species. The ProteoSpin plasma depletion kit 
(Norgen Biotek Corp, Ontario, Canada) was used. This kit allow the depletion of major serum 
proteins including albumin, a-antitrypsin, transferrin and haptoglobin and it is based on an ion-
exchange mechanism and not on the use of specific antibodies. The kit can be used to deplete 
serum proteins from a wide variety of samples, including human and various animals. The 
complete procedure is available at: 
http://www.norgenbiotek.com/product resources/abundant serum protein depletion kit a 
bundant serum protein depletion kit protocol 17300 959.pdf. For each group, triplicates 
of pooled protein extracts (15 ~g/replicate) were mixed with equal volume of Laemmli sample 
buffer (lOOmM Tris-CI pH 6.8, 4% 50S, 20% glycerol, 0.2% bromophenol blue, 200mM On) 
and resolved on a -manually cast 12% polyacrylamide 50S-PAGE using the Mini Protean" 
electrophoresis system at 90V, for 2 h (BioRad, Milan, Italy). The samples were loaded in the 
following order in each gel (from left to right) : 7'MCAo, pMCAo, 7'MCAo/pMCAo, SHAM 
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7'MCAo, SHAM 7'MCAo/pMCAo and a SHAM merge obtained mixing an equal amount of 
protein from the two SHAM samples (e.g Figure 4.7, page 123 section results) . 
Proteins were visualized after staining the gel with colloidal Coomassie Blue (Invitrogen, 
Carlsbad, CA, US). Each gel lane was manually cut with a sterile surgical blade into 24 bands of 
equal height (about 3 mm); in Figure 4.7, page 123 (Results chapter), the last lane from left to 
right represent an example of how were selected the 24 bands. Each band, placed into an 
Eppendorf tube and crushed into very small fragments, was submitted to the same in-gel 
digestion protocol applied for 2-DE approach (Mathe rials and Methods, page 90), but doubling 
the amount of each buffer. 
3.3.2. Liquid chromatography-ESI-tandem mass spectrometry 
An aliquot of each digest (2 Ill) was directly analysed by liquid chromatography-tandem mass 
spectrometry (lC-MS/MS). All digests from triplicate gel samples were analysed (576 digests in 
total). HPlC-MS/MS analyses were carried out with an lTQ Orbitrap Xl™ (Thermo Scientific, 
Waltham, MA, US), interfaced with a 1200 series capillary pump (Agilent, Santa Clara, CA, 
USA). Peptides were separated on a Thermo Scientific Biobasic 18 column (150xO.18mm, 
particle size 5 11m). lC condition were: column flow 2 Ill/min; eluent A, H20 and 0.1% formic 
acid; eluent B, CH 3CN and 0.1 % acid formic; gradient program: from 2% of B to 60% of B in 35 
minutes, then 98% of B in 11 minutes for 4 minutes and re-equilibration to 2% of B for 24 
minutes. MS conditions were : source DESI Omni Spray (Prosolia, Indianapolis, IN) used in 
nanospray mode with positive ions; ion spray voltage: 2100V; interface capillary temperature: 
220·C; capillary voltage: 42V. MS spectra (mlz 400-2000) were acquired on the Orbitrap 
analyzer at 60,000 resolution, in parallel with low-resolution MS/MS scans of the four most 
abundal]t precursor ions being acquired in the lTQ, excluding single charged ions. The lock 
mass option was used to obtain the most accurate mass measurements in MS mode. The 
polydimethylcyclosiloxane ion generated in the electrospray process from ambient air 
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(protonated (Si(CH 3hO)6, m/z 445.120025 was used for internal recal ibration in real time. 
MSjMS analysis was performed in data-dependent mode using XCalibur software (Thermo 
Scientific), with dynamic exclusion and 30 seconds exclusion duration . 
3.3.3. Database searching and criteria for protein identification 
Tandem mass spectra were extracted and the charge states deconvoluted by BioWorks version 
3.3 .1 (Thermo Scientific, Waltham, MA, US). Deisotoping was not performed. For each sample, 
the MSjMS data from the 24 gel bands were merged and submitted as "mgf" file to the search 
engine Mascot (in-house version 2.2.06, Matrix Science, London, UK) to simplify the 
comparison of results between samples and to allow peptides from any protein that had not 
migrate exactly within a single (blindly cut) gel slice to be included in the same search, thus 
increasing the probability of its identification. Mascot searches were performed against the 
Swiss-Prot database, version 57.8. Search parameters were: no restriction on molecular 
weight; Taxonomy: Mus Musculus; enzyme: trypsin (one missed cleavage allowed); fixed 
modification: carbamidomethylation of cysteine; variable modification: deamidation of 
glutamine and oxidation of methionine; experimental mass values: mono isotopic; peptide 
mass tolerance : ±2 ppm (our experimental mass accuracy was constantly better than 1 ppm); 
MSjMS mass tolerance: 1 Da; peptide charge: 2+,3+. Decoy search: active, so that this type of 
search was performed automatically. In this way during the search, every time a protein 
sequence from the target database is tested, a random sequence of the same length is 
automatically generated and tested. The average amino acid composition of the random 
sequences is the same as the average composition of the target database. The number of 
matches that are found from the decoy database is an excellent estimate of the number of 
false po.sitives that are present in the results from the real or target database (Elias and Gygi 
2007). If TP is true positive matches and FP is false positive matches, the number of matches in 
the target database is TP + FP and the number of matches in the decoy database is FP. The 
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quantity that is reported is the False Discovery Rate (FOR) = FP / (FP + TP) . False positive 
peptide identification is widely acknowledged to be a problem (Keller, Purvine et al. 2002; Elias 
and Gygi 2007), so the knowledge of FOR is very important since it allows to estimate the 
quality of the results (Keller, Purvine et al. 2002; Elias and .Gygi 2007) . To further validate the 
proteins lists generated by Mascot search, Scaffold software (version 3.00.02, Proteome 
Software Inc., Portland, OR, US) was used. All MS/MS data were analyzed using both Mascot 
(Matrix Science, London, UK; version 2.2.06) and X! Tandem (www.thegpm.org; version 
2007.01.01.1). Mascot was set up to search both the forward and reversed sequences of the 
SwissProt_201O database (version 57.8, taxonomy Mus musculus) assuming the digestion 
enzyme trypsin (1 missed cleavage allowed). X! Tandem was set up to search a subset of the 
uniprot_sprot database also assuming trypsin (2 missed cleavages allowed). Mascot and X! 
Tandem were searched with a fragment ion mass tolerance of 1.00 Da and a parent ion 
tolerance of 2.0 ppm. lodoacetamide derivative of cysteine was specified in Mascot and X! 
Tandem as a fixed modification. Deamidation of asparagine and glutamine and oxidation of 
methionine were specified in both Mascot and X!Tandem as variable modifications. Peptide 
identifications were accepted if they could be established at greater than 95.0% probability as 
specified by the Peptide Prophet algorithm (Keller et al., 2002). Protein identifications were 
accepted if they could be established at greater than 99.9% probability and with a least 2 
identified peptides. Protein probabilities were assigned by the Protein Prophet algorithm 
(Nesvizhskii, Keller et al. 2003). Proteins which contained similar peptides and could not be 
differentiated based on MS/MS analysis alone were grouped to satisfy the principles of 
parsimony. These f iltering criteria established a protein false positive identification rate (FOR) 
of 0% for the mouse proteome dataset based on the reported decoy database search strategy. 
3.3.4. ?rotein quantification by spectral counting 
Identified proteins were quantified using spectral counts directly computed by Scaffold 
software, where the number of MS/MS spectra are grouped into "counts" associated to a 
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specific protein. Spectral counts normalization was performed by Scaffold averaging the 
spectrum counts across the samples within an experimental group, followed by averaging the 
spectral counts across all experimental groups, and then multiplying the spectrum counts in 
each sample or experimental group by the average divided by the individual sample or 
experimental group sum. Since one or two spectra identifications are often irreproducible and, 
as such, finding of significant difference based on their presence are highly suspect, a 
minimum value of 3 was set for spectral counting. For each identified protein, the number of 
spectral counts was exported to Excel and normalized counts were averaged for replicate 
samples. Subsequently estimation of differential protein abundance was expressed as fold-
change. 
3.3.5. Statistical analysis 
Statistical comparisons of the individual protein abundance in the experimental groups (one-
way ANOVA) and between-groups comparisons (multiple comparison test, TukeY-Kramer 
honestly significant difference (HSD), p < 0.05) were computed using JMP vB software (SAS 
Institute, Inc., Cary, NC). Proteomic data were analyzed by multivariate techniques . The 
analysis was performed with Simca-P 13 software (Umetrics AB, Umea, Sweden) . The data was 
mean-centered and Pareto-scaled prior to multivariate statistical analysis. The dataset was 
examined using Partial-Least Square-Discriminant Analysis (PLS-DA) . In this pattern recognition 
technique, a regression model is formed between the expression value of features and class 
membership (e.g. sham and/or 7'MCAopiasma samples). The loadings plot was examined to 
identify which feature (variable) was significant in classifying the data. Differential variables 
(features) responsible for the clustering were then selected based on a threshold of variable 
importance in the projection (VIP) value (VIP>l) . This threshold is based on the fact that the 
sum of squares of all VIP values is equal to the number of terms in the model, hence the 
average VIP is equal to 1. 
3.3.6. IGF-l validation by ELISA 
The complete ELISA procedure is available at http://www.rndsystems.com/pdf/mg100.pdf. 
Briefly, 10 microl of plasma for each animal in each experimental group (three biological 
replicates for sample) were diluted 1:500 with the Calibrator Diluents, loaded in the plate and 
after the incubation with the Substrate Solution, the optical density was assessed at 450 nm 
using the Tecan I-control microplate reader (Tecan Group ltd, Mannendorf, Switzerland) . The 
IGF-1 concentration in each animal was obtained from the standard curve, the statistical 
comparison of the IGF-1 concentration in the experimental groups (one-way ANOVA) and 
between each group (multiple comparison test, Tukey-Kramer honestly significant difference, 
p < 0.05) were obtained using Prism 6.01 (GraphPad Software, Inc). 
3.3.7. Protein network and pathways analyses 
The lists of differentially expressed proteins were analysed by network and pathway analysis 
using the MetaCore analytical suite version 5.3 (GeneGo, MI, US). Metacore is an integrated 
ana lytical suite of algorithms, based on a manually annotated and regularly updated databases 
of human and rodent protein-protein interactions, transcriptional factors, Signalling, 
metabolism and bioactive molecules linked to functional processes and diseases 
(www.genego.com/) . MetaCore's default background was used as background dataset for two 
main reasons: (i) my protein identification was potentially "proteome-wide" , meaning that my 
global workflow was not restricted to predetermined protein sets (as it happens, for example, 
with the genes on a microarray); (ii) in statistical evaluation the use of larger backgrounds (e.g., 
all genes in the genome) gives in general more solid results (as indicated by the lower P-values) 
as compared to a restricted set of genes (e.g., the genes existing on a microarray) (Huang da, 
Sherman et 01. 2009). Once the list of significantly differently expressed proteins (with Uniprot-
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Swiss Prot ID and fold-changes values) was uploaded to MetaCore, the size of their 
intersection between the subset of uploaded proteins and the proteins on all the possible 
pathways mapped in the MetaCore database was computed using the hypergeometric 
distribution probability test, where the p-value represents the probability that a process 
appears in the data set relative to that expected by chance. A p-value <0.05 was used to 
identify pathways that are assumed to be affected by treatment. Subsequently, networks of 
proteins from our experiment against the default background were built using two different 
algorithms: 1) the analyze network algorithm generating sub-networks ranked by a P-value and 
interpreted in terms of Gene Ontology processes to deduce top scoring process that are 
regulated by differentially expressed proteins; and 2) the standard Dijkstra's shortest path 
algorithm to map the shortest path for interaction. The resulting networks were evaluated to 
determine which algorithm succeeded in creating modules that have higher than random 
saturation with the protein of interest. Networks were then visualized graphically as nodes 
(proteins) and edges (relationship between proteins) alongside the expression pattern. 
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3.4. PLASMA METABOLOMICS PROFILING 
3.4.1. Plasma samples preparation 
As already mentioned, due to budget and sample limitations for biological variability 
assesment, I adopted a sample pooling strategy to overcome the resource constraints. I 
pooled plasma samples from individual animals (20 ~g proteins/animal) in each of the 
experimental group (5 animals/experimental group)and run technical replicates . 
I am aware that results based solely on technical replicates might have a limited statistical 
relevance. Neverthless the identification of metabolites with different abundance from pooled 
samples does not mean that these metabolic species are not interesting with the respect to 
the underlying biological population. It just means that the statistical confidence is limited and 
the use of additional methods of validating the findings is highly recommended. 
Metabolites were extracted by adding four volumes of cold methanol to the plasma sample; 
samples were vortexed and incubated at -20°C for 1h. They were then centrifuged 10 min at 
14,000 x g, and the supernatant (rich in small-molecule analytes) was collected, dried in a 
SpeedVac and resuspended in 20 ~L of 0.1% formic acid . 
3.4.2. Metabolomic profiling by L TQ-Orbitrap mass spectrometry 
A portion (2 ~L) of metabolite extract from each groups was directly analysed by LC-MS/MS, 
using an LTQ Orbitrap XL™ (Thermo Scientific, Waltham, MA, US), interfaced with a 1200 series 
capillary pump (Agilent, Santa Clara, CA, US). The MS instrument was operated in positive 
(POS) and negative (NEG) ionization modes and the analyses were run in triplicate. Metabolites 
were separated on an Agilent Technologies Zorbax C18 SB column (150 x 0.5 mm 10, particle 
size 5 Tm) . Flow rate 10 ~L/min with mobile phases: water containing 0.1% formic acid (A) and 
acetonitrile (B) for the positive ion. For negative ion mode, 2 mM of ammonium acetate was 
substituted for the 0.1% formic acid . The gradient consisted of 5% B for 5 min, followed by a 
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linear gradient to 95% B over 45 min, hold at 95% B for 5 min, and re-equilibration at 5% for 2 
min. MS conditions were: source DES I Omni Spray (Prosolia, Indianapolis, IN) used in 
nanospray mode with positive and negative ion modes; ion spray voltage 2100 V; capillary 
temperature 220°C; capillary voltage, 42 V. MS spectra (m/z 100-1000) were acquired in the 
Orbitrap analyzer at 60,000 resolution, in parallel with the low-resolution MS/MS scans of the 
four most abundant precursor ions being acquired in the L TO, selecting singly charged ions. 
The lock-mass option was used to obtain the most accurate mass measurements in MS mode. 
The polydimethylcyclosoloxane ion generated in the electrospray process from the ambient air 
(protonated (Si(CH3)20)6, m/z 445.120025) was used for internal recalibration in real time. 
MS/MS analysis was done in data dependent mode (DTA) using Xcalibur software (Thermo 
Scientific, Waltham, MA, US) with target ions previously selected for the MS/MS dynamically 
excluded for 30 sec. To ensure the stability and repeatability of the LC-MS systems, ten runs of 
pooled samples were done on the system before the sample run sequence. Samples were run 
in an order that alternated the SHAM 7'MCAo/SHAMpMCAo and pMCAo groups to reduce any 
systematic error associated with instrumental drift. 
3.4.3. Untargeted metabolomics data processing 
All LC-MS files were analyzed using the MS label free differential analysis software SIEVE v1.3 
(ThermoFisher, Cambridge, MA, US). SIEVE was run on all the LC-MS full-scan chromatograms 
using the small molecule setting. The chromatograms were time-aligned, referencing the 
SHAM7'MCAo/SHAMpMCAo samples acquired in the middle of the sequence. The framing 
parameters were set at 0.01 Da for the m/z window and 0.35 min for the retention time (RT) 
window; 500,000 was used as the intensity threshold. SIEVE software was used to determine 
signifiq;lnt differences in the frame profiles of SHAM7'MCAo, 7'MCAo, SHAM7'MCAo/pMCAo, 
pMCAo, 7'MCAo/pMCAo plasma samples by applying the following filtering criteria: frame 
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intensity coefficient of variation (CV%) <20%, and unpaired t -test for unequal variance 
(Welch's test) p:50.01. 
3.4.4. Stastical Analysis 
Metabolomic data were analyzed by multivariate techniques. The analysis was performed with 
Simca-P 13 software (Umetrics AB, Umea, Sweden). The data was mean-centered and Pareto-
scaled prior to multivariate statistical analysis. The dataset was examined using Partial -Least 
Square-Discriminant Analysis (PLS-DA). In this pattern recognition technique, a regression 
model is formed between the expression value of features and class membership (e.g. sham 
and/or 7'MCAo plasma samples) . The loadings plot was examined to identify which feature 
(variable) was significant in classifying the data. Differential variables (features) responsible for 
the clustering were then selected based on a threshold of variable importance in the 
projection (VIP) value (VIP>l). This threshold is based on the fact that the sum of squares of all 
VIP values is equal to the number of terms in the model, hence the average VIP is equal to 1. 
3.4.5. Identification of plasma metabolites 
For metabolite identification, the frame m/z values were used for batch searches on the KEGG 
database (http://www.genome.jp/kegg/) and Human Metabolome Database (HMDB, 
http://www.hmdb.ca/) . Accurate mass data and isotopic distribution for the precursor and 
product ion were compared to spectral data of the reference compounds in the databases. 
Identifications were reported only for metabolites with accurate mass match <5 ppm. 
The resulting metabolite identifications based upon spectral similarities with public spectral 
librieries, as performed in this study, are defined as putative (Sumner et al 2007, Dunn 
2012) .The final unambiguous identity of a metabolite can be achieved only referencing to 
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authentic chemical standards, a strategy that has not been performed at this stage of my 
study. 
3.4.6. Mapping metabolic pathways 
For biological interpretation of the metabolite dataset by our untargeted strategy, we mapped 
the identified metabolites to the KEGG pathway database (Kyoto Encyclopedia of Genes and 
Genomes; (www.genome.jp/kegg/).using MetaboAnalyst 2.0, a comprehensive online tool 
suite for metabolomic data analysis and interpretation (www.metaboanalyst.ca). Metabolite 
sets were analyzed to identify biologically meaningful patterns that were significantly enriched 
in our metabolomic data. The OverRepresentation Analysis (ORA) algorithm was applied and 
the hypergeometric test was used to see whether a particular metabolite set was represented 
more than expected by chance in the given compounds list. Then the Pathway Analys is Module 
was used to combine the enrichment analysis results with t he pathway topology analysis 
(centrality measures to estimate node importance) to identify the most important pathways 
involved. 
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CHAPTER 4 
RESULTS 
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4.1. PROFILING THE BRAIN PROTEOME BY 2-DE AND LC-MSjMS 
The expression profiles of brain proteins derived from animals subjected to different ischemia 
regimes were examined to evaluate the effects of brain IPC on a subsequent more severe 
ischemic event, and to highlight putative IPC mediators. To achieve this goal technical 
replicates of pooled cortex proteins were separated by two-dimensional gel electrophoresis (2-
DE) and protein expression was analysed in 5 different experimental conditions, namely, IPC 
stimulus (7'MCAo), severe ischemia (pMCAo), the combination of the two (7'MCAo/pMCAo), 
and 2 groups of sham-operated controls (figure 4.1). 
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Figure 4.1. Representetive gel images of the five experimental conditions: (A) 7' MCAo, (8) pMCAo, (e) 
7'MCAo/pMCAo, (0) SHAM 7'MCAo, (E) SHAM 7'MCAo/pMCAo. 
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Analysis of gel images and statistical comparisons of the two sham groups (sham7'MCAo and 
sham7'MCAo/pMCAo), indicated that they were not significantly different (data not shown). 
Therefore, the two groups were merged for all subsequent image analyses and statistical 
comparisons to obtain a larger sham group, named SHAM. This had the advantage of 
increasing the statistical power of the study, allowing for better detection of differences 
among the experimental groups. Overall, gel image analysis by Progenesis SameSpot software 
detected about 800 spots/gel. Further, 89 protein spots matched in all the experimental 
conditions and showed changes in intensity in at least one of them (one-way ANOVA p<0.05, 
FDR < 5%). The SameSpot data were exported to PG240 for further statistical analysis on the 
normalized spot volumes. Normalization was against the total volume of all spots in the gel. 
The technical reproducibility of the replicates was assessed by calculating the coefficient of 
variation (CV %) of the protein spot volumes. The CV percentages (mean ± SO) were 25 ± 5, 22 
± 9, 18 ± 8, and 23 ± 8 in SHAM, TMCAo, pMCAo, and TMCAo/pMCAo, respectively. To 
minimize incorrect data interpretation, protein spot volumes with CV ~ 35% were not 
subsequently included in the statistical analysis; only relevant expression changes greater than 
1.5 times (up- or down-regulation) were considered. To note that the use of pooled samples 
and technical replicates can affect the strenght of my statistical analysis as I already stated at 
page 53 in the Introduction chapter. 
Using the Tukey-Kramer test, a number of protein species with a significant change in 
abundance (p <0.05) were detected. However, only 28 out of the initial 89 met the above 
requirements. Figure 4.2 reproduces a typical averaged 2-0E gel image, obtained using 100 ~g 
proteins from SHAM samples and generated by Progenesis SameSpot (at least four replicate 
gels/group were used). Protein species whose level changed significantly (one-way ANOVA 
p<0.05) in at least one of the experimental conditions tested are circled. Numbered spots 
indicate protein species with a change in expression ~ 1.5-fold vs. SHAM (TukeY-Kramer 
p<0.05). 
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Figure 4.2. Image of a Colloidal Coomassie blue stained 2-DE gel of pooled brain cortices from SHAM samples (100 
~g proteins) . The average 2-DE map generated by image analysis of 10 replicates is shown. The 2-DE map shows 89 
differentially expressed protein spots (circled spots, ANOVA p<O.OS) and 28 protein spots with expression levels of 
1.S-fold or greater (numbered spots). 
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4.1.1. Protein identification by HPLC-Chip-MSjMS 
All numbered spots have been identified. Their identities are listed in Table 4.1, together with 
their respective UniProCSwissProt accession number and name, theoretical and observed 
isoelectric point (pi) and molecular weight (MW), number of peptide identified for each 
protein, coverage percentage, and Phenyx score. All proteins were identified with high 
confidence and t he observed pi and MW values were in good agreement with the theoretical 
ones. Phenyx mass spectrometric parameters are reported in material and methods, page 89. 
The 28 proteins corresponded to 26 different identities, which were confirmed using the 
search engine Mascot. 
Table 4.2 summarizes the expression fold changes of the identified proteins in the 
experimental ischemia models as compared to SHAM. Up-regulation is shown in bold (fold 
change ~ 1.5), whereas down-regulation is shown in bold-italic (fold change ~ -1.5). 
The most relevant expression changes were induced by pMCAo, where 22 out of 28 proteins 
(79%) resulted increased compared to SHAM. In the preconditioned group (7'MCAo/pMCAo) a 
number of proteins overexpressed after pMCAo returned to SHAM levels, but the abundance 
of 12 proteins was changed compared to SHAM. 7 of these proteins remained up-regulated as 
in pMCAo, whereas 5 proteins (namely, succinate dehydrogenase (DHSA), dihydrolipoyl 
dehydrogenase (DLDH), fascin, one of the two isoforms of glutamine synthetase (GLNA), one of 
the two isoforms of fructose-biphosphate aldolase C (ALDOC), that were unchanged in pMCAo, 
were found to be down-regulated only in this experimental condition, suggesting their possible 
role in brain preconditioning. The IPC stimulus alone (7'MCAo) affected only a limited number 
of proteins as compared to SHAM. The expression of 2 proteins (namely, L-Iactate 
dehydrogenase (LDHA), and glutathione S-transferase M1 (GSTM1), was down-regulated by 
IPC. Remarkably, only the heat shock protein 70 (HSP70) was increased in this group when 
compared to SHAM. However, its expression remained unchanged after pMCAo, both in 
preconditioned and non-preconditioned brains. 
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Further statistical comparisons (Tukey-Kramer test) on the normalized spot volumes of the 
identified proteins are shown in the Figure 4.3, which highlights the differences between 
paired experimental groups. From this figure the preconditioning effect (7'MCAo/pMCAo) in 
preventing the robust protein over-expression observed after severe ischemia (pMCAo) is even 
more evident, since the trend observed for almost the totality of the proteins was a decreased 
expression in preconditioned brain cortices. 
Table 4.1. Proteins differentially expressed in mouse brain cortex ischemia models. Identification was by LC-MS/MS 
and use of the Phenyx search engine. The table reports the access num bers and entry names associated with the 
UniProt-Sprot database. 
°Theor.: Theoretical, data-based annotation; Exp.: experimental, from two-dimensional gels 
b#Unique pept.: number of unique peptide matches found for a given protein. 
[Cov%: all amino acids from valid peptide matches as a percentage of the total number of amino acids in protein. 
dScore: the protein score is calculated from the individual normalized Z-score of validated peptides. Peptide Z-score 
refers to the distribution of calculated scores compared with that of random peptide sequence in order to find the 
mean and variance (VI/\'liV\' i li IPI IV):, 111"~.,~ (llD). 
Spot# Protein name Uniprot-Sprot Uniprot-Sprot pi, theor.lexp.' MW IkD_), theor.lexp.' # Unique pept.' Cov%C Scored Ace number entry name 
99 Aconltate hydratase Q99KI0 ACON MOUSE 76/8 8J86 16 16 1029 
116 VeSlcie-fusln ATPase P46460 NSF MOUSE 667/65 82/83 3 4 25 " 
129 Heat shock 70 P20029 HSP70 MOUSE 50/50 7046170 44 38 2151 
161 Succinate dehydroQenase 08K2B3 OHSA MOUSE 6.4/70 68/70 20 19 959 
214 Proleln disulfide-Isomerase A3 precursor P27773 POIA3 MOUSE 578/60 54.2/57 4 7 286 
224 Olhydrollpo I dehydrogenase 008749 OLOH MOUSE 6.5/80 50.2/50 30 33 1334 
231 pyruvate kinase P52480 KPYM MOUSE 69/70 579/60 77 55 2937 
273 Fascln 061553 FSCN1 MOUSE 66/60 54 5155 43 47 181 .5 
303 Septln·11 08C1B7 SEP11 MOUSE 6.5/6.0 489/50 28 45 1452 
338 AI ha-enolase P17182 ENOA MOUSE 663/60 47/45 29 37 1746 
362 Creatme kinase P30275 KCRU MOUSE 85/8.0 47/50 34 34 1165 
366 Betalne~-homocystelne S-meth Itransferase 1 035490 BHMT2 MOUSE 8.3/8.0 45/50 22 47 126 
378 Glutamine synthetase P15105 GLNA MOUSE 6.85/65 42140 9 20 724 
379 Phosphoql cerale kmase 1 P09411 PGK1 MOUSE 83/80 44 5140 46 47 18 1 5 
380 Glutamine synthetase P15105 GLNA MOUSE 6.85/65 42/40 12 22 97 
397 Septln·5 09Z206 SEPT5 MOUSE 63/6.0 427140 7 12 3095 
418 Fruclose-blsphosphale aldolase C P05063 ALDOC MOUSE 7.0/6.5 394/45 13 35 '273 
423 Fruclose-blsphosphate aldolase C P05063 ALOOC MOUSE 7.2/65 46145 25 30 '293 
431 NAOH dehydrogenase 099LC3 NDUAA MOUSE 6.117.0 36.9140 7 21 497 
502 L·lactate dehydro~enase A P06151 LOHA MOUSE 8.0/75 365/35 9 22 '4 
557 Vacuolar ATP synthase subunit E 1 P50518 VATE1 MOUSE 87/85 26.1125 41 47 '08 
615 Phosphoglycerate mutase 1 Q90BJ1 PGAM1 MOUSE 7.0/6.5 28.8/28 22 43 1:48 
635 Peroxlredoxln-6 008709 PROX6 MOUSE 5.9/5.5 24.8/25 8 34 661 
642 Triose hosphale Isomerase P17751 TPIS MOUSE 758/75 267/25 7 28 5' 6 
650 Glutathione S-transferase Mu 1 P10649 GSTM1 MOUSE 85/80 25.8/25 69 58 1551 
674 Ras-related protem Rab-11A P62492 RB11A MOUSE 58/6.0 245/20 9 20 396 
693 Glutathione S-Iransferase P 1 P19157 GSTP1 MOUSE 8.35/7.5 236/25 6 23 3L, 
703 Superoxlde dlsmulase P09671 SOOM MOUSE 89/90 246/25 '7 37 96 • 
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Table 4.2. Fold changes of proteins in the mouse brain cortex after preconditioning alone (7'MCAo) or severe 
ischemia with (7'MCAo/pMCAo) or without preconditioning (pMCAo) as compared to SHAM. Up- or downregulation 
is shown in bold (fold change ~ 1.5), or in bold-italic (fold change ~ -1.5). 
SPOT No. PROTEINS IDENTIFIED EXPRESSION FOLD CHANGE V. SHAt1 
1""CIIO ,,"ClIO 7 '"CAoIlf'ICAo 
99 Awn,tate hydratase -1.23 4.5 3.8 
116 VeSlde-1UsmgATPase 1.2 2.1 1.~ 
129 Heatshod< protein 70 1.3 1.3 -1.3 
161 Sumnate dehydrolJ'nase 1.1 -1.0 
-Z.' 
214 Protem dIsulfide-Isomerase A3 p reOJrsor -1.4 1.6 1.2 
224 Dih yd rolipoyt de hyd rolJ'nase -1.0 -1.5" 
-1.' 
LJ1 ~yruvate kinase ·1.2 2.1 1 _ 
273 FasCJn -1,0 -1,2 ·Z.8 
30J Septin·11 ·1,0 1.1 -11 
338 Alpha·endase -1,1 2.1 1.2 
362 Creatine kinase ·1.7" 3.3 2.4 
366 Beta,ne -homocysteme S-methyttransferase 1 1.3 1.9 -1.l' 
378 Glutamme synthetase -1,1 1,2 
-1.' 
379 PhosphogJyreratekinase 1 1.4 2.4 ·1.5" 
380 Glutamine synthetase -1.3 2.2 ·1.2 
J97 ).ptln·, 1.1 .1 -1.~ 
~l" ruemse-Dlspnosp ."'.,OOl.seC ,1 -.0 
~LJ ru em se-o'spnospnate alDol ase c - ,q .J 
~31 NADH dehyd rolJ'nase 1.3 1.7 -1.:1" 
502 l-Iactate dehydrolJ'nase A -l.~ 2.2 1.' 
557 VaOJolarA I ~ synthase subunitE 1 1.0 1.' 1.' 
615 Ph 0 sphC\ll yrerate mutase 1 -1,1 1.7 -1,2 
635 Pe roxlredoxln-6 -1,2 2.1 1,1 
641 T no se phosphate isome rase -1,3 1.1 -1.1 
650 Glutathione ;-transfe rase Mu 1 -Z.4 J.J 2.2 
67~ Ras-related p rote'n Rab-11A -1,2 1.5 -1,0 
6~J Glutath,one;-transfe rase P 1 -1.5" J.t 2.5 
103 sup. roxide Dismutase -1.1 1.' 1., 
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Figure 4.3. Histograms of normalized spot volumes of the identified proteins and paired statistical comparisons 
(Tukey-Kramer HSD p < 0.05), Each bar represents the normalized spot volume (mean ± SD). The vertical axis shows 
arbitrary normalized volume unit. Spot numbers are given in parenthesis and are from the Progenesis SameSpot 
analysis. Asterisks mark significant expression changes. 
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4.1.2. Pathway analysis 
MetaCore software was used to identify pathways and processes significantly perturbed in our 
experimental conditions. Individual protein expression changes were compared using the 
'Compare Experiments Workflow' tool to analyse their distribution in MetaCore's ontologies. 
The histograms of Figure 4.4A indicate that glycolysis and the tricarboxylic acid cycle are 
among the top 10 most significant pathways affected . As shown in Figure 4.4B, the top 10 
most significant process networks include the response to unfolded proteins, immune 
response, response to hypoxia and oxidative stress. The list of proteins significantly involved in 
the perturbed pathway maps and process networks is reported in Table 4.3. 
I used the MetaCore's network algorithm "shortest paths" (two steps) to map the shortest 
path for protein-protein interactions among the dysregulated proteins. The pathway analysis 
generated the global network of Figure 4.5, which shows direct and indirect interactions 
among all the dysregulated proteins; however, alpha-enolase was not linked to any network 
protein. 
The presence of androgen receptor (AR) among the most highly connected proteins (hubs) 
defined by the network statistics is noteworthy. AR was directly linked to 9 dysregulated brain 
proteins, including HSP70 (involved in protein folding and stress responseL the anti-oxidant 
proteins superoxide dismutase-2 (SOD2) and GSTPl, ALDOC (glycolysisL aconitate hydratase 
(ACON, tricarboxylic acid cycle), DLDH, (tricarboxylic acid cycieL GLNA (glutamate and GABA 
synthesis), betaine homocysteine s-methyltransferase (BHMT, amino acids synthesisL and 
protein disulphide-isomerase A3 (PDIA3, rearrangements of 5-5 bonds) . Two further hubs, 
namely hypoxia inducible factor 1 (HIF-l) and nuclear factor-kappa B (NF-KB), attracted our 
attention since they were directly connected to many of the remaining proteins. Seven 
proteins, phosphoglycerate mutase 1 (PGMn fascin, HSP70, pyruvate kinase (KPYML LDHA, 
ALDOC, and phosphoglycerate kinase (PGKl) were directly linked to hypoxia inducible factor 1 
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(HIFl), and 10 proteins (fascin, ACON, GLNA, H5P70, 5eptin 11, ALDOC, PGK1, 50D2, G5TM1, 
and G5TP1) to nuclear factor KB (NF-KB). 
A 
.. ;.---
. 
-
-. 
Maps 
. 
-
B 
·1og·pVolJt 
Figure 4.4. MetaCore analysis using the 'Compare Experiments workflow' application . The bars represent the ten 
most significant biological pathway maps (Panel A) and biological process networks (Panel B) in which the 
differentially expressed proteins are involved. The results are ranked by the -Iog(p-value). Yellow, blue, and red bars 
refer to 7'MCAo, pMCAo, and 7'MCAo/pMCAo, respectively. White and hatched bars indicate similar or common 
pathway maps and biological processes, respectively . 
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Table 4.3. Biological processes involving the dysregulated proteins, together with the direction of their expression 
change, as indicated by the GeneGo (MetaCore) and GO software tools, 
Bioloclc.t Process Pr(jeins Expression ch.ncedrections 
l'HCAo pHCAo 7 'HCAOIpttCAo 
EnerW metab,'i,~'TI Alpha-endase 1 
Pho sphogJ)ICe rare kinase 1 1 
F ru ctD se-bisphosphare aldolase C 1 J 
L -Iactare deh)l:lroiJlnase A J 1 , 
Pho sphogJ)oI::e rare mutase 1 1 
Trio se phosph.;;e iso me rase , 
Pyru vare kin ase t 
Aoonitare h)l:lratase t 1 
Suoonare deh)l:lro~nase J 
Dih)l:l rolipo)o1 deh)olJro~nase l-
NA DH de h)l:l roil'nase 1 
Creatine kinase 1 1 
AAtioxvdant Gluta1t1ione S-transfe rase Mu 1 ~ 1 1 
Gluta1t1ioreS·transre rase P 1 t 1 
Supe roxide d ism utase 2 1 , 
Peroxiredoxin6 1 
Synaptic vf!sicle transport Veside rusingA TPase t 
VaruolarATP syn1t1ase subunitE1 1 1 
k tin binding Fascin 1 
Cy to sI< ei eton rf!modellms Septin 5 t 
Septin 11 t 
Mf!moranf! rramc Has-relateo p rote1l1 K<lo-lla T 
Aminoocid j{nthesi5 Glutamine sin1t1etase t ~ 
Betaine homocysreine ~-metiltansfe rase 1 
Pf!Orrongmf!ntofS'S prorein disulfide-isomerase AJ p rerursar t 
Strf!55rf!sponSf! Heatshockp rorein 70 t 
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Figure 4.5. Global network associated with the proteins differentially expressed in transient and permanent 
ischemia models. MetaCore's network algorithm "shortest paths" (two steps) was used to map the shortest path for 
protein-protein interact ions. Individual proteins are represented as nodes of different shapes, according to their 
functional class. Circled nodes denote proteins identified in this study; small full red and blue circles indicate up-
and down-regulation, respectively. Lines between nodes indicate direct protein-protein interaction, the arrowheads 
indicate the direction of the interaction. Br9ken line circles highlight network hubs highly connected with the 
dysregulated proteins, as indicated by network statistics. Yellow lines highlight the direct interaction between these 
hubs. Blue, purple, and green lines highlight, respectively, direct interactions between HIF1, AR, and NF-KB and the 
dysregulated proteins. In the figure Peroxiredoxin 6 is referred as PLA2. 
4.1.3. Western blot validation 
Immunoblotting experiments were used to confirm key proteomic data and were performed 
on technical replicates of pooled samples. Specifically, the expression profile of HSP70 was 
validated by Western blotting, as this was the only protein found upregulated after 7'MCAo, 
and S002 was analysed as an example of a protein whose expression was highly increased 
both after severe ischemia and after 7'MCAojpMCAo. In addition, on the basis of the pathway 
analysis results, AR was checked by Western blotting to verify its expression in our 
experimental models, since it appeared to be a major hub in the affected network. The 
Western blot analysis of HSP70 and S002 confirmed the 2-0E data (Figure 4.6 A and B 
respectively) . AR expression paralleled HSP70 expression, though the difference reached 
statistical significance only for the comparison 7'MCAo vs. pMCAo (Figure 4.6 C). 
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Figure 4.6 A. HSP70 expression analyzed by Western blot. Protein bands in the autoradiograms were quantified by 
scanning densitometry. Expression data were normalized relative to a-actin . Each bar represents the normalized 
volume density (mean ± SD, n=3). The vertical axis shows arbitrary density unit. Asterisks mark Significant 
expression changes (Tukey-Kramer HSD p < 0.05). 
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Figure 4.6 B. 5002 expression analyzed by Western blot. Protein bands in the autoradiograms were quantified by 
scanning densitometry. Expression data were normalized relative to a-actin. Each bar represents the normalized 
volume density (mean ± SO, n=3) . The vertical axis shows arbitrary density unit. Asterisks mark significant 
expression changes (Tukey-Kramer HSO p < 0.05). 
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Figure 4_6 C. AR expression analyzed by Western blot. Protein bands in the autoradiograms were quantified by 
scanning densitometry. Expression data were normalized relative to a-actin. Each bar represents the normalized 
volume density (mean ± SD, n=3) . The vertical axis shows arbitrary density unit. Asterisks mark significant 
expression changes (Tukey-Kramer HSD p < 0.05). 
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4.1.4. Preliminary conclusions 
To elucidate the molecular mechanisms involved in IPe two-dimensional electrophoresis 
coupled to liquid chromatography-tandem mass spectrometry on brain cortex pool samples 
for each experimental conditions were performed to overcome resource constraints. Technical 
replicates were run. Overall, twenty-eight proteins were detected as differentially expressed, 
as compared to SHAM controls, and identified. Pathway analysis indicated that they were 
mainly involved in energy metabolism, mitochondrial electron transport, synaptic vesicle 
transport, and antioxidant processes. Differentia l expression of HSP70 in the brain cortex was 
paralleled by increased abundance of AR, as validated by western blot on pooled samples. 
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4.2.1-DE-LC-MS/MS PLASMA PROTEOME ANALYSIS 
During the development of this thesis, a linear ion trap Orbitrap instrument (LTQ Orbitrap XL) 
became available to the laboratory. This instrument combines the fast duty cycle of linear ion 
traps for MS/MS along with the high resolution and high mass accuracy capabilities of the 
Orbitrap. Thus, it is wel l suited for quantitative proteomics using a label-free strategy. 
This prompted an investigation of changes in the plasma samples by a one-dimensional (lD) 
gel approach following protein pre-fractionation (Figure 4.7 shown the 1D ge ls used to excise 
gel bands for tryptic digestions), which was integrated into a typical LC-MS/MS workflow for 
protein identification, using the L TQ Orbitrap XL mass spectrometer. A simple and convenient 
label-free approach (spectral counting) was then used to estimate the relative abundance of 
proteins in 5 different experimental conditions (Matherials and Methods, Figure 3.3, page 86 ), 
namely, IPC stimulus (7'MCAo), severe ischemia (pMCAo), the combination of the two 
(7'MCAo/pMCAo), and 2 groups of sham-operated controls sham7'MCAo and 
sham7'MCAo/pMCAo. For convenience, sham7'MCAo will be referred to as sham lOP (sham 
animals with one surgical operation) and sham7'MCAo/pMCAo will be referred to as sham 20P 
(sham animals with two surgical operations). Analysis was performed on pooled samples for 
each experimental condition to overcome resource constrains. 
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Figure 4.7. One-dimensional gels used to excise gel bands for tryptic digestions; in each gel samples were loaded in 
the following order (from left to right) : 7'MCAo, pMCAo, 7'MCAo/pMCAo, SHAM 7'MCAo, SHAM 7' MCAo/pMCAo 
and a SHAM merge obtained mixing an equal amount of protein from the two SHAM groups. In the last lane was 
reported an example of the mask that was used to cut the bands for tryptic digestions. 
4.2.1. Differential protein expression 
Proteomic analysis identified 143 proteins in mouse plasma that differed between the 
experimental groups. The quantitative data trend (normalized spectral counts for each protein 
in each replicate sample for each experimental group Table 4.4) was explored by PLS-DA to 
evaluate differences in the levels of protein expression in the different experimental groups. 
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As shown in Figure 4.8, the scores demonstrated an acceptable separation between set 1 
(7'MCAo and sham lOP) and set 2 (pMCAo, 7'MCAo/pMCAo and sham 20P) (Figure 4.8 panel 
A), using two principal components (R2(X) = 0.332, R2(y)= 0.205, Q2= 0.0456); a good separation 
within each set was also obtained as shown in Figure 4.8 panel B and Figure 4.8 panel C (for set 
1: R2(X) = 0.385, R2(y)= 0.846, Q2= 0.61; for set 2: R2(X)= 0.267, R2(y)= 0.419, Q2= 0.148). 
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Figure 4,8. Panel A: PLS-DA score of plasma proteomic profiles from 7'MCAo mice (pale blue spots renamed tia), 
Sham 7'MCAo mice (red spots renamed sham lop), pMCAo mice (blue spots), 7'MCAo/pMCAo mice (green spots 
renamed 2op) and Sham 7'MCAo/pMCAo mice (yellow spots renamed sham 2op); panel B: PLS-DA score of plasma 
proteomic profiles from 7'MCAo mice (green spots renamed tia), Sham 7'MCAo mice (blue spots renamed sham 1 
op); panel C: PLS-DA score of plasma proteomic profiles from pMCAo mice (blue spots), 7'MCAo/pMCAo mice 
(green spots renamed 2op) and Sham 7'MCAo/pMCAo mice (yellow spots renamed sham 2op) . 
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The loading scatter plots (not shown) obtained from the comparison of the two datasets 
identified proteins responsible for the plasma samples class separation in all groups. It will be 
recalled that the 2-DE proteomic analysis of brain cortex proteins, indicated no statistically 
significant difference in the proteome profile between sham lOP and sham 20P, and hence, 
these were consequently merged together as unique sham group. In contrast, analysis of the 
plasma proteome by PLS-DA showed a difference between the two Sham groups. This 
prompted the use sham lOP as a suitable control for the 7'MCAo group and sham 20P for the 
pMCAo and 7'MCAo/pMCAo groups. 
A threshold was set (variable importance in the projection, VIP>l) to define those proteins that 
played significantly roles in distinguishing the 5 experimental groups. There were 41 proteins 
out of 143 with a VIP>l. To assess the reproducibility of the protein quantitation in the 
replicates, the average coefficient of variance (CV %) for normalized spectral counts in the VIP-
proteins was calculated for each experimental group. The CV percentages (mean ± SD) were 48 
± 8, 45± 9, 44 ± 6, 43 ± 8, 44 ± 9 in 7'MCAo, sham lOP, pMCAo, 7'MCAo/pMCAo and sham 
20P, respectively. To minimize incorrect data interpretation, proteins with CVs of ~ 35% were 
not subsequently considered. Thus, the focus was on a protein subset having VIP values of> 1 
and CVs of $ 35% (11 plasma proteins in total). The identities of these proteins, and their 
differential expression data, are reported in Table 4.5. 
As shown in Table 4.5, there were only 4 proteins whose change in abundance were 
statistically significant using a Univariate test (Anova and post-hoc test Tukey-Kramer HSD 
p<O.05). Althought the use of pooling strategies and technical replicates makes the statistical 
results with limited relevance, these findings may be of interest as global viwe of the most 
relevenat changes that occur during IPC. The expression of Insulin-like Growth Factor-binding 
protein complex Acid Labile Subunit (IGFALS) was more than doubled in 7'MCAo compared to 
sham lOP, whereas it was almost halved in 7'MCAo when compared to pMCAo and 
7'MCAo/pMCAo. The abundance of Epidermal Growth Factor Receptor (EGFR) was decreased 
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1.6-fold in 7'MCAo when compared to sham lOP. The fibrinogen gamma and beta chains were 
downregulated by almost 2-fold in 7'MCAo when compared to pMCAo and/or 
7'MCAo/pMCAo. 
Table 4.5. Protein expression fold change in mouse plasma after preconditioning alone (7'MCAo) or severe ischemia 
with (7'MCAo/pMCAo) or without preconditioning (pMCAo) as compared to SHAM. Up- or down regulated proteins 
are shown in bold (fold change ~ 1.5), or in bold-italic (fold change ~ -1.5), respectively (Tukey-Kramer HSD p < 
0.05). 
# Identified Proteins 
Access 
number 
Entry name Expression fold changes 
7'MCAoVs pMCAoVs 7'MCAo/pMCAo Vs 7'MCAo/pMCAo Vs pMCAoVs 7'MCAo/pMCAo Vs 
sham lOP sham 2 OP sham 20P pMCAo 7'MCAo 7'MCAo 
2 Complement C3 P01027 C03 MOUSE 1 11 1 1.1 ·13 ·;2 -
6 Serotransfernn 092111 TRFE MOUSE ·1 ·11 1 1.2 :.1 13 
8 Alpha·2·macroglobulin 061838 A2M MOUSE .1.2 
·1.4 ·1 1.4 1.11 1.5 -
10 Complement factor H P06909 CFAH_MOUSE 1 1.2 1.3 1 -118 ., - ... 1 
lIb· h . 08VCM7 FIBG_MOUSE FI nnogen gamma ( aln 1.2 ·13 .1.2 1 ·2 ·1.9 
14 Fibnnogen beta chain 08KOE8 FIBB_MOUSE 1.4 ·1 ·1 ·1 ·2.1 ·2.1 
32 Gelsolin P13020 GELS MOUSE 11 ·1.4 ·1.4 1 .1.3 13 
34 Epidermal growth factor receptor 001279 EGFR MOUSE ·1.5 ·1 jj 1.2 11 1.4 
42 Prothrombin P19221 THRB MOUSE ·13 11 ·11 ·13 1.3 1 
4S Clusterin 006890 (lUS MOUSE ·12 1 1.2 :2 .1.1 1 
80 Insulin·like growth factor·binding 
protein complex aCid labile subunit P70389 LGFALS MOUSE 2.4 ·13 ·1.4 'j ·2 ·2.2 
I··, r 
To understand the biological relevance of the differentially expressed plasma proteins, the 11 
proteins identified above (i.e. with VIP values of> 1 and CVs of $ 35%; Table 4.5) and their 
expression data were visualized using the pre-existing pathway maps application of MetaCore 
(Matherials and Methods, page 100). Pathway reconstruction identified Immune response-
complement system and blood coagulation (Figure 4.9 and Table 4.6), as the main pathways 
differently modulated in the mouse plasma from different experimental groups. 
With this subset of 11 plasma proteins, biological network were built using the "shortest 
paths" (two steps) Metacore's network algorithm to evaluate protein-protein interaction 
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network. All the 11 plasma proteins of the subset used were brought together in the network 
(Figure 4.10). 
The network statistics indicates Epidermal Growth Factor Receptor (EGFR), Clusterin and 
Insulin-like Growth Factor 1 (IGF-1) as the major hubs of this network, with respectively 15, 11 
and 11 connections. Interestingly EGFR was directly connected with the Androgen Receptor 
(AR) and Heat Shock 70kDa Protein 5 (GRP78), member of the HSP70 family, proteins already 
highlighted by proteomic profiling of the brain cortex samples. Moreover, a further plasma 
protein, Clusterin, was directly linked to AR and to GRP78. Furthermore, the third hub, IGFl 
was directly linked to the plasma protein IGFAlS and again to Clusterin and to AR, suggesting 
again that AR might be an important player in the preconditioning stimulus (7'MCAo group). 
IoglpV31uo) 
~-
, -
2 _ 
Figure 4.9. Functional Ontology Enrichment generated by the MetaCore software. The bars represent the most 
significant biological pathway maps overrepresented in the list of plasma proteins perturbed in the experimental 
models. Results are ranked by the -log(pValue) . 
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Table 4.6. Mapping differently modulated proteins to pathways using the Metacore software package. 
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Immune response 
Blood Coagulation 
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Figure 4.10. The global network associated with proteins that are differentially expressed in transient and 
permanent ischemia models. The MetaCore network algorithm "shortest paths" (two steps) was used to map the 
shortest path for protein-protein interactions. Individual proteins are represented as nodes of different shapes, 
according to their functional class. Circled nodes denote proteins identified in this study. Lines between nodes 
indicate direct protein-protein interactions, the arrowheads indicate the direction of the interaction. Black circles 
highlight network hubs highly connected with the dysregulated proteins, as indicated by network statistics. 
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4.2.3. IGF-l plasma expression. 
Since IGFALS was directly connected to IGF1 protein by network analysis, and IGF1 
represented a major hub in the network, it was decided to validate the IGF1 expression trend 
in plasma biological replicates by a standardized and commercially available ELISA method 
(Matherials and Methods, page 100). 
As shown in Figure 4.11, the expression trends of plasma IGFALS measured by label-free MS 
(panel A) paralleled those of IGF1 measured by ELISA (panel B). Indeed, an increased 
expression of both proteins was observed in the 7'MCAo group when compared to the proper 
SHAM group and also to pMCAo and 7'MCAo/pMCAo. 
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Figure 4.11. Comparison of the plasma expression profiles of IGFALS (Panel A) and IGF-1 (Panel B), as measured by 
10 LC-MS/MS and ELISA, respectively. In Panel A, each bar represents the normalized spectral counts (mean ± SO, 
n=5). The vertical axis shows the arbitrary quantities unit expressed as normalized spectral counts . Asterisks mark 
significant expression changes (Tukey-Kramer HSO p < 0.05). Panel B reports an ELISA to measure IGF-1 plasma 
levels as reflected by optical density assessed at 450 nm. Each bar represents the concentration expressed in pg/mL 
(mean ± SO, n=5) . Asterisks mark significant expression changes (Tukey-Kramer HSO p < 0.05). 
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4.2.4. Preliminary conclusions 
The application of a 1D gel approach for plasma protein pre-fractionation integrated into a 
typical LC-MS/MS workflow successfully highlighted a small subset of plasma proteins (11 
proteins), involved in inflammation and blood coagulation pathways, whose abundance 
significantly changed in different settings of the ischemic mouse models analyzed . 
It has to keep in mind that the above results are based on pooled samples and technical 
replicates and no information on biological variation is available, limiting the statistical 
confidence. However the assumption of biological averaging is usually met in animal models 
where the source of bias (subject-to-subject variation) are small and can be neglected (Karp et 
01. 2009). Nevertheless the identification of up- and down-regulated proteins expression from 
pooled samples does not mean that these proteins are not interesting with the respect to the 
underlying biological population. Interestingly, following IPC stimulus, the downregulation of 
EGFR and the upregulation of IGFALS was observed. IGFALS expression in technical replicates 
of plasma pools was paralleled by increase in the level of IGFl in plasma biological replicates, 
as validated by ELISA. 
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4.3 CORRELATION BETWEEN BRAIN CORTEX AND PLASMA 
PROTEOMIC RESULTS 
As mentioned in the aims of this thesis (page 77), there was particular interest in evaluating to 
what extent the changes in protein expression observed in the brain of the IT mouse model 
correlate with those in their plasma, in order to discover a panel of candidate protein 
mediators for stroke progression and prognosis. 
To achieve this goal it is necessary to integrate the proteomic results obtained from the 
different methodological approaches and scrutinize them using bioinformatic tools such as 
MetaCore (Matherials and Methods, page 100). 
The protein sets that were used in this analysis are those reported in the 2-DE-LC-MS/MS brain 
results (Table 4.2 page 112) and in the lD-LC-MS/MS plasma results (Table 4.5 page 128). 
The two proteomics dataset were merged into a unique list of proteins (together with their 
expression data in each experimental group), which was subsequently used for network 
analysis to find the shortest path of interaction between the differentially expressed brain and 
plasma proteins (nodes). The MetaCore algorithm employed was 'Shortest paths', with a 2 
steps maximum length for a path to be included and with a "Through" list of nodes, meaning 
that every path pass through all the nodes. All plasma and brain proteins were brought 
together in the network either by direct and indirect connections (Figure 4.12). 
Interestingly, the 3 main hubs of this network were: Androgen Receptor (AR), Epidermal 
Growth Factor Receptor (EGFR) and the Insulin-like Growth Factor 1 (lGF-1), with respectively 
102, 45 and 21 connections (Figure 4.13) . These three protein hubs were in turn directly 
connected among each other. More precisely, AR exerted an activation effect on IGF-1 and it 
had an inhibitory effect on EGFR. 
The reduc.tion of the maximum length for the path (1 step instead of the previous 2 steps) 
highlights the important role of AR in controlling the expression of 8 brain proteins (GRP78: 
Heat shock protein 78; GSTP1: Glutathione S-transferase P1; ACON : Aconitate hydratase; 
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BHMT: Betaine homocysteine S-methyltransferase; V-ATPase E subunit: Vesicle fusing ATPase 
E subunit; NSG peroxidase: Peroxiredoxin-6; DLDH: Dihydrolipoyl dehydrogenase; PDIA3: 
Protein disulfide isomerase A3; and 4 plasma proteins (EGFR: Epidermal Growth Factor 
Receptor; Gelsolin; IGF-1: Insulin-like Growth Factor 1; Clusterin) (Figure 4.14). 
An important detail from the previous network is reported in Figure 4.15 where the type of 
connections between the proteins changed following the preconditioning stimulus (7'MCAo 
group) are shown, suggesting again the important role of AR in this model setting. 
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Figure 4.12. Global network associated with the proteins that were detected as differentially expressed in transient 
and permanent ischemia models. The MetaCore network algorithm "shortest paths" (two steps) was used to map 
the shortest path for protein-protein interactions. Circled nodes denote proteins identified in this study, small full 
red and blue circles indicate up- and down-regulation, respectively. Individual proteins are represented as nodes of 
different shapes, according to their functional class. Lines between nodes indicate direct protein -protein 
interactions, the arrowheads indicate the direction of the interaction. Rectangles indicate the identified brain 
proteins and circles indicate the identified plasma proteins. 
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Figure 4.13. Traced network analysis. The 3 major hubs of the network and the directly linked objects are 
highlighted and their connections traced . Direct connections between hubs are represented by blue lines. 
Rectangles indicate the identified brain proteins and circles indicate the identified plasma proteins. 
Figure 4.14. Global network associated with the proteins that were detected as differentially expressed in transient 
and permane!)t ischemia models. The MetaCore network algorithm "shortest paths" (one step) was used to map 
the shortest path for protein-protein interactions. Circled nodes denote proteins identified in this study, small full 
red and blue circles indicate up- and down-regulation, respectively. Individual proteins are represented as nodes of 
different shapes, according to their functional class. Lines between nodes indicate direct protein -protein 
interactions, while the arrowheads indicate the direction of the interaction. Rectangles indicate the identified brain 
proteins and circles indicate the identified plasma proteins. 
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Figure 4.15. The network associated with the proteins that were differentially expressed in the 7' MCAo group. The 
MetaCore network algorithm "shortest paths" (one step) was used to map the shortest path for protein -protein 
interactions. Circled nodes denote proteins identified in this study, small full red and blue circles indicate up- and 
down-regulation, respectively. Individual proteins are represented as nodes of different shapes, according to their 
functional class. Lines between nodes indicate direct protein-protein interaction, wh ile the arrowheads indicate the 
direction of the interaction. Rectangles indicate the identified brain proteins and circles indicate the identif ied 
plasma proteins. 
4.3.1. Preliminary conclusions 
To evaluate to what extent the protein expression changes observed in the brain of the IT 
mouse model may correlate with those in their plasma, a protein network analysis was 
performed using the MetaCore software package. All the identified plasma and brain proteins 
were brought together in the network either by direct or indirect connections. The network 
analysis highlighted 3 main protein hubs: Androgen Receptor (AR), Epidermal Growth Factor 
Receptor (EGFR) and Insulin-like Growth Factor 1 (IGF1) . These three hubs were in turn directly 
connected among each other. Interestingly, AR was directly linked to the majority of the 
identified brain and plasma proteins. 
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4.4. METABOLOMIC PROFILING OF PLASMA IN THE ISCHEMIC 
PRECONDITIONING MOUSE MODEL 
An unbiased metabolomic profiling approach using mass spectrometry was adopted to explore 
perturbations in circulating metabolites in the ischemic preconditioning mouse model. The 
rationa le was that, together with the identified plasma and brain proteins, these might 
represent an innovative array of candidate mediators. 
Experimental groups were compared to their respective sham group. Mass-spectral data of the 
single charged ions, [M+Ht (e.g Figures 4.16,4.17,4.18), were subject to peak alignment and 
data pre-processing by SIEVE v2. To evaluate the number and percentage of features that 
varied significantly between the different sample sets, filtering criteria were applied and 
significant differences were considered only for features with intensity coefficients of variation 
(CV%) of <20% and unpaired t -test for unequal variance (Welch's test) of p~O.01. For 
convenience, sham7'MCAo is denoted as sham lOP (Le. sham animals with one surgical 
operation) and sham7'MCAo/pMCAo is denoted as sham 20P (Le. sham animals with two 
surgical operations) . Althought the use of pooling strategies and technical replicates makes the 
statistical results with limited relevance, these findings may be of interest as global view of the 
most relevant changes that occurs during IPC. 
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Figure 4.16. Carnitine [M+Ht m/z 162.1124; mass spectra acquired using LTQ Orbitrap XL'M (Thermo Scientific, 
Waltham, MA, US)in data depending mode. In the upper panel the MS spectrum is reported; in the lower panel the 
MS/MS spectrum is reported . 
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Figure 4.17. Propionylcarnitine [M+Hf m/z 218.1386; mass spectra acquired using LTQ Orbitrap XL'M (Thermo 
Scientific, Waltham, MA, US)in data depending mode. In the upper panel the MS spectrum is reported; in the lower 
panel the MS/MS spectrum is reported. 
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Figure 4.18. Adenosine [M+Hj' m/z 268.1041; mass spectra acquired using LTQ Orbitrap XL'M (Thermo Scientific, 
Waltham, MA, US)in data depending mode. In the upper panel the MS spectrum is reported; in the lower panel the 
MS/MS spectrum is reported. 
Overall, in the positive ion mode 12,436 features were detected for the comparison pMCAo vs. 
sham 20P; 12,433 features for the comparison 7'MCAo/pMCAo vs. sham 20P, and 14,940 
features for the comparison 7'MCAo vs. sham lOP. In the negative ion mode, 645 features 
were detected for the comparison pMCAo vs. sham 20P; 642 features for the comparison 
7'MCAo/pMCAo vs. sham 20P, and 513 for the comparison 7'MCAo vs. sham lOP. 
Subsequently, the filtered data were analyzed for global changes by using PLS-DA to evaluate 
the separation of the groups. As reported in Figure 4.19, the scores demonstrated an 
acceptable separation within each set either in positive ion mode (for set 1: R2(X) = 0.778, 
R2(y)= 0.99, Q2= 0.976; for set 2: R2(X)= 0.536, R2(y)= 0.498, Q2= 0.289); and in negative ion 
mode as shown in Figure 4.20 (for set 1: R2(X) = 0.798, R2(y) = 0.981, Q2= 0.968; for set 2: R2(X) 
= 0.833, R2(y) = 0.492, Q2= 0.432). 
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Figure 4.19. Panel A: PLS-DA score of plasma metabolic profiles from 7'MCAo mice (blue spots renamed tia), Sham 
7'MCAo mice (green spots renamed sham lOp); panel B: PLS-DA score of metabolic profiles from pMCAo mice 
(green spots), 7'MCAo/pMCAo mice (red spots renamed 2op) and Sham 7'MCAo/pMCAo mice (blue spots renamed 
sham 2op). Data acquired in positive ion mode. 
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Figure 4.20. Panel A: PLS-DA score of plasma metabolic profiles from 7'MCAo mice (blue spots renamed tia). Sham 
7'MCAo mice (green spots renamed sham lOp); panel B: PLS-DA score of metabolic profiles from pMCAo mice 
(green spots), 7'MCAo/pMCAo mice (red spots renamed 2op) and Sham 7'MCAo/pMCAo mice (blue spots renamed 
sham 2op). Data acquired in negative ion mode. 
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A threshold was set (variable importance in the projection, VIP>l) to define those features that 
appeared to playa role in distinguishing the experimental groups. Overall, there were 191 
features in the positive ion mode and 45 features in the negative ion mode with VIPs larger 
than 1. For the comparison pMCAo vs. sham 20P the number of features obtained in positive 
ionization mode was 104, 101 for the comparison 7'MCAo/pMCAo vs. sham 20P, and 87 for 
the comparison 7'MCAo vs. sham lOP. In negative ion mode, 23 features where obtained for 
the comparison pMCAo vs. sham 20P, 20 for the comparison 7'MCAo/pMCAo vs. sham 20P 
and 22 for the comparison 7'MCAo vs. sham lOP. 
4.4.1. Identification of metabolites 
By searching the KEGG and HMDB databases, 50% of the overall features in positive ion mode 
with VIPs> 1 were identified. 38% of the overall features in negative ion mode with VIPs> 1 
were also linked to defined molecular species. The complete list of the identified metabolites is 
reported in Tables 4.7, 4.8 and 4.9. 
It should be noted that a given molecule may be identified as several different features, such 
as naturally occurring components of its isotopic cluster or non-specific adduct ions. Several 
ana lytes were detected only in positive mode, whereas others were observed only in the 
negative ion mode, as already reported for plasma samples (Nordstrom, Want et al. 2008). 
A further bottleneck in metabolomics is the metabolite identification. Confident unambiguous 
assignments of observed metabolic features to a single metabolite are not always achievable. 
The Chemical Analysis Working Group of the Metabolomics Standards Initiative (MSI; 
http://msi-workgroups.sourceforge.net) has defined four different levels of metabolite 
identification confidence and methods on how to report metabolite identities (Sumner et al. 
2007; Dunn et al. 2012) . 
In my study the confidence of identity was mainly based upon mass spectral similarities with 
public spectra l libraries (as reported in Matherial and Methods page 104), without reference to 
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authentic chemical standards. Therefore the resulting identifications herein reported are 
defined as putative (Sumner et 0/. 2007; Dunn et 0/2012). 
The 7'MCAo group was the only group with metabolites whose level was more than 10 times 
higher than the Sham counterpart instead in the other groups (pMCAo and 7'MCAo/pMCAo), 
the changes were all quite modest (Tables 4.7,4.8 and 4.9). 
Table 4.7. Metabolites whose abundance is significantly changed (VIP>l) in the pMCAo vs. Sham7'MCAo/pMCAo 
(sham 20P) group. In each case, the following parameters are reported: the measured mass, mass error (delta 
ppm), type of adduct, expected mass value and the intensity ratio expressed as fold change value and calculated 
against the sham counterpart. 
Metabolite Measured Mass Delta ppm Adduct MW pMCAo Vs sham 20P fold 
changes 
2-Aminooctanoic aCid 1591257 13 +lH 1601330 .1.2 
3a, 12a·di hydroxy· 7·oxo· 5b·chol all· 24·oic '-4062717 06 +lH 4072790 
·41.3 
acid 
3·A m i no, 3· (4· hyd roxyphe nyl) propa n oic 181.0739 01 +lH 1820812 1.6 
acid 
3·Hydroxy· 7·oxocholan· 24·oi( aCid 3902769 03 +lH 3912841 
·1.3 
4·Hydroxy·4·( 3·pyridi nyl) butanOIc acid 1810740 01 +lH 1820813 1.6 
4·0xo·4 (3'pyridinyl)butanoic acid 179.0581 06 +lH 1800654 
·1.4 
4·0xopentanoic acid 1160477 29 ·lH 1170562 
·1.3 
Indoleacrylic acid 1870635 08 +lH 1880708 1.3 
Indolelactic acid 2050740 03 +lH 206.0812 ·1.3 
indoxyl 133.0526 11 +lH 134 0599 1 
_. 
isocitric acid 1920272 09 ·lH 2250615 1.3 
L·(· )·methionine 1490509 09 +lH 1500582 1.2 
L (·)·Phenylalanine 1650790 03 +lH 1660863 1.7 
L·( +)·Carniti ne 161.1052 0.01 +lH 162.1125 1.8 
L·(+)·Leucine 131 0946 06 +lH 1321018 2 
L·Valine 117.0788 13 +lH 1180861 1.7 
LysoPC( 18:3(9Z, 12Z, 15Z)) 517.3166 0.5 +lH 5183239 4.2 
LysoPC(20:3(8Z, l1Z, 14Z)) 5453472 16 +lH 5463544 6.2 
LysoPC(20:4(8Z, l1Z, 14Z, 17Z)) 5433317 05 +lH 544 3390 2.7 
LysoPC(20:5(5Z,8Z, 11Z, 14Z, 17Z)) 5413163 09 +lH 5423236 11.6 
LysoPC( 226(4Z, 7Z, lOZ, 13Z, 16Z, 19Z)) 5673320 08 +lH 5683393 2.5 
LysoPE( 18:2(9Z, 12Z)/0:0) 4772854 02 ·lH 5002782 2.4 
LysoPE( 20:4( 8Z, 11Z, 14Z, 17Z)/00) 5012855 01 ·lH 5242784 2.3 
Proline betaine 1430943 22 +lH 144.1016 1.7 
propionylcarniti ne 2171313 03 +lH 218.1386 -1 
tryptophan 2040898 03 +lH 2050971 1.3 
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Table 4.8. Metabolites whose abundance is significantly changed (VIP>l) in the 7'MCAo/pMCAo (2op) group vs. 
Sham7'MCAo/pMCAo (sham 20P) group. In each case, the following parameters are reported: the measured mass, 
mass error (delta ppm), type of adduct, expected mass value and the intensity ratio expressed as fold change value 
and calculated against the sham counterpart. 
Metabolite Measured Mass Delta ppm Adduct MW Zop Vs sham ZOP fold changes 
2-Aminooctanoic acid 1591257 1.3 +lH 1601330 1.4 
3-Amino-3-(4- 1810739 01 +lH 182.0812 1.2 
hvdroxvphenvl)propanoic acid 
3-Hvdroxv-7-oxocholan· 24-oic acid 390.2769 0.3 +lH 391.2841 -1.4 
4-Hvdroxv-4-( 3-pvridi nvl) butanoi c acid 1810740 0.1 +lH 1820813 12 
4-0xo-4-(3-pvridinvl)butanoic acid 1790581 06 +lH 1800654 2.5 
4-0xopentanoic aCid 1160477 2.9 -lH 1170562 -1 
Indoleacrylic acid 1870635 0.8 +lH 188.0708 1.2 
Indole lactic acid 2050739 0.2 +lH 2060812 1.8 
i ndoxvl 133.0526 1.1 +lH 1340599 -1.3 
isocitric acid 192.0272 0.9 -lH 225.0615 1.3 
L-( -)-methionine 149.0509 0.9 +lH 150.0582 1.1 
L -( -)- Phe nvlal ani ne 1650789 0.4 +lH 1660862 1.5 
L-(+)-Carnitine 1611052 001 +lH 162.1125 2 
L-(+)-Leucine 1310946 06 +lH 132.1018 1.5 
L Valine 1170788 1.3 +IH 118.0861 1.4 
LvsoPC( 18:3(9Z, 12Z, 15Z)) 517.3166 0.5 +lH 518.3239 4.8 
LvsoPC(20:3(8Z, HZ, 14Z)) 545.3472 1.6 +lH 546.3544 5 
LvsoPC(20:4( 8Z, 11Z, 14Z, 17Z)) 543.3317 0.5 +lH 544.3390 2.6 
LvsoPC(20:5(5Z,8Z, lIZ, 14Z, 17Z)) 541.3163 0.9 +IH 542.3236 6.7 
Lv soPC(22:6(4Z, 7Z,10Z, 13Z, 16Z, 19Z)) 5673320 OB +lH 568.3393 2.4 
LvsoPE( 18:2(9Z, 12Z)/0:0) 477.2854 0.2 -lH 500.2782 4 
LvsoPE(20:4( 8Z, 11Z, 14Z, 17Z)/O:O) 501.2855 0.1 -lH 524.2784 4 
Proline betaine 1430943 2.2 +IH 144.1016 -2.6 
propionvlcarniti ne 217.1313 0.3 +lH 218.1386 -1.4 
tryptophan 2040898 0.3 +lH 2050971 1.2 
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Table 4.9. Metabolites whose abundance is signif icantly changed (VIP>l) in the 7'MCAo (TlA) group vs. 
Sham7'MCAo (sham lOP) group. In each case, the following parameters are reported: the measured mass, mass 
error (delta ppm), type of adduct, expected mass value and the intensity rat io expressed as fold change va lue and 
calculated against the sham counterpart. 
Metabolite Measured Mass Delta ppm Adduct MW TIA Vs sham lOP fold changes 
(2R)-1-1 (Hydroxy( [( 15, 3R)-2, 3,4,5,6-
pe n tahyd roxycyd oh exyl) oxy )phosphoryl lox 
y)-3-(pa lm itoyloxy)-2-propanyl (5Z,SZ,l1Z)-
860.5410 0.6 -lH 883.5339 1.4 
S,B,11-icosatrienoate 
(2R)-2-Hyd roxy-3-(( 5Z, SZ,l1Z,14Z, l 7Z)-
5,8,l1,14, 17- icosapentaenoyloxy)p ropyl 2- 541.3161 1.3 +lH 542.3234 1.4 
(t ri methylam monio)ethyl phosp ha te 
(2R)-2- Hyd roxy-3-1 (9Z)-9-
octadece noyloxy) propyl 2- 521.3476 0.8 +lH 522.3549 1 
(t rime thylammon io)ethyl phosphate 
(2R) -3-[ (9Z) -9- Hex adece noyl oxy) -2-
hyd roxypropyI2- (t rimethylammon io)ethyl 493.3162 1.2 +lH 494.3235 -1.1 
phosphate 
(4Z)-2-A m i no-3-hyd roxy-4-oClade ce n- l -yl 379.2484 0.9 +lH 3802557 2.1 
di hyd roge n ph osphate 
2,2- Dim ethyl succinic Acid 146.0578 0.9 +l H 147.0650 -28 
2-Me thylbutyrylglycine 159.0894 1.0 +lH 160.0966 4 
3- M ethyl -2-oxopentanoic acid 130.0632 1.6 -lH 131 .0715 1.3 
Ade nosin e 267.0969 0.2 +lH 268.1042 39.3 
Ad ip ic acid 146.0581 0.4 -lH 147.0665 9.1 
butyryl carni tine 231.1472 0.5 +lH 232.1544 19.2 
D-Panthotenic Acid 219.1108 0.4 +lH 220.1180 1.8 
Glucose 180.0636 1.1 - lH 145.0507 -11.3 
Hippuric aci d 179.0583 1.5 +lH 180.0655 2 
homaci tri c aci d 206.0425 0.9 - lH 171.0276 1.9 
Hypoxanthine 136.0387 2.0 - l H 137.0457 2.6 
i ndol-3-ylacetal dehyde 159.0683 1.9 +lH 180.0756 61.2 
indol eacryli c acid 187.0634 0.4 +lH 188.0707 1.4 
Indole laeti c aci d 205.0740 0.3 +lH 206.08 12 3.3 
L-(-) -m e thi o nine 149.0510 0.1 +lH 150.0583 1.3 
L-( -)-Phe nyl alanine 165.0790 0.1 +l H 166.0862 1.4 
L-(+)-Carn it ine 161.1052 0.01 +lH 162.11 25 1.4 
L- Hexanoyl carni t ine 259.1785 0.8 +lH 260.1858 58.1 
LysoPC( 18:2(9Z,12Z)) 519.3324 0.02 +lH 520.3397 1.1 
LvsoPC( 20 :4( SZ, 11Z,14Z, 17Z)) 543.3320 0.02 +l H 544.3392 1.5 
LysoP E( 18: 2(9Z,l2Z)/ 0:0) 4n.2853 0.5 -lH 5002783 2.4 
LysoP E( 18:2(9Z,12Z)/0:0) 477.2852 0.7 +lH 4782925 2.4 
N_Acetyl_L_phenyl alanin e 207.0898 1.1 +lH 208.0970 12.3 
N-Acetvl ne uraminic acid 309.1064 1.3 +lH 
310.11 37 -1.1 
N-caproylglvcine 173.1051 0.3 +lH 
174.1124 15.3 
Ni aci namide 122.0478 1.4 +lH 
123.0551 -1.1 
Phe nylpyruvi c acid 164.0471 0.6 +lH 
165.0544 1.5 
pro pi o nyl carniti ne 217.1314 
0.Q1 +lH 218.1387 4.9 
Se rotonin 176.0950 0.01 
+l H 177.1022 54.9 
threonic acid 136.0374 
1.4 -lH 137.0457 2.1 
t ryptophan 204.0900 
0.7 +lH 205.0973 1.5 
tyrosi ne 181.0739 
0.1 +l H 182.08 12 1.6 
4.4.2. Biological pathways and metabolic networks 
To further interpret the biological significance of the overall metabolomics data, the software 
tool MetaboAnalyst was used to link the identified metabolites to metabolic pathways (Figure 
4.21 and Figure 4.22). Panel A gives the summary plot for the metabolite set enrichment, panel 
B shows the difference in the abundance of the metabolites, mapped into enrichment 
categories, and panel C shows all metabolic pathways arranged according to the scores from 
enrichment analysiS (y axis) and topology analysis (x axis). 
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The analysis of the differences between the two data sets indicated that the protein 
biosynthesis and oxidation of branched fatty acids were the most over-represented metabolic 
pathways for all the groups (Panel A, Figure 4.21 and Figure.4.22). 
The 7'MCAo group showed plasma changes mainly in amino acids involved in protein 
biosynthesis and, more specifically, phenylalanine and tyrosine metabolism (Figure 4.21, panel 
A). For example, there was an overall increase, albeit modest, in the concentrations of 
methionine, phenylalanine, tyrosine and tryptophan compared to the sham control (Figure 
4.22, panel B). Mice from the 7'MCAo group also had higher levels of carnitine and 
propionylcarnitine, which are involved in the oxidation of branched fatty acids, compared to 
the sham animals. Interestingly two metabolites (serotonin and indole-3-acetaldehyde), which 
contributes to the tryptophan metabolism, showed striking increases in their concentrations in 
the 7'MCAo compared to the sham. 
Similarly, both pMCAo and 7'MCAO/pMCAo groups had a modest increase in the plasma levels 
of amino acids involved in protein biosynthesis (e.g. leucine, valine, methionine, 
phenylalanine, and tryptophan) when compared to their respective sham controls. In contrast 
to the 7'MCAo group, the pMCAo and 7'MCAO/pMCAo groups showed a slightly reduced 
plasma concentration of propionylcarnitine when compared to their controls (panel A and 
panel B Figure 4.22). 
Metabolic pathway analysis arranged according to enrichment analysis (Panel C Figure 4.21) 
showed that tryptophan and phenylalanine metabolism are more likely to be perturbed as a 
consequence of preconditoning stimulus (7'MCAo group); whereas valine, leucine and 
isoleucine biosynthesis might have a major impact in the pMCAo and in 7'MCAo/pMCAo 
groups (Panel C Figure 4.22). Tables 4.10 and 4.11 report the lists of metabolites with the 
enriched and network pathways in which they are involved for the two experimental sets. 
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(A) Metabollt. S.ts Enrichment Overview 
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Figure 4.21. Metabolic pathway analyses related to the metabolites that specifically differ in the comparison 
7'MCAo vs. SHAM 7'MCAo (sham lOP) utilizing the MetaboAnalyst functional interpretation tools. 
Panel A, graphic summary of metabolite set enrichment ana lysis; the horizontal bars summarize the main 
metabolite sets identified in this analysis; the bars are coloured according to the p-values and the bar length is 
based on the fold enrichment. Panel B shows the difference in abundance expressed as Fold change of the 
metabolite subset mapped into the enrichment categories. Panel C shows all metabolic pathways arranged 
according to enrichment analysis (y axis) and topology analysis (x axis) scores. 
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(A) Metabolite Sets Enrichment Overview 
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Figure 4.22. Metabolic pathway analyses related to the metabolites that specifically differ in the comparison 
pMCAo and 7'MCAo/pMCAo Vs sham 7'MCAo/pMCAo (sham 20P) utilizing the MetaboAnalyst functional 
interpretation tools. Panel A, graphic summary of metabolite set enrichment analYSis; the horizontal bars 
summarize the main metabolite sets identified in this analysis; the bars are coloured according to the p-values and 
the bar length is based on the fold enrichment. Panel B shows the difference in abundance expressed as Fold 
change of the metabolite subset mapped into the enrichment categories; full bars represent pMCAo metabolites; 
striped bars represent the 7'MCAo/pMCAo metabolites. Panel C shows all metabolic pathways arranged according 
to enrichment analysis (y axis) and topology analysis (x axis) scores. 
Table 4.10. Metabolites identified in set 1 (7'MCAo and SHAM7'MCAo) and the enriched and network pathways in 
which they are involved. 
!HRDMNIAHAlliS PAlIM'AI AHAlliS 
IJrniune OXlll\noNOf BRA'IOIEDOWN fAm ADD! 
Ind~+~lCetildeliyde moPIWl MflABOUSM Tl)1ltDphinlll'llbo/ilm 
Ind~!lailic add TRll'lOPlWIMflABOUSM TI)1l!o!Wnlll'llbo/ilm; 
1~~ac1icadd TRIl'TOPIWI MflABOUSM Tl)1l:opNnlll'llbo/ill!l 
Methionine PROruN ~OSl!llHfllS; BflNtf MflABOUSM Miooa()i·tRNA~lIIinlh!sil 
tt/(e!jl·l-p/l!n)jalanilll PH£I/\1AlA~tf AND ll1IOSItfMflABOUSM Pll!nj!alaninelll'llbo/ilm;PiI!I!y!III~III,I)IOIinellld~Jrellbo/ill!l 
PlnlDiltnic/(id P~~1H£II\T£ANDCOA~OSl!llHfllS Pinm:hmi~ /lid COA~os)lllh!sil 
PMlyIalanilll PROruN ~D!~~ PH£/M.IlANI/fA'«lll1lO~Nl MflABOUSM PIl/JI~alaninelll'llbolilm;AniIMll()i.tRNA~OSinlflelil; PiI!I!y!alanine,I)IOIinelnd~nJrellbo/ill!l 
Pherr,ip)llMcadd PH£M'IAWINl A'ID ll1IOSltf MflABOUSM Pil!l!y!lllnillllll'llbo/ilm;pt,e.~~IIIine,l)IlIIillllndll)1llilNnJrellbo/ilm 
PrqJjon~Clr~ulII OXI~TIONOf BRA'(If!DOWN fAm ADD! 
Serotonin TRIl'TOPIWI MflABOUSM; lXOTATORY NlUMl ~GNAllJr«i Tl)1lilllNnlll'llbo/ilm;PiI!I!y!alanilll,l)Iosilllandll)1l!op,anlll'llbo/ilm 
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Table 4.11. Metabolites identified in set 2 (pMCAo, 7'MCAo/pMCAo and SHAM7'MCAo/pMCAo) and the enriched 
and network pathways in which they are involved. 
ENRICHMENT ANALYSIS PATHWAY ANALYSIS 
(arnitine OXIDATION Of BRANCHED CH~N fATTY ACIDS 
lfIicine PROTEIN BIOSYNTHESIS; VAUN~ LEL(INE AND ISOLEUCINE DEGRADATION Aminoaeyl·tRNA biosinthes is; Va lin~ leucine and isoleucine biosynthesis 
Methionine PROlBN BIOSYNTHESIS; BfT~NE MfTABOUSM Ami noaeyl· tRNA bios inthesi s 
Phenylalanine PROlBN BIOSYNTHESIS; PHEN\1AlANINE AND TYRO~NE MfTABOUSM Phen~alanine, tyrosinmd tryptophan biosynthesis 
Propionylcarnitine OXIDATION Of BRANCHED CH~N fATTY ACIDS 
Tryptophan PROTEIN BIOSYNTHESIS Tryptophan melabolism;Aminoaeyl·tRNA biosinthesis; Phen~alanin~ tyros ine and tryptophan biosynthesis 
4.4.3. Preliminary conclusions 
A global metabolomic approach employing LC-MS was used to obtain a broad view of changes 
in plasma metabolites associated to three different ischemic models. This approach 
highlighted a subset of 191 features in the positive ion mode, and 45 features in the negative 
ion mode. Metabolite identification was successful for 50% and 38% of the features in positive 
and negative ion modes, respectively. The IPC stimulus group was the only in which the levels 
of certain metabolites was altered more than lO-fold relative to the Sham counterpart. 
As already stated, althought the use of pooling strategies and technical replicates affect the 
strenght of the statistical analysis, these findings may be of interest as global view of the most 
relevant metabolomics changes that occur during IPC. 
The profiling data was then used to detect altered biochemical processes using bioinformatics-
based pathway mapping. The processes mainly affected by the different ischemic stimuli were 
'proteins biosynthesis', 'phenylalanine and tyrosine metabolism', 'oxidation of branched fatty 
acid' and 'tryptophan metabolism'. 
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CHAPTER 5 
DISCUSSION AND CONCLUSIONS 
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5.1. DISCUSSION 
The molecular mechanisms underlying cerebral preconditioning are not well-understood, 
although it is generally accepted that this phenomenon requires a subthreshold dose of an 
otherwise harmful stimulus to induce protection against subsequent injurious challenge 
(Dirnagl, Becker et 01. 2009). The use of experimental animal models may help understanding 
the molecular mechanisms of neuroprotection and lead to the identification of potential 
therapeutic targets. Gesuete et 01. (Gesuete, Orsini et 01. 2011) have previously shown that 7 
min of ischemia (7'MCAo) is an ischemic pre-conditioning stimulus (IPC) capable of reducing 
the ischemic volume (as assessed 7 days after injury) induced by a subsequent severe 
ischemia. The 7'MCAo-induced protective mechanisms were effective 3 days after the IPC 
stimulus and lasted for 2 days (Gesuete, Orsini et 01. 2011). I have used this mouse model of 
different ischemia sets to study the molecular mechanisms involved in the neuroprotection 
induced by IPC. In particular I performed a differential expression profiling of proteins and 
metabolites in brain and plasma of mice exposed to: (i) an IPC stimulus alone (7'MCAo), (ii) 
severe ischemia alone (pMCAo) and (iii) the IPC stimulus followed by severe ischemia 
(7'MCAo/pMCAo), in comparison to their sham operated counterparts. 
I used mass spectrometry-based proteomics and metabolomics approaches to obtain a global 
overview of proteins and metabolites profile changes induced by IPC, with the ultimate aim of 
identifying possible mediators and their corresponding biological processes that may have a 
key role in the IPC induced protective mechanisms. 
I am aware that there are some limitations in the overall strategy of my study. Firstly, the 
different time points used for samples collection (4 days for 7'MCAo and 11 days for pMCAo 
and 7'MCAo/pMCAo) might have affected proteomics and metabolomics profiles. Secondly, 
the use of pooling samples strategy and only technical replicates to overcome resources 
constraints weakened the strength of the statistical anaylses. Nevertheless I think this 
explorative study provides the following three main findings: 
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1. Brain and plasma proteomics highlighted a neuroprotective profile in ischemic tolerance, 
characterized by a hitherto unrecognized cross-talk mechanism between AR and HSP10, IGF-
1, EGFR. 
The protein profile changes were initially assessed in mouse brain cortices. Fewer proteins 
were affected after IPC stimulus alone (7'MCAo) than after severe stroke or the combination of 
two. A peculiarity four days after the IPC stimulus alone was a specific increase in the 
expression of HSP70. In line with this, HSP70 upregulation at transcriptional and protein 
expression levels 24h after an IPC stimulus consisting of 10 min transient MCAo in rats has 
been previously shown (Dhodda, Sailor et 01. 2004). HSP70 and other heat shock proteins may 
playa role in the protection of the nervous system, particularly when induced before severe 
ischemia (Obrenovitch 2008; Ottens, Bustamante et 01. 2010). I observed the increase in HSP70 
four days after the IPC stimulus, whereas its expression was no longer affected seven days 
after severe ischemia, in either preconditioned or not preconditioned brains. 
The pathway analysis of brain dysregulated proteins showed evidence of a direct interaction 
between HSP70 and AR. I showed that AR protein expression parallels that of HSP70, 
suggesting a role of this receptor in the preconditioning. 
Androgen receptor is a nuclear receptor expressed in many tissue including both male and 
female brains (Dart et 01. 2013); AR is activated by steroidal androgens (eg. testosterone, 5-a-
dihydrotestosterone) exerting a transcriptional activity and can also be activated by non-
steroid mechanism inducing the activation of MAPK pathway (Heinlein and Chang 2002); AR is 
involved in cell growth (Cai et 01. 2011), in the remielization of axon in neurons (Hussain et 01. 
2013) and in the neurological effects associated to androgens also in brain ischemia (Uchida et 
01. 2009, Cheng et 01. 2009). Male sex is an acknowledged risk factor for human stroke and the 
outcome from brain ischemic injury is sex-linked also in animals (Appelros et 01. 2009; Cheng 
and Hurn 2010). However, the roles of steroidal androgens in brain ischemia is not clear and in 
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some cases contradictory (Cheng et a12007; Uchida 2009). In fact, AR was also associated with 
a neuroprotective profile in castrated male mouse ischemic models (Ayala et al. 2011) 
although the signalling mechanism remains unclear. 
As reported by others (Meehan and Sadar 2003), AR is associated in the cytoplasm with a 
complex of HSP90 and HSP70 that undergoes dissociation from AR in cells exposed to 
androgen. Moreover, Lu et al. (Lu, Tan et al. 2010), demonstrated that AR could regulate the 
expression level of HSP70-1 in prostate cancer cells, suggesting a feedback mechanism that 
regulate the homeostasis of HSP70 family (Lu, Tan et al. 2010). 
My findings support the notion that HSP70 participates in the induction of ischemic tolerance 
and that its increased expression might be the result of synergistic effects of several 
mechanisms, including AR mediated androgen neuroprotection. 
Besides upregulating HSP70 and AR, the IPC stimulus alone caused the downregulation of 
GSTM1 and LDHA. Glutathione S-transferases are detoxifying enzymes that catalyze the 
conjugation of reduced glutathione to reactive molecules from xenobiotics or products of 
oxidative stress, including reactive oxygen species (ROS). Thus, one would expect GSTM1 
expression to increase, even after a mild ischemic insult. Instead, GSTM1 was dowregulated 
after four days of reperfusion, an adaptive response that might compromise the brain's 
capacity to deal with oxidative stress. However, mitochondrial ROS generation plays an 
important role in preconditioning so it is plausible to hypothesize that GSTM1 is 
down regulated to maintain a favorable mitochondrial redox status (Correia, Carvalho et al. 
2010). 
LDHA is the enzyme that converts pyruvate into lactate and back to pyruvate which is a 
substrate for the mitochondrial TCA cycle. Lactate has been proposed as a major energy source 
in the brain, since its oxidation can produce a significant amount of ATP (Schurr 2006). The 
decreasing LDHA expression observed in this study might be an indicator of metabolic 
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down regulation, suggested to playa role in IPC (Stenzel-Poore, Stevens et 01. 2003; Stenzel-
Poore, Stevens et 01. 2007; Yenari, Kitagawa et 01. 2008). 
The involvement of metabolic downregulation is even more evident from protein expression 
after severe injury in preconditioned and non-preconditioned brains. Ischemia alone caused a 
strong upregulation of nearly all the proteins, and those with the largest expression changes (-
fold change greater than 2) mainly coordinate energy metabolism, mitochondrial electron 
transport, synaptic vesicle transport and antioxidant processes. The response to ischemic 
injury after preconditioning revealed a striking difference. Preconditioning (TMCAo/pMCAo) 
caused clear downregulation of energy metabolism (glycolysis, TCA cycle and mitochondrial 
electron transport) compared to pMCAo alone. These changes are unlikely to be long-lasting 
effects of IPC alone (TMCAo) since when pMCAo was performed 5 days after 7'MCAo, the IPC 
stimulus was no longer protective (Gesuete, Orsini et 01. 2011). 
Downregulation of the energy metabolism at both transcriptional and protein levels is a clear 
outcome in animals preconditioned with brief ischemia before exposure to injurious ischemia 
(Stenzel-Poore, Stevens et 01. 2003; Dhodda, Sailor et 01. 2004). In line with this, 
preconditioned brains displayed strong downregulation of DHDL (Table 3, expression 3.6 times 
lower than in SHAM), one of the subunits of the pyruvate dehydrogenase complex that serves 
as the critical link between glycolysis (anaerobic energy metabolism) and TCA cycle (aerobic 
metabolism) by catalyzing the oxidative decarboxylation of pyruvate to form acetyl-CoA 
(Martin, Rosenthal et 01. 2005). Reduced cerebral glucose metabolism and oxygen 
consumption after cerebral ischemia might depend on the low activity of pyruvate 
dehydrogenase complex (Fukuchi, Katayama et 01. 1998). 
Besides the decrease in expression of DHDL after preconditioning, I observed downregulation 
of succinate dehydrogenase (DHSA), and NADH dehydrogenase, both of which are involved in 
the generation of ROS by the mitochondrial electron transport chain. In line with these 
findings, respiratory chain inhibition may induce tolerance to focal cerebral ischemia 
153 
(Wiegand, Liao et 01. 1999). The downregulation of these proteins could be indicative of an 
IPC-induced process aimed at mitochondrial preservation during ischemia. When ischemia is 
followed by reperfusion, the increase in oxygen supply results in a burst of mitochondrial ROS 
production (Oirnagl and Meisel 2008). These highly reactive molecules may damage nucleic 
acids, proteins and lipids. Mitochondrial biomolecules are especially susceptible to oxidative 
stress because of their proximity to ROS production. Thus, mitochondria are at the same time 
ROS generators and targets of oxidative stress (Oirnagl and Meisel 2008). To cope with the 
danger induced by ROS, protective mechanisms must be called into play and in fact antioxidant 
proteins such as GSTM1, GSTP1, and S002 remained upregulated in preconditioned brains 
Previously it has been shown that astrocytes are involved in IPC, both in vivo and in vitro 
(Gesuete, Orsini et 01. 2011). This is further supported by the present findings indicating 
downregulation of one of the GLNA isoforms. GLNA is a glial-specific enzyme that converts the 
glutamate released during synaptic transmission to glutamine, which is then transported back 
to neurons, where it is converted to glutamate to close the glutamine-glutamate cycle in the 
brain (Zwingmann and Leibfritz 2003). The literature on GLNA expression in the brain after 
ischemia or hypoxia is scanty and contradictory (Hoshi, Nakahara et 01. 2006; Lee, Lingwood et 
01. 2010) In the general metabolic down-regulation scenario uncovered in the present study, 
the reduction in GLNA expression after ischemic tolerance induction might reflect a lower 
energy demand, since glutamine has been reported to be an energy substrate in cultured 
neurons during glucose deprivation (Peng, Gu et 01. 2007). 
Another feature of preconditioning is the decrease in expression of fascin, a key regulator of 
cytoskeleton dynamics that organizes actin filaments and is abundant in the brain. Using an in 
vitro model, Meller et 01. (Meller, Thompson et 01. 2008) showed that two actin-binding 
proteins (MARCKS and fascin) are degraded by the ubiquitin-proteasome system soon after 
preconditioning ischemia and suggested that the loss of these actin-binding proteins promoted 
actin filament reorganization and could be involved in the acquisition of rapid (protein 
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synthesis-independent) ischemic tolerance (Meller, Thompson et 01. 2008). The data in the 
present study suggest that regulation of proteins involved in cytoskeleton remodeling occurs 
also after IPC-induced delayed ischemic tolerance, as fascin downregulation was observed 
seven days after ischemia. However, the mechanism underlying these results could be 
different, possibly linked to protein synthesis modifications. 
The proteomic approach used here was also successful in identifying circulating protein 
changes in the plasma of the different ischemic sets. When the ischemic preconditioning group 
was compared to its proper control, I observed an increased level of IGFALS, a glycoprotein 
that forms a ternary complex with IGF-l, IGF-2 and Insulin-like Growth Factor Binding Protein 
species (e.g. IGFBP-3) (BOisclair, Rhoads et 01.2001). Even though there is no direct correlation 
between IGFALS and neuro-protection, the latter has been associated with IGF-l and IGFBP3 in 
the treatment of acute ischemic stroke (Kooijman, Sarre et 01. 2009; De Smedt, Brouns et 01. 
2011). As reported by Boisclair et 01. (Boisclair, Rhoads et 01. 2001), IGFALS is a critical 
component that contributes to the development of a large reservoir of serum IGFs to facilitate 
their endocrine actions, to prolong their half-lives and to minimize their local effects. The 
increased abundance of plasma IGFALS, observed 4 days after the IPC stimulus, but no longer 
present at seven days after severe ischemia, suggests its involvement in the induction of 
tolerance. The increase in plasma IGF-l parallels that of IGFALS, pointing toward a contribution 
of both proteins in the induction of the neuroprotective profile in ischemic preconditioning. 
This is in accordance with the notion that IGF-l, an endogenous survival factor for neurons, 
glia and endothelial celis, probably exerts its neuroprotective role in stroke by its anti-
apoptotic, anti-inflammatory and regenerative properties (De Smedt, Brouns et 01. 2011). 
The IPC stimulus alone also induces lower levels of Epidermal Growth Factor Receptor (EGFR), 
a tyrosine kinase receptor that binds ligands of the Epidermal Growth Factor family. These 
ligands induce receptor activation by autophosphorylation. The activated receptor initiates a 
signal transduction cascade leading mainly to cell growth. The levels of EGFR may be 
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modulated at the genomic level by aldosterone, a steroid hormone produced by adrenal cortex 
considered a risk factor for stroke, due to its role in the pathogenesis of vascular disease 
(Dorrance, Osborn et 01. 2001). The remodelling of the cerebral vasculature induced by EGFR 
activation, contributes to the pathogenesis of cerebral ischemia and the administration of 
spironolactone, an aldosterone antagonist, reduces the expression of mRNA for EGFR and the 
size of the ischemic damage (Dorrance, Osborn et 01. 2001). Thus, the decreased level of 
plasma EGFR observed after the pre-conditioning stimulus alone could reflect an adaptive 
mechanism leading to a reduction in the remodelling of the cerebral vasculature and in the 
infarct size. 
Changes in the levels of plasma fibrinogen gamma and fibrinogen beta, two polypeptide chains 
of fibrinogen, were observed in the severe stroke and ischemic-tolerant groups, when 
compared to the IPC stimulus alone. Fibrinogen is an hexameric plasma glycoprotein that is 
converted by thrombin in cross-linked fibrin taking part in the blood clot formation. Mediators 
of the acute-phase inflammatory response like glucocorticoids or IL-6, stimulate an increase of 
fibrinogen mRNA and protein levels; increased fibrinogen levels replenish fibrinogen lost due 
to bleeding or clotting, and contribute to wound healing (Fish and Neerman-Arbez 2012). 
Therefore the changes observed for the two fibrinogen chains could be related to the different 
time points at which the plasma samples were collected (4 days for 7'MCAo and 7 days for 
pMCAo and 7'MCAo/pMCAo) rather than to the different ischemic sets. As a matter of fact, no 
significant changes of these proteins were found when each ischemic set was compared to its 
proper sham. My explanation could be supported by Shenhar-Tsarfaty's work (Shenhar-
Tsarfaty, Ben Assayag et 01. 2008), which reported an increase in the human fibrinogen levels 
in the first few days after ischemia reflecting the acute-phase related to the inflamation. Since 
the final infarct size depends on the occlusion time of the MCA, and some processes involved 
. f 'on e g blood coagulation, could increase the size of infarct, the involvement of In reper USI , ., 
156 
blood coagulation processes in some models of brain ischemia is still debated (Braeuninger, 
Kleinschnitz et 01. 2012). 
Nevertheless, blood coagulation processes undoubtedly have a role in my differential ischemic 
sets, since plasma Alpha-2-macroglobulin (a2M) was increased in ischemic-tolerant mice when 
compared to the preconditioning stimulus group. a2M is a glycoprotein involved in blood 
coagulation, exhibiting a procoagulant activity by inhibiting plasmin and hence blocking the 
dissolution of the fibrin polymers (Schaller and Gerber 2011). At the same time, a2M can have 
an anticoagulant activity in antithrombin-deficient subjects inhibiting thrombin and the 
conversion of fibrinogen to fibrin (Mitchell, Piovella et 01. 1991; Tripodi, Chantarangkul et 01. 
2000). Although no clear correlation exists between a2M and brain ischemia, its expression 
has been associated with genes related to the STAn pathway in the traumatic brain injury 
(TBI) (Oliva, Kang et 01. 2012) a model known to share many aspects with brain ischemia. 
Moreover, STAn activation has been related to the neuroprotective role of IL-6 in the 
ischemic stroke (Jung, Kim et 01. 2011) and it has been reported that STAn in Middle Cerebral 
Artery Occlusion (MCAo) mice models works as mediator of neuronal function after injury 
controlling metabolic, synaptic, structural and transcriptional pathway (Di Domenico, Casalena 
et 01. 2012). On the basis of the above considerations, it is reasonable to assume that an 
activation of a2M by STAn might also occur in brain ischemia, and the levels changes 
observed could be associated with the protection induced by preconditioning against the 
severe stroke. 
The key finding arising from the integration of the results of the brain and plasma proteomic 
study is the evidence of a neuro-protective profile characterizing the ischemic preconditioning 
group. As a matter of fact, in the brain of mice exposed to IPC only, HSP70 and AR could 
contribute to a neuroprotective profile, whereas in their plasma the neuro-protection could be 
related to the activity of the Insulin-like Growth Factor-I. This scenario represents a novel 
finding in the ischemic settings, since cross-talk among these proteins has previously been 
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suggested only in cancer-related studies, where IGF-l may influence the expression of AR 
(Cohen, Peehl et 01. 1991; Iwamura, Sluss et 01. 1993; Pietrzkowski, Mulholland et 01. 1993; 
Tong da, Wu et 01. 2012). Similarly, the cross-talk between AR and EGFR has been suggested in 
prostatic and bladder cancer, where EGFR, in association with other tyrosine kinase receptors, 
e.g. ErbB2, could directly or indirectly induce a modulation in the expression and functions of 
AR (Cai, Portnoy et 01. 2009; Izumi, Zheng et 01. 2012). 
On the basis of these data and the protein network findings, it is tempting to speculate that in 
the preconditioning stimulus alone group, crosstalk between IGF-l, AR and EGFR might occur 
and contribute to the restoration of an ischemic tolerant profile. Notably, combination of the 
brain and plasma proteomics findings through network analysis indicates that the AR was 
directly connected to proteins involved in energy metabolism (Aconitate hydratase, 
Dihydrolipoyl dehydrogenase), antioxidant processes (Glutathione S-transferase PI, 
Peroxiredoxin-6), stress response (Heat shock protein 78), amino acid biosynthesis (Betaine 
homocysteine 5-methyltransferase), synaptic vesicle transport (Vesicle fusing ATPase E subunit), 
rearrangement of disulfide bonds (Protein disulfide isomerase A3) and cell growth (Epidermal 
growth factor receptor, Insulin like growth factor 1). Considering that some of these biological 
processes are upregulated in mice with severe stroke where AR is downregulated, it is 
reasonable to hypothesize that an inverse correlation between AR expression and those 
biological processes might occur. 
2. Untargeted metabolomics analysis reveals fatty acids oxidation and branched-chain 
amino acid metabolism as the main biological processes modulated in ischemic tolerance 
{IT}. 
An unbiased metabolomic profiling approach using mass spectrometry was used to identify 
perturbations in circulating metabolites that could be involved in ischemic preconditioning and 
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might reflect amplifications of the changes that occurred in the transcriptome and the 
proteome (Kell 2005). 
It is readily acknowledged that the metabolomics study that was performed is preliminary and 
that further validation of the changes in the concentration of metabolites found in the IT mice 
model is warranted. 
Moreover, these metabolomics findings are purely observational and do not allow the 
identification of causal relationships to determine whether changes in circulating molecules 
are likely to be the consequence of the observed ischemic phenotypes. Moreover it is not 
known to what extent changes in plasma metabolites might interfere with brain metabolism 
and vice-versa. 
Nevertheless, my preliminary data have shown that the IPC stimulus alone lead to the highest 
number of metabolites changes, when compared to severe stroke or preconditioned settings. 
Many biochemical alterations were in line with those already reported in the literature on 
cerebral ischemia, supporting the feasibility and robustness of this explorative untargeted LC-
MS strategy. For example, there were changes in the plasma levels of carnitine and its esters, 
which play pivotal roles in transporting fatty acids into the mitochondria, where they are 
oxidized to produce energy (Virmani and Binienda 2004). Their role in brain neuropathology 
has been extensively investigated, providing evidence of neuro-protective, neuro-modulatory, 
and neurotrophic properties that may counteract various neurological disease processes 
(Virmani and Binienda 2004). Indeed, the supplementation of carnitine and its esters have 
shown beneficial effects in some neurological dysfunctions and in hypoxia-ischemia 
(Wainwright, Kohli et 01. 2006; Jones, McDonald et 01. 2010). In line with these observations, 
the levels of plasma carnitine esters particularly elevated in IPC animals, but generally reduced 
in severe-stroke and ischemic-tolerant mice, might corroborate the neuro-protective 
phenotype of the IPC mice. Changes in energy homeostasis pathways to sustain ischemic stress 
by IPC stimulus may be also supported by the elevation of plasma adipic acid, a dicarboxylic 
159 
acid derived from omega-oxidation of fatty acids. A plausible acceleration in fatty acid 
metabolism would inhibit an intracellular accumulation of detrimental fatty acids as proposed 
for myocardial ischemic preconditioning (Matsuki, Nozawa et 01. 2009). 
Evidence of a neuro-protective metabotype of the IPC setting can be inferred also from the 
high levels of plasma adenosine. Adenosine is a well known neuromodulator (Cunha 2001) that 
plays a key role in the induction of brain tolerance thought the activation of Al receptors, 
which induces mitochondrial K+ATP channels opening, mitochondrial membrane depolarization 
and ROS reduction (Rudolphi, Schubert et 01. 1992; Fellows, Boutelle et 01. 1993; Heurteaux, 
Lauritzen et 01. 1995; Perez-Pinzon and Born 1999). The surge in plasma adenosine likely 
mirrors an increased production in brain after TIA, where its accumulation may reflect an acute 
adaptation to the transient ischemic stress with a negative feedback modulation on 
hemodynamic causes and metabolic consequences of TIA, as suggested by Laghi Pasini et 01. 
(Laghi Pasini, Guideri et 01. 2000). 
There is a convincing body of evidence for the role of branched-chain amino acids (BCAA) in 
brain functions. BCAA are integral to the glutamate/glutamine cycle, which is critical for the 
efficient uptake of glutamate during excitatory neuronal signaling (Hutson, Lieth et 01. 2001; 
Fernstrom 2005). In the present study, mice exposed to severe stroke showed increased 
plasma levels of BCAA such as valine and leucine, suggesting a metabolic imbalance with a 
plausible detrimental effect on neurological functions due to their impaired catabolism 
(Kasinski, Doering et 01. 2004). These results are in apparent contrast with the recent findings 
by Kimberly et 01. (Kimberly, Wang et 01. 2013) reporting a reduction in plasma concentration 
of BCAA associated with stroke severity. The conflicting data might be explained by the 
different animal models of acute ischemic stroke used and also by the different plasma 
sampling time following ischemia. Alternatively the increases in BCAA level we observed may 
reflect a slow-down in metabolic pathways leading to BCAA incorporation into structural 
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proteins, since BCAA are also known to have role in protein metabolism and in catabolic 
energy metabolism. 
Notably, the BCAA leucine is an important regulator of the mammalian target of rapamycin 
(mTOR) and strongly inhibits autophagy by mTOR modulation (Pignataro, Capone et al. 2011 ; 
Ishizuka, Kakiya et al. 2008). Autophagy has been implicated in mediating neuroprotection in 
response to IPC (Papadakis, Hadley et al. 2013; Sheng, Zhang et al. 2010). Therefore it is likely 
that the systemic elevated level of leucine found in severe ischemia-exposed mice could 
participate in the mTOR activation, which might in turn result in the inhibition of autophagy 
and consequent cerebral damage. 
3. The integration of -omics data points toward androgen receptor as a core molecule 
connecting protein and metabolite profiles to sustain brain ischemic tolerance. 
Results from the literature demonstrate that androgens can regulate multiple molecular 
pathways involved in neurodegeneration exerting both neuroprotective and neurotoxic effects 
in an age- and dose-dependent way, likely involving AR signalling (Cheng and Hurn 2010, 
Uchida, Palmateer et al. 2009). However, recent findings show that AR deficiency is associated 
with greater ischemia-induced cellular apoptosis, providing evidence of a novel 
neuroprotective role of AR in promoting sex-independent angiogenesis (Yoshida, Aihara et al. 
2013). 
So far, in the present study, the AR-related implicated mechanisms could be solely inferred by 
network analysis. 
As indicated by my proteomics findings, AR is likely to participate with many brain and plasma 
proteins (e.g. HSP70, IGF-1, EGFR) to improve brain defence and to reduce the abnormal 
response to an ischemic stress. Such an IPC-induced neuro-protection is likely to be achieved 
by reducing energy metabolism and mitochondrial respiratory chain activity. 
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I observed that AR is involved also in the instauration of a neuro-protective metabotype, being 
correlated with carnitine/carnitine esters and adenosine, whose systemic levels increased in 
the ischemic preconditioning set. 
It has been reported that in prostatic cancer cells (Lin, Lu et 01. 2010), AR activation increases 
the expression of carnitine palmitoyltransferases 1 (CPTl). CPTl with carnitine 
palmitoyltransferases 2 compose the carnitine shuttle responsible for the mitochondrial 
import and export of long-chain acylcarnitines (Violante, Ijlst et 01. 2013). The AR-induced 
increased expression of CPT might therefore increase the mitochondrial uptake of fatty acids, 
leading to their oxidation. As reported for myocardial ischemic preconditioning (Matsuki, 
Nozawa et 01. 2009), this would lead to an accelerated oxidation of fatty acids and would 
inhibit an intracellular accumulation of detrimental fatty acids metabolites. IPC could induce an 
ischemic tolerant state with enhanced capacity for mitochondrial respiration and ATP 
synthesis. 
Enhanced plasma levels of adenosine fits perfectly into this scenario of a homeostatic 
bioenergetic network, due to its direct biochemical interactions with energy homeostasis, 
nucleic acid metabolism, methylation status and adenosine receptor signialling pathways 
(Shen, Lusardi et 01. 2011). The interaction between adenosine and AR could be mediated by 
adenosine kinase (ADK), which controls cellular levels of adenosine (Shen, Lusardi et 01. 2011). 
Recently, it has been proposed that ADK activates protein kinase A and positively regulates the 
expression of the AR (Sarwar, Sandberg et 01. 2013). The protective role of ADK in brain 
ischemia was previously demonstrated through the maintenance of energy homeostasis by 
promoting catabolic pathways for ATP production and limiting processes that consume ATP 
(Manwani and McCullough 2013). 
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Mass spectrometry-based proteomics and metabolomics strategies once again offer promise 
for the discovery of potential biomarkers in cerebral ischemic preconditioning, despite some 
limitations intrinsic to the technologies, e.g. partial proteome/metabolome coverage. 
My study provides the first application of both approaches in cerebral ischemic sets, 
highlighting the cross-talk between the metabolome and proteome, through the identification 
of biological entities relevant to ischemic preconditioning. Althought some weakness and 
limitations in the experimental design of my work (e.g. the use of technical replicates of pooled 
samples, the different time points for sample collection), overall, my study recapitulates some 
of the findings in the literature and provides evidence of an anticipated role of AR as point of 
convergence for a proteomic and metabolomic neuro-protective profile. 
I had no chance to measure androgen or estrogen hormones, that could have supported the 
data on AR, so the use of additional methods and approaches for validating the AR role and 
related pathways in preconditioning is warrented. 
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